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Abstract 
Vaccine development for intracellular pathogens, where a protective and long lasting T 
cell response is desirable, has proved to be a significant challenge. Dendritic cell (DC) 
vaccination has been used to both elucidate mechanisms important in providing 
protection against a range of pathogens and more recently as a vaccine strategy in its 
own right. Additionally, targeting of vaccine antigens via monoclonal antibodies specific 
to DCs has developed as a more clinically appropriate alternative. This thesis 
investigates whether DC manipulation can enhance survival and reduce bacterial load in 
murine models of anthrax and melioidosis.  
 
Prophylactic DC vaccination for B. anthracis required CpG ODN 1826 for the maturation 
of antigen-stimulated DCs in vitro. Following their adoptive transfer, DCs failed to induce 
an antigen-specific response. However, when combined with the rPA and alum anthrax 
vaccine, DC vaccination enhanced antigen-specific T cell responses. This approach 
increased murine survival and significantly reduced bacterial load.  
 
DC vaccination as a therapeutic strategy for B. pseudomallei again required CpG ODN 
1826 for DC maturation and activation. Antigen stimulated DCs migrated to lymph 
nodes within 48 hours of adoptive transfer where they induced an antigen-specific T cell 
response with a mixed Th1/Th17 profile. DC vaccination failed to affect survival with 
increased splenic weight and bacterial load in two out of three murine efficacy studies. 
Targeting of the protective B. pseudomallei antigen LolC, conjugated to a monoclonal 
antibody specific for DEC205, an endocytic DC receptor, failed to induce either a specific 
immune response or impact survival or bacterial load. 
 
Overall, DC vaccination reduced B. anthracis bacterial load when used prophylactically in 
combination with rPA and alum. As a therapeutic strategy the results are suggestive of 
DC vaccination enhancing B. pseudomallei infection. Future studies should examine the 
potential for antigen specific immune responses generated by DC vaccination to be used 
as an adjunct to antibiotic therapy, when B. pseudomallei replication is controlled.  
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Chapter 1: General Introduction  
1.1 Dendritic Cells 
 Innate and adaptive immunity 1.1.1
The immune system has a complex multi-organ arrangement with the primary role of 
preventing infection whilst protecting the host against disproportionate damage. The 
immune system can be broadly divided into the two distinct arms of innate and adaptive 
immunity between which there is significant crosstalk. The innate immune system is the 
front line against infection and enables the rapid detection and elimination of infectious 
organisms [1]. Innate immunity has a range of effector mechanisms, for example: 
phagocytic cells (including dendritic cells, macrophages, monocytes and neutrophils), 
innate lymphoid cells, natural killer T cells, γδ T cells and B-1 cells, cytokines, 
chemokines, Complement, natural antibodies and defensins. The innate response is 
often able to clear pathogens but is non-specific, remaining unchanged to subsequent 
infections with no capability to remember previous encounters. Pathogens that are able 
to overcome or subvert the innate immune response are confronted by the adaptive 
arm of the immune system, consisting primarily of cellular and antibody responses 
providing pathogen specific immunity. This is highly adaptable due to somatic 
hypermutations and V(D)J recombinations providing a huge array of potential antigen-
specific receptors. Furthermore the adaptive immune response has the capacity for 
memory, enabling a rapid response to antigens that have been previously encountered. 
 
 Dendritic cells 1.1.2
At the interface between innate and adaptive immunity lie dendritic cells (DCs) [2] [3] a 
heterogeneous group of functionally specialised antigen presenting cells (APCs) located 
in tissues that represent pathogen entry routes, including the skin, lungs and 
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gastrointestinal tract. It took until the 1970’s for the functional specialisation of DCs to 
be identified based on their distinct morphological features, differentiating them from 
macrophages [4] and their incorporation into the mononuclear phagocyte system (MPS) 
alongside macrophages and monocytes [5]. Numerous DC subsets influenced by 
developmental pathways have been identified, additionally whilst there are many 
similarities there are also important differences between mouse and human DC subsets.  
 
 Dendritic cell subsets 1.1.3
DCs, macrophages and monocytes exhibit multiple shared functions at both the steady 
state and under inflammatory conditions with multiple subsets of each identified [6,7]. 
Previously these have been classified based on their tissue distribution, immune 
function, expression of cell surface molecules or dependence on transcriptional 
regulators [8] [9]. Identification of DC subsets can be difficult as many molecules at the 
cell surface are transient in their expression, depending on developmental stage and 
inflammatory conditions, whilst others are shared with multiple cell lineages. For 
example, CD11b and CD103 are shared with cells of monocyte and macrophage lineage 
that can resemble DCs in terms of protein expression at the cell surface under 
inflammatory conditions [10]. Consequently their description and the separation of 
individual functions has become confused [11]. 
 
Recently Guilliams et al. [11] proposed a new two level nomenclature for the murine 
MPS that should be applicable to the human MPS. The first level proposes an initial 
division of mononuclear phagocytes into three developmental lineages: DCs, 
macrophages (including Langerhans cells) and monocytes. The second level proposes to 
18 
 
divide cells of the MPS based on their function, location and/or morphology. This sees 
DCs divided into three subtypes whose development is mostly dependent on FLT3L [12]: 
classical type 1 DCs (cDC1s) for CD8a+, CD103+ DCs; cDC2s for CD11b+, CD172a+ DCs and 
plasmacytoid DCs (pDCs). Additionally there are subtype-specific transcription factors 
for each subtype: IRF8, BATF3 and NFIL3 for cDC1s; RELB, PU.1, RBPT and IRF4 for 
cDC2s; and E2-2, SP1B, IRF7 and IRF8 for pDCs [11]. It is important to note that cDC1s 
and cDC2s do not always regulate Th1 and Th2 type immune responses respectively. 
This nomenclature separates out monocyte and macrophage derived DC-like cells 
although they have many DC properties. This includes TNF and inducible nitric oxide 
synthase producing DCs (Tip-DCs) and Langerhans cells into the monocyte and 
macrophage lineages of the MPS respectively. 
 
cDC subsets share certain characteristics including high levels of phagocytosis at rest 
and maturation to become professional APCs upon pattern recognition receptor (PRR) 
ligation [9]. pDCs, a specialised population that have a lymphoid cell-like morphology, 
are characterised by expression of the B cell marker B220 but little or no expression of 
CD11c [13]. pDCs respond to viral infections by producing large quantities of type 1 
interferon’s [14].  
 
 Dendritic cell development 1.1.4
Development of murine DCs occurs via a series of committed progenitor cells that 
initiate in the bone marrow. cDCs and pDCs are derived from haematopoietic stem cells 
(HSC) via FLT3+ common myeloid progenitor (CMP) or common lymphoid progenitor 
(CLP) cells. These give rise to all cDCs and the majority of pDCs although some pDCs may 
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develop from the CLP [15]. These give rise to the common DC progenitor (CDP) and the 
pre-pDC and pre-cDC, Figure 1-1. The CDP found within the bone marrow, is committed 
to give rise to DCs only via a circulating pre-cursor, the pre-DC. This migrates through 
the blood to lymphoid and non-lymphoid organs to become lymphoid tissue and non-
lymphoid tissue DCs. Currently this development process has yet to be elucidated in 
humans with CDP and pre-DC equivalents yet to be identified [16]. cDC and pDC 
development arising from the CDP is controlled by cytokines including IFNα, Flt3L and 
GM-CSF which act upon Signal Transducers and Activators of Transcription (STAT)-1, 
STAT-3 and STAT-5 respectively, giving rise to populations of DCs with distinct 
characteristics. 
 
Type 1 interferons produced in response to viral infections regulate DC function with 
IFNα signalling via STAT-1, facilitating the generation and accumulation of pDC in the 
Peyer’s Patches [17] together with the development of cDCs. Signalling via STAT-1 is 
required for the induction of major histocompatibility (MHC) molecules, costimulatory 
molecules and antigen presentation, including cross-priming of antigens to CD8+ T-cells 
[18] with STAT-1 depleted mice producing deficient immune responses due to impaired 
T cell priming [19]. 
 
Engagement of Flt3L with Flt3 results in rapid phosphorylation of STAT-3. STAT-3 
expanded cells have a homeostatic role, inhibiting other leucocyte populations via the 
suppression of toll-like receptor (TLR) dependent cytokine production by macrophages 
and neutrophils. This inhibits DC development from monocytes together with inhibition 
of T-cell responses via suppression of MHC-II and CD80/CD86 signalling [20]. 
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Figure 1-1: DC commitment and differentiation.  
The common myeloid progenitor (CMP) and common lymphoid progenitor (CLP) give 
rise to the common DC progenitor (CDP), Pre-cDC, pDCs and cDC1s and cDC2s. Adapted 
from Merad et al 2013 [21], Guilliams et al 2014 [11] and Perie and Naik 2015 [22]. 
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The generation of non-lymphoid organ cDCs is regulated through STAT-5 and these 
signalling cascades are crucial for survival with Stat5a-/- Stat5b-/- mice dying perinatally 
[23], whilst STAT-5 deficient mice have significantly reduced numbers of cDCs in the liver 
and lymph nodes. Additionally STAT-5 activation suppresses the development of pDCs 
[24]. 
 
 Role in the immune system 1.1.5
DCs are responsible for immune surveillance, the maintenance of immunological 
tolerance and the initiation and direction of adaptive immune responses following 
exposure to pathogen or injury-induced “danger” signals. DCs are strategically located at 
sites for antigen capture, including the skin, lungs and intestine. Subsequently DCs are 
able to migrate to lymphoid organs, enter T cell areas and initiate the induction of an 
adaptive immune response with clonal expansion of antigen-specific T cells and 
production of antibody by B cells. 
 
DCs are the most potent activators of the immune system [25] and are critical for host 
defence against pathogens. Immature DCs perform a surveillance function, constantly 
sampling their surrounding environment, taking up antigen by macropinocytosis or 
phagocytosis and with greater efficiency by receptor-mediated endocytosis [26]. The 
development of an adaptive immune response requires the maturation of DCs which 
can be induced by highly conserved microbial molecules. Pathogen Associated 
Molecular Patterns (PAMPs) are critical to pathogen function and include proteins, 
lipids, sugars and nucleic acids. PAMPs are recognised by germ-line encoded PRRs [27] 
and DC expression of PRRs includes two of the most important groups for pathogen 
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recognition, TLRs and C-type lectin receptors. PRR ligation by PAMPs serves as an 
adjuvant for maturing DCs and initiating immune responses.  
 
Circulating immature DCs exit the blood and migrate in response to proinflammatory 
chemokines. Non-lymphoid tissue DCs express certain chemokine receptors dependent 
on their maturation stage [28]. Specific receptor-ligand signalling pathways include 
CCR2–CCL2, CCR5–CL5 and CCR6–CCL20, enabling recruitment to sites of inflammation. 
Maturation signals induce phenotypic and morphological changes including the 
upregulation of CCR7, enabling DC trafficking to draining lymph nodes in response to 
CCL19 and CCL21 [29]. Concurrent changes include the arrest of antigen uptake, with 
internalised antigen processed and presented on MHC-I and MHC-II to CD8+ and CD4+ T 
cells respectively. Further phenotypic changes include the upregulation of costimulatory 
molecules, required for the development of T and B cell responses whilst the 
development of dendrites provides an enlarged surface area for DC – T cell interactions. 
 
 Of mice and men 1.1.6
There have been 80 million years of diverging evolution separating mice and men [16]. 
As a consequence whilst there are many similarities between murine and human DC 
populations there are also important differences, particularly when considering 
translational studies [30]. To enable the in vitro study of human DCs and development of 
DC therapies, protocols have been developed for generating human DCs from blood 
monocytes using GM-CSF and IL-4 [31] [32] and also from CD34+ haematopoietic stem 
cells from cord blood using GM-CSF and TNF [33]. These approaches have enabled 
advances in human DC biology enabling comparison to murine equivalents based on 
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transcriptomics, phenotypic and functional analyses. However the relevance of using in 
vitro generated cells to elucidate in vivo physiology is limited due to discrepancies in the 
transcriptional pattern of primary human DCs compared to those in culture [16]. 
 
Comparative studies have revealed murine lymphoid tissue CD8+ DCs to be the 
functional equivalents of human CD141+ DCs with both subsets having enhanced cross-
priming abilities compared to other DC subsets [34]. Other subsets that have been 
identified as being equivalents are murine CD4+ and the human CD1c+ DC subset. 
Identification of these functional equivalents has allowed extrapolation of functional 
experiments in mice to human immunology [16]. There are however several well 
defined differences between murine and human DCs. All murine DCs express high levels 
of the integrin CD11c, whilst in humans CD11c is highly expressed on CD1c+ DCs but with 
lower expression on CD141+ DCs [35]. Human DCs do not express CD8 whilst CD4 is a 
pan-DC and monocyte marker in humans but only expressed on murine CD4+ splenic DCs 
and pDCs [36]. Langerin is expressed on both mouse and human Langerhans cells and 
murine CD8+ DCs but not on CD141+ human equivalents [37].  These examples highlight 
the difficulty of comparing murine and human DC populations but also demonstrate 
commonalities between the two species, enabling the mouse to be used as a pre-clinical 
model for DC based therapies. 
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1.2 Adaptive immune response  
 T cell responses 1.2.1
Non-lymphoid tissue DCs migrate to lymph nodes in response to gradients of the 
chemokines CCL19 and CCL21. Within lymph nodes, DCs present exogenous antigens 
derived from the phagosomal compartment to CD4+ T cells on MHC-II molecules. Unlike 
other MHC-II expressing APCs (predominantly macrophages and B cells), DCs are the 
principal activator of naïve CD4+ T cells [38]. DCs also present endogenous antigens, 
derived from the cytosol on MHC-I molecules to CD8+ T cells. Furthermore MHC-I 
molecules can be loaded with antigens that enter the cytosol from the phagosome or 
from apoptotic vesicles from infected macrophages or DCs that enter the MHC-I 
processing and presentation pathway, termed cross-presentation [39]. DCs have several 
characteristics that contribute to their ability to control T cell responses. These include 
their positioning at strategic points to capture and present antigens; presentation of 
antigens on MHC molecules to CD4+ and CD8+ T cells; a variety of subsets in different 
locations expressing different PRRs and producing distinct cytokines enabling the 
polarisation of different immune responses [40]. It is these characteristics that make 
DCs critical for host defence against pathogen challenge. 
 
To activate naïve T cells multiple signals are required. The first is the recognition by the 
T cell receptor (TCR) of its cognate antigen displayed on an MHC molecule; the CD4+ TCR 
recognises sequences of generally 15-24 amino acids presented on MHC-II whilst the 
CD8+ TCR recognises shorter sequences of 8-10 amino acids. The second signal required 
is a costimulatory signal, this is provided by molecules including CD80, CD86 and CD40 
on the DC ligating CD28 and CD40L on the T cell and demonstrates the antigen to be 
dangerous, whilst lack of a costimulatory signal results in T cell anergy. Once these two 
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signals have been received T cells produce IL-2 which can act in an autocrine or 
paracrine way causing rounds of proliferation. Once clonal expansion has occurred the 
costimulatory signal is no longer required to activate effector cells. Thus with 
appropriate costimulatory signals and cytokine production an adaptive immune 
response can be initiated. T cell activity can be inhibited via the interaction of CTLA-4 on 
T cells with CD80 and CD86 on APCs and also via PD-1 ligation by PD-L1 and PD-L2 [41]. 
 
1.2.1.1 CD4+ T cells 
Helper T cells or Th cells are CD4+ T cells are able to direct immune responses via 
communication with other leucocyte populations. Naïve T cells can differentiate upon 
activation into cells that can activate different components of the immune system based 
partially on the cytokines produced by cells of the innate immune system in response to 
pathogen challenge. The polarisation of effector T cells in lymph nodes is controlled by 
key cytokines activating population-specific transcription factors and includes Th1, Th2, 
Th17 and follicular helper T cell (TFH) populations, Figure 1-2. Regulatory T cells (Treg) can 
develop in either the thymus as natural CD4+ CD25+ FoxP3+ Tregs or the periphery as 
induced CD4+ CD25+ FoxP3+ Tregs, other populations include Tr1, Th3 and CD8
+ CD28- Tregs 
[42] [43].  
 
CD4+ T cells have several key activities to aid protection against pathogen challenge. 
These include: recruitment of lymphoid cells to secondary lymph nodes where CD4+ T 
cells promote the engagement of CD8+ T cells with DCs [44]; recruitment of innate and 
antigen-specific cells to infected tissues [45]; help for the expansion or function of other 
effector cells; direct effector functions via cytokine production or cell-mediated 
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cytotoxicity; the maintenance of CD8+ T cell functions during chronic infections, 
particularly due to IL-21 production [46]; the development of CD8+ T cell memory [47]; 
provide help to B cells and are essential for germinal centre responses and 
differentiation of plasma cells with this function primarily restricted to TFH [48]. 
 
Th1 cells differentiate from naïve T cells in the presence of IFNγ or IL-12, and are able to 
recruit and activate macrophages to phagocytose and digest infected cells, important 
for the control of intracellular pathogens [49]. They are also required for the activation 
and maintenance of CD8+ T cells and induction of IgG class switching. 
 
Th2 cells differentiate from naïve T cells in the presence of IL-4 and produce IL-4, IL-5 
and IL-13. They counter-regulate Th1 cell responses and are important for protection 
against extracellular pathogens resulting in the production of IgE, and activation of mast 
cells releasing histamine, serotonin and leukotriene. Th2 responses can inhibit Th1-
biased protective immunity against intracellular pathogens [50]. 
 
Th17 cell development requires IL-6 and TGF-β and their activation leads to the 
production of IL-17, which is chemotactic for neutrophils. Initially it was thought Th17 
cells were important for protection against extracellular infections [51] but not critical 
for protection against intracellular infections [52]. However more recently Th17 cells 
have been shown to play a crucial role against intracellular pathogens [49] [53] and are 
able to recruit monocytes and Th1 cells. However Th17 responses need to be tightly 
controlled as an excessive response can result in immunopathology [54].  
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Figure 1-2: Development of effector CD4+ T cell populations.  
Naïve T cells can differentiate into distinct effector subsets depending on the specific 
cytokine milieu. This is driven by key transcriptional regulators: T-bet for Th1; GATA3 
and IRF4 for Th2; RORγt for Th17; and Bcl6 for TFH subsets. Adapted from Cretney et al 
2013 [55]. 
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Tregs play an important role in resolving inflammatory responses and are also important 
in preventing excessive immunopathology as an absence of Tregs either due to deletion 
or impaired FoxP3 expression results in a severe rapid multi-organ autoimmune attack 
[56]. However Treg activity can also cause reactivation of an intracellular pathogen [49]. 
Tregs can develop in the thymus and have a relatively high affinity for self-antigens and 
prevent autoimmune related pathology [57]. They can also develop in the periphery, 
with their development dependent on TGF-β [58], here they regulate antigen specific 
immune responses and help maintain tolerance at mucosal surfaces. Tregs can mediate 
anti-inflammatory properties both by cytokine activity, including IL-10, TGF-β and IL-35, 
and also by other mediators including granzyme, Fas CTLA-4, CD39, CD73, neuropilin-1, 
lymphocyte activation gene 3, fibrinogen-like protein-2 [59] [60]. Additionally some 
pathogens have the ability to induce an IL-10 producing Treg population in the periphery 
by crosslinking the TCR with CD46, supressing pathogen specific immune responses.   
 
1.2.1.2 CD8+ T cells  
Following infection with intracellular pathogens, antigen-specific CD8+ T cells become 
activated, proliferate and differentiate into cytotoxic T lymphocytes (CTL). CTLs have an 
important role in controlling intracellular infections and have several effector 
mechanisms by which to do so. These include direct cytotoxicity using perforin, 
granzyme, TNF-related apoptosis-inducing ligand (TRAIL) or Fas-FasL, or via the secretion 
of cytokines including TNF and IFNγ [61]. Perforin acts by inserting holes into target cell 
membranes triggering an influx of Ca2+ ions enabling perforin and granzyme to enter the 
early endosome [62]. Granzymes, TRAIL and Fas-FasL interactions induce apoptosis of 
the target cell by cleaving caspases, inducing an apoptotic cascade [63] [64] [65]. 
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1.2.1.3 Development of T cell memory 
The development of T cell memory responses, those that can be reactivated upon 
secondary encounter, can be generated either by infection with a pathogen or by 
successful vaccination. T cell responses to an antigen are characterised by a proliferative 
phase with clonal expansion of antigen-specific effector T cells. Following the resolution 
of an infection there is a loss of T cell survival signals followed by a phase of contraction 
where the majority undergo apoptosis [66]. During the immune response, memory cells 
develop that enable a rapid response to subsequent challenges with the pathogen.  
 
Memory cells can be identified by surface expression of adhesion molecules, memory 
markers and chemokine receptors enabling tissue homing [67]. There are dozens of 
individual memory populations that can be identified based on lineage, cellular function, 
tissue specificity together with surface and intracellular markers [67]. Broadly speaking, 
memory T cells can be divided into central memory (TCM) cells, which are CCR7
+ cells 
that home to secondary lymph nodes producing large amounts of IL-2 but low levels of 
other effector cytokines. On the other hand effector memory (TEM) cells are CCR7
- 
, 
produce high levels of cytokines, exert rapid effector functions and home to peripheral 
tissues [68]. 
 
 B cell responses 1.2.2
 
B cells can be distinguished from other lymphocyte populations by the expression of the 
B cell receptor (BCR) at the cell surface. The BCR is a member of the immunoglobulin 
superfamily and has the same specificity as the antibody molecules the B cell will 
secrete. In contrast to the TCR, the BCR recognises free antigen in the blood or lymph. B 
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cells have several important functions within an adaptive immune response including 
the production of antibodies by differentiated plasma cells, APC functionality, 
differentiation of memory B cells, cytokine production and the ability of regulatory B 
cells to suppress immune responses [69].  
 
Antibody production by B cells can either be T cell-independent or T cell-dependent. 
There are two methods by which B cells can be activated independently of T cells. The 
Type-1 T cell-independent B cell activation requires BCR ligation with concomitant TLR 
ligation; Type-2 T cell-independent B cell activation involves cross linking of multiple 
BCRs by repetitive molecules on a pathogen’s surface; both methods restrict B cells to 
IgM production.  
 
The majority of naïve B cells are activated in a T cell-dependent manner. B cells take up 
pathogen-related antigens via their BCR and process and present these on MHC-II to 
differentiated CD4+ T cells. CD4+ T cells are then able to activate naive B cells via surface 
interactions including CD40L:CD40 and CD30L and CD30 together with the secretion of 
cytokines that help determine the isotype of the antibody produced. T cell help is 
required for B cell clonal expansion, isotype switching, affinity maturation and the 
differentiation of memory cells. 
 
B cells are capable of secreting five main antibody isotypes: IgM, IgA, IgD, IgE and IgG, 
each with distinct properties. IgD and monomeric IgM form the BCR on naïve B cells. The 
pentameric form of IgM is produced as the earliest antibody isotype during an adaptive 
immune response and is capable of inducing opsonophagocytosis and activation of the 
31 
 
Complement system. The secreted form of IgD is rare in serum but has a role in 
activating basophils and mast cells [70]. There are four subclasses of human IgG (IgG1-4) 
and four subclasses in the mouse (IgG1, IgG2a, IgG2b and IgG3). These are found in the 
serum and are all capable of opsinophagocytosis with IgG1-3 capable of activating the 
Complement system. IgA consists of two subclasses IgA1 and IgA2 and the dimeric 
secretory IgA has an important role in preventing the establishment of pathogens at 
mucosal surfaces. The main protective function of IgE is against parasites where it is able 
to activate basophils and mast cells. Other functions of B cells include cytokine secretion 
which is able to modulate immune function [71], this may be imprinted on the B cell by 
activating Th1 or Th2 cells with secreted cytokines working in an autocrine way giving B 
effector (Be)1 and Be2 cells [72]. 
 
1.3 Dendritic cell therapy 
The majority of successful vaccines developed induce a protective antibody response 
either directly against a pathogen (poliomyelitis, measles) or neutralise a toxin (tetanus 
toxin from Clostridium tetani; anthrax toxin from Bacillus anthracis). However there are 
many diseases where antibody as the predominant immune response is insufficient to 
provide protection and there is an additional requirement for protective cell-mediated 
immunity (CMI). These include diseases such as HIV, malaria, tuberculosis, Leishmania as 
well as many cancers. Live vaccines such as vaccinia induce both strong humoral and 
cellular responses [73] whilst the live attenuated Yellow Fever vaccine, YF17D activates 
multiple DC subsets, again with strong humoral and cellular responses [74]. Key 
components of the CMI response include IFNγ producing CD4+ T cells, exerting cytolytic 
activity on MHC-II targets and sustaining functional CD8+ T cells [75]. Many of the 
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etiological agents of diseases for which there are no available licensed vaccine share 
common features including, an intracellular lifestyle and the ability to establish a chronic 
infection. In these cases, it is likely that CMI with pathogen-specific CD4+ and CD8+ T 
cells will be important protective vaccine responses.  
 
DC therapy has great potential in medicine for the treatment of a variety of different 
diseases [40] with considerable research focussing on the development of therapeutic 
DC vaccination for a variety of tumours [76]. The first antigen-specific cellular 
immunotherapy was licensed in 2010 by the US Food and Drug Administration (FDA) for 
use against late stage prostate cancer [77] and Phase III trials are underway for 
advanced glioma (NCT00045968), renal cell cancer (NCT01582672) and melanoma 
(NCT01875653). This approach demonstrated the development of CMI responses with a 
Th1 polarisation and antibody production, characteristics that also are important for 
immunity to many pathogens.  
 
DC vaccination for infectious disease, the ex vivo pulsing of DCs with pathogen-derived 
material and/or defined stimulatory antigens, with or without adjuvants, induces the 
maturation of DCs ex vivo and has been shown to be able to prime naïve syngeneic 
lymph node T cells in vitro [78]. DCs are administered to the host and are able to direct 
the development of protective T cell responses in vivo. DCs pulsed with pathogen-
specific synthetic peptides [79], proteins [80] [81], transfected with RNA/DNA [82] or 
transduced with recombinant virus [83] have all induced a specific immune response 
following adoptive transfer. Pulsed DCs alone are able to induce specific Th1 immune 
responses via their ability to secrete IL-12 and act as natural adjuvants [84]. This effect 
33 
 
has been enhanced when the ex vivo pulsing of DCs occurs in the presence of CpG, a 
potent inducer of Th1 responses [85] [86]. However several pathogens have immune 
evasion strategies to counteract DC activity which include blocking DC maturation (e.g. 
Coxiella burnetii, Vaccinia), modulating immune responses to switch from a protective 
Th1 bias to a susceptible Th2 profile (e.g. Leishmania spp.), whilst others are able to 
inject toxins using Type three secretion systems to kill DCs (e.g. Burkholderia 
pseudomallei and Yersinia pestis). 
 
Inaba et al. were the first to demonstrate that ex vivo pulsed DCs could generate an 
antigen specific in vivo immune response in naive mice to a variety of protein antigens 
[87]. The development of methods to generate large quantities of highly pure DCs from 
mouse bone marrow or human PBMCs has greatly aided the expansion of DC research. 
Their use as a potential vaccine for infectious diseases, particularly for those requiring 
strong CMI responses, including parasitic, fungal, bacterial and viral pathogens has been 
widely explored and is briefly summarised.  
 
1.3.1.1 Dendritic cell vaccination for bacterial pathogens 
Mbow et al. [88] published the first account of DC vaccination inducing protective 
immune responses to infectious disease in vivo. Langerhans cells or splenic DCs were 
pulsed with the Outer Surface Protein A (OspA) from Borrelia burgdorferi, the etiological 
agent of Lyme Disease and a Gram-negative bacterium. Lyme disease, transmitted by 
Ixodes ticks, is characterised by an ameliorated antibody response in the early stage of 
infection. OspA pulsed DCs were able to generate antibodies both in vitro and in vivo, 
inducing protection against challenge. 
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Estimates of Mycobacterium tuberculosis infection indicate one in three people to be 
infected globally. The current vaccine Bacillus Calmette-Guérin (BCG) provides only 
limited protection against M. tuberculosis, leading to much research to elucidate 
immune responses required for protection. Approaches to load M. tuberculosis antigen 
into DCs prior to adoptive transfer have included: BCG, M. tuberculosis and an 
auxotrophic M. tuberculosis mutant used to infect DCs [89] [90] [91]; M. tuberculosis 
CD4+ or CD8+  T cell restricted epitopes [79] and sonicated antigens [92]. These induced 
strong CD4+ and CD8+ T cell responses with a Th1 bias, IgG2a antibody, reduced bacterial 
burden and provided protective efficacy [79,89] [90] [91] [92]. These reports highlight 
the importance of DCs in M. tuberculosis control, particularly the ability of DCs to induce 
protective CD8+ responses with a Th1 profile essential for disease resistance [79] [92]. 
  
Other studies with DCs pulsed with bacterial pathogens have shown that both human 
and murine DCs pulsed with Coxiella outer membrane protein 1 (Com1) a major 
immunodominant antigen, undergo maturation [80] [81] and following adoptive 
transfer induced the proliferation and activation of CD4+ T cells with secretion of IFNγ 
and protection of naive mice [81]. DCs pulsed with killed Chlamydia secrete IL-12 and 
present chlamydial antigens to T cells. When transferred to naive mice, pulsed DCs 
induced a Chlamydia-specific Th1 response, IgG2a antibody and a reduction in bacterial 
load following infection [93] [94]. DCs isolated from mice infected with Chlamydia and 
adoptively transferred to naïve mice have also been shown to induce protective 
immunity, with a Th1 biased immune response [95]. DCs loaded ex vivo with P. 
aeruginosa have been shown to induce protective immunity against lethal challenge 
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characterised by antigen specific CD4+ T cells [96]. DCs have also been transduced to 
over express CCL22; when pulsed with P. aeruginosa and subsequently transferred to 
naïve mice these DCs enhanced specific immune responses and provided protection 
against lethal respiratory challenge [97]. A defined P. aeruginosa antigen (OprF) rather 
than a crude whole cell preparation, has demonstrated an ability to induce Th1 
mediated resistance to infection and ameliorate inflammatory pathology, when used to 
pulse DCs prior to adoptive transfer [98]. 
 
1.3.1.2 Dendritic cell vaccination for protozoan pathogens 
Currently there are no prophylactic or therapeutic vaccines for Leishmania infections 
with current treatment requiring extensive chemotherapy [99]. DC therapy has the 
potential to be exploited for the therapeutic treatment of Leishmaniasis as protective 
immunity and disease resolution to both cutaneous and visceral Leishmania are  
correlated with an antigen-specific CD4+ and CD8+ T cell response with a strong Th1 bias, 
[100] [101] [102] whilst a Th2 immune profile following infection exacerbates disease. 
DCs pulsed with a Leishmania major lysate were able to induce protection in susceptible 
mice with the development of a Th1 biased immune response characterised by IL-12p40 
and IFNγ production, indicating that the adoptively transferred DC are able to act as 
natural adjuvants [84]. Subsequently different approaches to pulsing DC with antigen 
preparations from different Leishmania species has been reported including the use of 
soluble L. donovani antigens [103], molecularly defined parasite proteins from L. major 
[104], L. infantum histones with or without CpG [105] [106] , L. major lysate [107], and 
antigen-loaded DCs that were subsequently either fixed with paraformaldehyde, UV-
irradiated or disrupted by freeze-thawing. These strategies have demonstrated an ability 
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of DCs to induce Leishmania specific CD4+ and CD8+ T cell responses with a Th1 bias 
[103] [104] [108] together with restricted Th2 and FoxP3+ regulatory T cells [105], 
important for protective efficacy [103] [104] [105] [106] [108]. DCs transduced to 
increase IL-12 production provided enhanced protection to L. donovani [103]. Pulsed 
cells from IL-12-/- mice abrogated protection against L. major [104] further indicating the 
ability of donor DCs to induce a Th1 immune response with greater IFNγ rather than IL-
10 production,  and with IgG2a antibodies [99]. To enhance induction of a Th1 bias, DCs 
pulsed with L. major antigens together with CpG induced an antigen-specific response 
with a Th1 bias and decreased parasite burden mediated by IL-12 [109]. Conversely, 
whilst L. major lysate-pulsed pDC induced protective T cell mediated immunity, a mixed 
Th1/Th2 profile occurred, characterised by increased IFNγ, IL-4 and IL-10, together with 
a mixed pathogen-specific IgG1 and IgG2a response [107]. 
 
1.3.1.3 Dendritic cell vaccination for fungal pathogens 
Candida albicans is a harmless commensal yeast that can cause severe infections in 
immunocompromised individuals including those suffering with AIDS, undergoing 
chemotherapy or who have recently undergone bone marrow transplantation. Innate 
and adaptive immunity are important in regulating responses to C. albicans with a Th1 
bias important for resistance [110]. DCs pulsed with viable Candida yeasts are capable of 
inducing protective Th1 immune responses when adoptively transferred [111]. 
Furthermore DCs transfected with Candida RNA are able to induce Th1-dependent 
antifungal resistance in naive mice. This resistance is also able to provide protection in 
allogeneic bone marrow-transplanted mice, by accelerating the functional recovery of 
Candida-specific IFNγ producing CD4+ donor lymphocytes [82]. The fungus 
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Paracoccidioides brasiliensis causes a systemic granulomatous disease that is 
widespread in South America. The immunologically dominant antigen of P. brasiliensis, 
glycoprotein-43 (gp43) contains a 15mer peptide (p10). DCs pulsed with p10 have been 
shown to significantly increase T cell proliferation and provide protective efficacy with 
an associated decrease in pulmonary damage and reduced fungal burden. This effect 
was correlated with an increase in the Th1 cytokines IFNγ and IL-12 and a decrease in 
the Th2 cytokines IL-4 and IL-10 [112]. 
 
1.3.1.4 Dendritic cell vaccination for viral pathogens 
Viruses are obligate intracellular pathogens with many causing transient infections that 
are resolved by the rapid induction of appropriate immune responses including 
neutralising antibodies (e.g. poliomyelitis). Other viruses establish persistent infections 
which are controlled by specific T cell responses (e.g. Varicella zoster virus) whilst there 
are several viruses that establish infections that are poorly controlled (e.g. HIV, Hepatitis 
B Virus (HBV), Hepatitis C Virus (HCV)). In addition to DC vaccination, T and B cell cellular 
therapy has the potential to be a valuable tool in combating important viral infections 
including Cytomegalovirus, Epstein-Barr Virus and Human T-Lymphotrophic Virus-1 
following haematopoietic stem cell transplantation.  
 
HIV has infected 0.6% of the world’s population and killed in excess of 39 million people 
[113]. HIV infects CD4+ T cells, initially those of a memory phenotype with early 
infections controlled by CD8+ T cells. Over time the number of uninfected T cells 
decreases and the architecture of lymph nodes is destroyed, resulting in poor immune 
responses to both infections and malignancies. DC vaccination has been explored as a 
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therapeutic tool to expand HIV-1 specific T cell responses, inducing a potent immune 
response helping to control viral replication [114]. Early work using animal models 
demonstrated that DCs transfected with recombinant adenovirus expressing Simian 
immunodeficiency virus (SIV) gag antigen were able to prime SIV T cell responses in 
rhesus macaques [83]. Furthermore DCs pulsed with chemically inactivated SIV 
decreased plasma SIV DNA and RNA and induced SIV-specific T cell responses and 
neutralising antibody [115]. Moreover DCs loaded with inactivated SIV decreased viral 
load by >99% with the induction of SIV-specific T cell responses and the preservation of 
the DC network and germinal centres [116]. 
 
Early clinical studies examining the potential of therapeutic DC vaccination for HIV-1 
demonstrated that both autologous and allogeneic DCs pulsed with HIV-1 peptides were 
able to induce HIV-1 specific responses in HIV-1 seronegative volunteers [117]. Other 
studies have utilised DCs loaded with different HIV-1 antigen formulations. These have 
included HIV lipopeptides [118], autologous inactivated HIV-1 [119] [120], 
electroporated with mRNA encoding Tat, Rev and Nef [121], or with Gag, Vpr, Rev and 
Nef [122], pulsed with Gag, Env and Pol peptides [123] or infected with Canarypox virus 
expressing Env, Gag, Pol and Nef [124]. These approaches have all been safe, well 
tolerated and demonstrated an ability to mature DCs and induce HIV-specific immune 
responses including enhanced T cell responses. Three of the studies have demonstrated 
an ability of DC vaccination to reduce plasma viral load, up to 90% in some patients 
[119] and to keep HIV-1 infected patients off antiretroviral therapy for prolonged 
periods of time [121]. The decrease in viral plasma load is directly correlated to the 
induction of HIV-1 specific CD4+ and CD8+ T cell responses [119] [120] [121]. Many of 
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these clinical studies are in the early stage of therapeutic vaccine development, Phase 1 
or Phase 2a, but these encouraging results have resulted in several of them advancing to 
enrol more patients.  
 
HBV is capable of establishing a chronic infection [125] associated with life-threatening 
liver disease, characterised by impaired T and B cell responses together with reduced 
proinflammatory cytokine production. DCs have been shown to induce HBV-specific 
responses with the adoptive transfer of DCs loaded with HBV subviral particles (HBVsvp) 
to naive mice enhancing HBV-specific T and B cell responses [126]. 
 
Immunity to HCV is correlated with a strong cellular response. However a significant 
number of individuals fail to clear the virus establishing a chronic infection in 75-85% of 
cases, associated with a decrease in DC function and maturation. Chronic HCV can cause 
cirrhosis of the liver or hepatocellular carcinoma and is the leading cause of liver 
transplantation globally. HCV has been a particular target for vaccine development [127] 
including several DC vaccine clinical trials with two HCV vaccines approved by the FDA in 
2011. There have been many studies utilising DC vaccination to enhance HCV immunity 
with numerous HCV antigens trialled. Strategies have included an HCV-core epitope 
fused to anthrax Lethal Factor and used to pulse DCs in combination with anthrax 
Protective Antigen [128]; DCs transfected with adenovirus expressing the HCV-core 
epitope [129]; DCs pulsed with recombinant HCV proteins and peptides [130]; DCs 
pulsed with HCV NS3 protein and matured with CpG [131] and DCs transfected with 
mRNA expressing NS3/4A [132]. These approaches have been shown to induce HCV-
specific CD4+ and CD8+ T cell responses with HCV-specific antibody responses together 
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with a Th1 bias [128] [129] [130] [131] [132]. Furthermore several of these studies 
demonstrated the protective ability of DC vaccination [129] [130] [131] [132] and 
enhanced protection when DCs were stimulated with CpG prior to adoptive transfer 
[131]. 
  
Other studies with DCs pulsed with viral antigens have shown that: UV inactivated 
Herpes Simplex Virus (HSV)-2 or purified HSV-2 envelope glycoprotein provided 
complete protection against challenge, dependent on CD4+ T cells for HSV-2 specific 
IFNγ and antibody responses [133]. Adoptive transfer of DCs pulsed with Lymphocytic 
Choriomeningitis Virus (LCMV) peptide GP33-41 showed rapid and persistent 
development of protective LCMV immunity [134]. DCs infected with influenza and then 
used to immunise naive mice have been shown to enhance viral clearance following 
infection, with the induction of a Th1 immune profile characterised by antigen-specific 
IFNγ production and IgG2a antibody [135]. 
 
Many of the models of infection described have shown the ability of DCs to provide 
pathogen-specific protection. However pathogens that modulate DC function to achieve 
persistence present a challenge to this vaccine approach, for example Trypanosoma 
cruzi is able to induce the over-expression of IL-10 by DCs [136] although it may be 
possible to instruct DCs to overcome this [137]. Studies have also shown that DC therapy 
may have the potential to overcome self-tolerance in prion disease [138] and conversely 
when using specific culture conditions to induce tolerogenic DCs preventing the onset of 
autoimmune disease [139].  
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Taken together the published literature demonstrates that DC therapy has wide 
potential for the treatment of a large number of conditions but that there remain 
technical and manufacturing issues to overcome before their application becomes 
widespread. These include the type of antigen and maturation signals to use, 
appropriate functional assays to assess immune responses, the collection and handling 
of DCs and the manufacture of sufficient cells for therapy. This could be overcome by 
the development of allogeneic off-the-shelf DC therapies, although the potential for HLA 
mismatching remains a problem [140]  or by the use of artificial APCs. The development 
of artificial APCs may enhance long term persistence of T cell responses and prevention 
of disease recurrence in chronic diseases [141]. Candidates include polystyrene beads 
[142], lipid vesicles [143] and exosomes [144]. These have the advantage in that they 
could be used off-the-shelf and that antigen loading conditions could be carefully 
controlled to induce desired immune responses. Furthermore, where the availability of 
protective antigens is limited, RNA-transfected DCs have the potential to enhance 
pathogen-specific responses [82] and DCs can be genetically modified to express 
molecules important in generating desired immune responses [145]. 
 
 It is also important to consider the route of administration in vaccine design to enable 
DC homing to physiologically appropriate sites, as different routes will target different 
lymphoid organs for T cell priming and affect the distribution of activated cells. Whilst 
some of the approaches described may not lead to the development of a pathogen-
specific prophylactic or therapeutic DC vaccine for clinical use, the reports have 
enhanced knowledge regarding the biology of host-pathogen interactions. They have 
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underlined that for many pathogens a Th1 bias is critical for a favourable prognosis with 
DCs at the centre of directing this response. 
 
1.4 In situ dendritic cell targeting 
DCs are crucial for the induction of CMI responses and are capable of inducing 
protective immunity to a range of pathogens due to their ability to provide a Th1 bias 
with the clonal expansion of CD4+ and CD8+ T cells. Due to the issue of HLA compatibility 
and hence the need for a personalised DC vaccine, it is unlikely that DC vaccination will 
be developed as a widespread prophylactic or therapeutic therapy. However, the in situ 
targeting of DCs has attracted much interest as this approach overcomes some of the 
technical problems presented by adoptive transfer and is more direct, less labourious 
and has been shown to induce potent immune responses at very low antigen 
concentrations. Moreover, this approach allows proteins, which are more easily 
produced, cheaper and safer but often poorly immunogenic, to be used to induce strong 
CMI responses [146].  
 
Several DC endocytic receptors are known to mediate the uptake of pathogens including 
C-type lectins with different subsets of DCs expressing different C-type lectins. In murine 
models, CD8α+ DCs expression of endocytic receptors includes DEC205, Clec9A and 
Langerin whilst CD8α- DCs expression includes DCIR2 and Dectin-1. Studies have shown 
CD8α+ DCs to have the ability to both present exogenous antigen on MHC-II to CD4+ T 
cells and cross-present this antigen to CD8+ T cells on MHC-I [147] [148] with the 
production of IL-12p70 important for the development of Th1 immune responses [149]. 
IL12p70 is necessary for the development of CD8+ T cells and CTL responses [150] which 
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are important for protection against intracellular bacterial and viral infections [151] 
[152]. CD8α- DCs drive Th2 responses with antigen presentation on MHC-II molecules 
[148], [149] with a mixed IFNγ and IL4 response with IgG1, IgG2a and IgG2c antibody 
[153].  
 
To target DCs in situ, antigen needs to be fused to a molecule capable of delivering it to 
the receptor of choice. Most studies have utilised antigens chemically conjugated or 
genetically engineered to monoclonal antibodies, whilst others have conjugated 
antigens to sugar moieties specific for the lectin being targeted. A fusion of the two is 
required, since simply mixing antigen and antibody is insufficient to generate strong 
immune responses. Initial studies targeted antigen to DEC205 and demonstrated this 
approach to be able to induce T cell responses several hundred fold greater than the 
delivery of antigen in Complete Freunds Adjuvant. However this effect decreased within 
seven days and mice became unresponsive, even when re-challenged. The co-delivery of 
DEC205 targeted-antigen with the DC maturation signal CD40L, induced prolonged 
immune responses rather than tolerance [154]. Responses include the development of 
antigen-specific CD4+ T cells, cross–presentation of antigen to CD8+ T cells with IL-2 and 
IFNγ production, in vivo cytolytic function of T cells, responsiveness to re-challenge 
[155,156] and long lived T cell help for antibody responses [157]. These responses 
require DC maturation via an adjuvant when targeting antigen. Indeed, the 
unresponsiveness induced by antigen targeted to DEC205 without an adjuvant [154] has 
been exploited as a method to mitigate both the onset and progression of autoimmune 
diabetes in NOD mice [158] [159] due to both autoreactive T cells becoming anergic 
[154] [155] and the induction of regulatory T cells [160], [161]. Furthermore the 
44 
 
targeting of antigen to sialic acid binding immunoglobulin-like lectin H (Siglec-H) inhibits 
T cell dependent autoimmunity, rendering CD4+ T cells to be hyporesponsive  with a 
reduction in Th1/Th17 polarisation but no induction of FoxP3+ T cells [162]. 
 
Other studies targeting antigen to DEC205 in vivo demonstrated EBV nuclear antigen 
(EBNA1) targeted to DEC205 with poly I:C induced IFNγ, CD4+ and CD8+ T cell responses 
and controlled autologous EBV infected human B cells in vitro, providing a potential 
strategy to combat EBV associated diseases [163]. Circumsporozoite protein (CSP) from 
Plasmodium falciparum targeted to DEC205 in a non-human primate model was able to 
induce cytokine production and limit sporozoite infection in vivo [164]. The additional 
treatment with Flt3L when targeting antigens to DEC205, expanded CD8α+ DEC205+ DCs 
with enhanced antigen presentation to CD8+ T cells in vivo [165]. A DNA construct 
encoding antigen targeted to DEC205 fused to CD40L, providing a DC maturation signal 
and additionally encoding Flt3L and GM-CSF for DC recruitment, induced IFNγ producing 
T cells, T cell proliferative responses and antibody responses, detectable one week post-
immunisation [166]. 
 
Antigen targeted to Clec9A, a C-type lectin expressed by CD8α+ DCs and pDC, induced a 
high titre antibody response, dominated by IgG1 but included other isotypes, and unlike 
antigen targeted to DEC205, the enhancement of CD4+ and CD8+ T cell responses in the 
absence of maturation signals [167]. However, adjuvants are required to induce 
functional CTL responses when antigen is targeted to Clec9A [168]. Functional responses 
to antigen targeted to Clec12A [167,169], DCIR2 [170], Dectin-1 [171], mannose 
receptor [172], Langerin [170], and BST2 [173] have all been shown to require a DC 
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maturation signal to generate persistent antigen-specific responses. Targeting HIV-gag-
p24 to Langerin, DEC205 or Clec9A with poly I:C induced strong Th1 and CD8+ T cell 
responses, particularly compared to antigen targeted to DCIR2 [170]. 
 
Several studies have examined the potential for targeting HIV antigens to DCs 
expressing DEC205 using both protein antigens [75] [170] and DNA vaccines [174] [175] 
[176]. These have demonstrated an ability to expand CD4+ and CD8+ T cells with a Th1 
bias and proliferative ability, characteristics associated with protective functions in 
mouse [75,170,174,175] and in non-human primates [176].  
 
Although much in situ DC targeting has been applied to tumour immunotherapy, there 
has been limited application to infectious disease models. The V antigen from Yersinia 
pestis targeted to DEC205 on CD8α+ DC with poly I:C, induced an antigen-specific Th1 
response with IFNγ CD4+ T cell responses, and the induction of IgG2a and IgG2c 
antibodies. On the other hand,  targeting the V antigen to DCIR2 on CD8α- DC induced 
fewer IFNγ CD4+ T cells but greater IL-4, IL-5, IL-10 and IL-13, cytokines, characteristic of 
a Th2 response and a strong antibody response [177]. A similar immune response is 
observed when V antigen is delivered in alhydrogel [178] or as F1-V conjugate [177,179]. 
In a lethal challenge model, V targeted to DCIR2 induced strong protection against a 
disease where the antibody response is important for protection [179]. In a further 
model antigen 85B of M. tuberculosis targeted to DEC205 gave strong humoral 
responses but weak T cell responses in vivo and failed to protect against M. tuberculosis 
challenge [180]. 
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The development of DC targeting may enable protein antigens to be used for vaccines 
requiring a CTL response, instead of vector delivered vaccines, mitigating vector induced 
immunity and enabling prime-boost strategies [181]. Other strategies to enhance 
immune responses following in situ DC targeting include the development of antigen 
coupled to receptor-specific single chain variable fragments (scFv). scFv have an 
advantage over whole antibody molecules as they are smaller, allowing greater tissue 
penetration [182], lack the Fc domain enabling administration of repeated doses 
without side effects [183] and reducing non-specific uptake [184]. There remain several 
challenges to overcome with targeting DCs in situ. These include the identification of 
suitable murine receptors and translating this to human DCs, targeting the appropriate 
DC subtype, the development of human monoclonal antibodies to target receptors, 
identifying suitable vaccine antigens and the optimum delivery route for maximal 
response [185].  
 
Due to the heterogeneity of DC subsets and their wide tissue distribution, there are 
several considerations for the development of DC targeting vaccines. These include: (1) 
biological function of target DC subsets, (2) effect of activation signals on DCs delivered 
through the targeted DC receptor, and (3) local and systemic effect of adjuvants [30]. 
The human equivalent of CD8α on DCs has been identified as CD141, recently described 
in a series of papers [34] [186] [187] [188] [189] and this finding will aid the translation 
of murine studies to clinical trials [189] [40]. DEC205 has also been identified on human 
DCs [190] and targeting of  antigen to DEC205 has been shown to induce antigen-
specific CD4+ T cell responses and cross-priming to CD8+ T cells [184].   
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1.5 CpG oligonucleotides 
 
The mechanism of action of CpG motifs was united by Krieg et al. in 1995. Prior to this 
the stimulatory effect of viral and bacterial DNA had been known for over 30 years [191] 
with the stimulatory effect of synthetic CpG ODNs recreating this effect [192]. CpG 
ODNs contain central cytosine and guanosine dinucleotide motifs with two flanking base 
pairs. There are key differences between bacterial and vertebrate DNA that make CpG 
sequences stimulatory. Vertebrate DNA contains far fewer CpG sequences compared to 
bacterial DNA [193].  Additionally approximately 70% of vertebrate CpGs contain 
cytosine methylation compared to bacterial DNA where the majority of CpG motifs are 
unmethylated [194]. Furthermore, CpG motifs in vertebrate DNA are flanked by cytosine 
and guanosine residues (CCGG) making vertebrate CpG sequences inert [195]. Moreover 
mammalian DNA is capped by telomeres that are rare in bacteria and highly 
immunosuppressive via the downregulation of IL-12 and IFNγ [196] [197]. Finally, 
bacterial CpG sequences are predominantly recognised by TLR-9, an intracellular PRR 
found within the endoplasmic reticulum and endosomal compartments of cells [198]. 
The intracellular location of TLR-9 also assists the discrimination of host and pathogenic 
DNA as these compartments are devoid of self DNA under normal conditions but may 
contain that of pathogens following uptake [199]. Furthermore self DNA is exposed to 
extracellular DNAses whilst pathogenic DNA is enclosed by the bacterial cell wall or viral 
particle [200].   
 
There are key differences in the expression of TLR-9 between mice and humans, both 
express TLR-9 on pDCs and B cells whilst mice also express TLR-9 on monocytes, 
macrophages and DCs [201]. This may present a problem in transitioning pre-clinical 
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research to clinical studies but murine experiments have proved to be a good model to 
predict therapeutic potential for clinical trials [200]. The TLR-9 binding of CpG motifs 
results in proteolytic cleavage of the receptor [202], recruitment of MyD88 and a signal 
cascade resulting in the activation of transcription factors including NFκB, AP-1 and IRF-7 
culminating in an inflammatory cascade [203]. 
 
Four main classes of synthetic CpG ODNs have been identified, each between 8 and 30 
bases long, that differ in their structure and immunological activity [200]. A-type (also 
called D-type) CpG ODNs are constructed from a phosphodiester/phosphorothioate 
backbone and contain a single CpG motif flanked by palindromic sequences. A-type CpG 
ODNs are potent inducers of pDC maturation and cause the production of Type-1 
interferons important in antiviral responses  but have no effect on B cells [204]. B-type 
(also called K-type) CpG ODNs consist of one or more CpG motifs on a phosphorothioate 
backbone which enhances resistance to nuclease digestion compared with native 
phosphodiester nucleotides [205]. B-type CpG ODNs causes maturation of pDCs with 
release of TNF and B cell proliferation and differentiation [206]. C-type CpG ODNs 
resemble B-type CpG ODNs as they consist of a phosphorothioate backbone and also 
resemble A-type CpG ODNs as they contain palindromic CpG motifs [200]. They 
stimulate B cells to produce IL-6 and pDCs to secrete IFNα. The final type of CpG ODNs, 
P-type, contain double palindromes enabling them to form higher order structures. P-
type CpG ODNs induce the greatest IFNα response of any CpG class [207]. 
 
CpG ODNs have a profound effect on DCs, enhancing DC maturation and their ability to 
present antigen on MHC-II and cross present extracellular antigens on MHC-I [208]. 
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Concomitantly they upregulate costimulatory molecules including CD40, CD80 and CD86 
together with the lymph node homing molecule CCR7, and produce TNF, IL-6 and IL-12 
eliciting a Th1 bias [204] [209] [210]. CpG ODN’s also enhance antibody responses 
driving the response towards an IgG2a isotype and cause the production of chemokines, 
attracting a variety of cells to the site of inflammation [211]. 
 
DEC205, a multi-lectin receptor expressed on DCs, B cells and T cells [212] has endocytic 
capacity and recycles through late endosomal and lysosomal compartments. [213]. 
Targeting antigen to DEC205 can also induce antigen presentation and adaptive immune 
responses [155]. Recently DEC205 has been demonstrated to be a B-type CpG ODN 
receptor, enhancing their uptake and delivery to TLR-9 and proving to be crucial for B-
type CpG immune responses [214] [215].   
 
Due to their ability to stimulate pDCs, cDCs and B cells in mice, B-type CpG ODNs are the 
predominant CpG class that have been used in clinical trials for both infectious diseases 
and cancer. Previous studies have shown BMDCs stimulated with heat-killed B. 
pseudomallei and CpG to provide prophylactic protection against lethal challenge with 
B. pseudomallei [85,86]. The B-type CpG ODN 1826 has been exclusively used in the 
studies described in this thesis.  
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1.6 Bacillus anthracis 
Bacillus anthracis, the etiological agent of anthrax, is a non-motile, facultative 
anaerobic, Gram-positive, endospore forming bacterium that is endemic globally, Figure 
1-3. B. anthracis is a member of the phylum Firmicutes, family Bacillaceae, genus 
Bacillus and found within the Bacillus cereus group which consists of seven closely 
related species: B. anthracis, B. cereus, B. medusa, B. mycoides, B. pseudomycoides, B. 
thuringiensis and B. weihenstephanensis with a shared pathogenic feature of toxin 
production [216]. Differentiation is based on the analysis of morphological, biochemical 
and immunological characteristics together with the use of 16S rRNA and 23S rRNA and 
gyrB gene sequence analysis to determine the phylogenetic relationship of the Bacillus 
cereus group [217]. 
 
B. anthracis is primarily a disease of herbivorous mammals with occasional transmission 
to other mammals, including humans. Infection of humans generally occurs via the 
consumption of infected animals or occupational exposure to contaminated animal 
products with person-to-person transmission not possible [218]. B. anthracis has 
evolved slowly due to the alteration from a short lived vegetative phase (20-40 
replications) to a metabolically dormant endospore phase which can persist for decades 
[219] [220]. The potential for B. anthracis to be used as a bioterrorism and/or 
biowarfare agent, as highlighted by the 2001 anthrax letter attacks in the USA, has 
greatly promoted recent research into this organism. The characteristics that provide 
the potential for the hostile use of B. anthracis are briefly outlined below together with 
a description of the clinical disease. 
  
51 
 
Figure 1-3 Global map of anthrax endemicity. 
Produced by the World Health Organization Collaborating Center for Remote Sensing 
and Geographic Information Systems for Public Health. While the absolute numbers of 
incident cases are not likely to be high on an annual basis, large geographic areas of 
endemicity occur across much of the world including Central America, the Andean 
region of South America, sub-Saharan Africa, and Central, South, East, and Southeast 
Asia [221]. 
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 The B. anthracis endospore 1.6.1
 
The B. anthracis endospore, Figure 1-4, confers survival advantages for the bacterium 
both within the environment together with infection, immune evasion and persistence 
within the host. Following infection, endospores are taken up by phagocytic cells and 
trafficked to draining lymph nodes where germination into vegetative cells occurs. 
Germination signals for B. anthracis endospores include small molecules found within 
suitable host cells such as amino acids and nucleosides, for example L-alanine and 
inosine. These host molecules bind to receptors within the endosporium membrane 
initiating a cascade which rehydrates the cell, activates intracellular proteases and 
extracellular hydrolases that degrade the coat and cortex together with the activation of 
proteins within the core leading to the emergence of a vegetative cell [222] [223]. 
 
 Virulence factors 1.6.2
B. anthracis possess two virulence plasmids: pXO1 and pXO2. pXO1, a 182kb 
temperature sensitive plasmid encodes the enzymatically active Lethal Factor (LF) and 
Edema Factor (EF) which combine with Protective Antigen (PA), a cell surface binding 
protein producing Lethal Toxin (LT) and Edema Toxin (ET) respectively [224] [225]. pXO2, 
a 96kb plasmid encodes the biosynthetic genes for the poly-D-glutamic acid capsule 
[226] required for immune evasion and intracellular survival within macrophages [227]. 
The capsule and toxins are the key phenotypic characteristics distinguishing B. anthracis 
from other closely related Bacillus species where lack of either plasmid results in 
attenuation [228]. 
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Figure 1-4: Structure of the B. anthracis endospore. 
Several intrinsic characteristics allow endospore persistence and appropriate 
germination. At the centre of the endospore is the core, composed of the B. anthracis 
chromosome bound to small acid-soluble proteins [229]. The core is surrounded by the 
cortex, a thick layer of peptidoglycan which itself is enclosed within the inner and outer 
layers of the endospore coat; a proteinaceous layer that forms a thick shell to maintain 
endospore dehydration and protection of genomic material prior to germination [222]. 
The endospore coat is in turn enclosed within the exosporium, consisting of a basement 
membrane and fine hair-like projections protecting the nap [230]. The nap is primarily 
composed of Bacillus collagen-like protein A (BclA), a 21 kDa glycoprotein that mimics 
C1q of the Complement system [231] and is thought to play a role in resisting host 
defence mechanisms. 
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1.6.2.1 Toxins 
Initial evidence for B. anthracis toxins came when filtered serum from B. anthracis 
infected guinea pigs killed recipient animals when injected i.v. [232]. Purification 
revealed two toxins that had a central common receptor binding protein, Protective 
Antigen (PA) [233-235]. PA was elucidated to be the common receptor binding protein 
for the formation of ET and LT, is required for toxin mediated pathology within the host 
and is also the primary vaccine and therapeutic target for B. anthracis. PA binds host 
cells via an extracellular domain of either of the anthrax toxin receptors (ATRs) trans-
epithelial membrane 8 (TEM8) or capillary morphogenesis factor 2 (CMG2) with a metal 
ion dependent adhesion site essential for PA binding [236]. After binding to an ATR, 
PA83 is cleaved by cell surface furin to release a 20 kDa polypeptide (PA20) from the N-
terminus and expose a binding site for LF or EF [237],  [238]. The cell bound PA63 self 
assembles to form a heptameric pore allowing LF and EF endocytosis into the cell. This is 
both lipid raft dependent and clathrin-mediated, delivering the toxins into the cytosol 
where they exert their toxic effects [239].  LF is a 90 kDa zinc metalloproteinase [240] 
that cleaves the N-terminal portion of mitogen-activated protein kinase kinases 
(MAPKKs). MAPKKs are important for cell signalling pathways and their disruption 
affects ERK1/2, JNK/SAPK and p38. This affects phosphorylation and transcription in the 
nucleus, inhibiting protein synthesis [241]. LT has a lytic effect on murine macrophages 
[242] and has been shown to have proinflammatory but non-cytotoxic effects on other 
cells leading to vascular collapse, shock and death [243]. EF is a 92 kDa calmodulin-
dependent adenylate cyclase [244] initially characterised by the oedema caused [234] 
but also modulates many cell signalling pathways via cAMP production. During the early 
stages of infection LT and ET suppress cytokine and cellular immune responses including 
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IL-12p70 and TNF production but with no effect on IL-10 resulting in the terminal 
differentiation of T cells with a Th2 bias [245] allowing bacterial growth and 
dissemination through the host [246]. 
1.6.2.2 Capsule 
Encapsulation by bacteria is a widely exploited mechanism to evade the immune 
system. The B. anthracis poly-γ-D-glutamic acid capsule is produced by a four gene 
biosynthetic operon, CapBCAD. Although the role of the capsule in pathogenesis is 
unclear, its synthesis is required for virulence and unencapsulated strains are 
attenuated, for example the Sterne strain, which is used as a veterinary vaccines [247]. 
The capsule enables disease to establish by protecting the bacillus against Complement 
fixation and phagocytosis. There is evidence to suggest that encapsulated strains may 
inhibit DC maturation [248] and reduce cytokine production compared to 
unencapsulated strains [249]. 
 
 Clinical disease 1.6.3
Humans are typically considered as accidental hosts for B. anthracis and compared to 
other bacterial pathogens, cases of anthrax in humans are rare. The symptoms and 
lethality of anthrax are primarily the result of systemic septicaemia and toxin production 
and although antibiotic treatment can clear the bacterium the systemic distribution of 
toxins can still be fatal [250]. The route of infection determines key clinico-pathological 
features that currently classify anthrax into three naturally occurring forms: cutaneous 
anthrax and the more aggressive gastrointestinal anthrax and inhalational anthrax; 
together with the more recently documented injectional anthrax. 
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Cutaneous anthrax forms the majority of clinical cases and many of those presenting 
with cutaneous anthrax have a history of working with animals or animal products. 
Infection is often aided by cuts and abrasions to exposed areas of the body with the 
legs, arms, hands, face and neck the most commonly affected areas. The initial 
manifestation includes a painless pruritic erythema which over the course of 48 – 72 
hours evolves into a papule or multivesicles with local oedema. By day seven the papule 
breaks leaving a painless ulcer with the characteristic black centre, an eschar [251]. 
Symptoms can include fever, malaise, toxaemia, oedema and lymphadenitis. 
Approximately 80% of cases resolve spontaneously, although secondary bacterial 
infections are common whilst in some outbreaks up to 20% of cases can be fatal [252]. 
The recommended treatment for cutaneous anthrax consists of ciprofloxacin, 500 mg 
orally twice daily or doxycycline, 100mg orally twice daily for 60 days. 
 
Gastrointestinal anthrax is caused by the consumption of contaminated meat that has 
not been thoroughly cooked. Diagnosis is difficult due to the non-specific clinical 
symptoms and can be fatal in 25-60% of cases [253]. Gastrointestinal anthrax consists of 
three phases; the first with non-specific flu-like symptoms, within 24 – 72 hours disease 
can progress to the second phase where symptoms can include abdominal pain, fever, 
nausea, anorexia, vomiting and diarrhoea, whilst in final phase the abdomen is 
distended with ascites, haemorrhage of the mesenteric lymph node, and 
gastrointestinal bleeding due to ulcers [253,254] [255]. 
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Inhalation of B. anthracis spores can lead to their deposition within the alveoli of the 
lower respiratory tract. As infection occurs distal to the lungs it is termed inhalational 
rather than pulmonary anthrax. The lungs are typically regarded as a gateway for 
ungerminated spores to access the body and to be translocated to the lymphatic system 
via phagocytic cells, particularly alveolar macrophages and lung DCs. Phagocytosis of 
spores causes the maturation of phagocytic cells and their migration to lymph nodes 
where subsequent germination occurs intracellularly [222]. This is followed by 
proliferation of vegetative cells and dissemination via the circulatory system and the 
production of anthrax toxin which suppress the host immune response. The innate 
response to ungerminated spores is limited whilst extracellular germinated spores are 
much more susceptible to host innate immune responses and are thus significantly less 
infectious [256]. The integrin Mac 1 (CR3 or CD11b/CD18) found on polymorphonuclear 
cells, natural killer (NK) cells and mononuclear cells mediates internalisation of B. 
anthracis spores [257]. Within lymph nodes, spores germinate resulting in a severe and 
acute infection that is fatal in the majority of untreated cases. Inhalational anthrax is a 
biphasic disease, the initial phase appears benign with non-specific flu like symptoms 
that persist on average for four days  [258]. The second phase is characterised by severe 
acute respiratory distress, shock and death with a mean duration of one day [258]. 
Further symptoms can include fever, lung abnormalities, chills, tachycardia, fatigue or 
malaise, cough, dyspnea or meningoencephalitis. The two most prominent findings in 
inhalational anthrax are pleural effusions with large numbers of bacilli on the pleural 
surface together with edema and haemorrhage of the mediastinal lymph nodes  [252]. 
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A fourth form of anthrax, injectional anthrax, was first described during 2000 [259] in a 
heroin injecting drug user in Norway. It is transmitted by subcutaneous, intramuscular 
or intravenous injection of contaminated drugs [260]. There were 52 laboratory 
confirmed cases in the UK during an outbreak in 2009-10 with contaminated heroin 
from central Asia the likely source. Typical presentations include edema surrounding the 
injection site often resulting in compartment syndrome or necrotising fasciitis [261]. 
Complications can include septic or cardiovascular shock, meningitis with death 
occurring in over 30% of patients despite antibiotic therapy [262]. 
 
 Vaccination 1.6.4
Louis Pasteur demonstrated in 1881 that an attenuated B. anthracis vaccine was 
efficacious in protecting sheep, cows and goats against disease. Attenuation was 
achieved by culturing the bacterium at high temperatures (42-43 °C) for 10-20 days to 
prevent sporulation [263]. This veterinary vaccine was in regular use until 1935 but as 
the degree of attenuation was highly variable [264] sporadic vaccine-associated 
outbreaks occurred [265].  The current veterinary vaccine for B. anthracis remains a live 
attenuated strain, Sterne [264] [266]. The Sterne strain is a non-capsulated, toxigenic 
strain isolated by extended culture on 50% horse serum agar in a 20% CO2 atmosphere. 
This proved to be safer than heat attenuated cellular vaccines with less frequent and 
severe reactions to inoculation [267]. The toxigenic, unencapsulated B. anthracis STI 
strain has been used as a live attenuated vaccine to protect healthy adults in the former 
USSR and was considered to provide better protection than acellular vaccines 
manufactured in the UK and USA [268]. 
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Early studies for the development of an acellular vaccine used sterile oedema fluid from 
B. anthracis infected animals as a protective immunising agent [269] with protection 
postulated to be mediated by a protein (PA) [270]. The development of the currently 
licensed UK Anthrax Vaccine Precipitate (AVP) and US Anthrax Vaccine Adsorbed (AVA) 
occurred concurrently [271] [272]. AVP is a sterile culture filtrate from B. anthracis 
Sterne 34F2 strain [273] with the antigenic component precipitated by the addition of 
alum (aluminium potassium sulphate). The vaccine contains detectable amounts of PA, 
LF and EF together with two cell associated s-layer proteins Sap and EA.1. Each is 
antigenic although it is unclear, with the exception of PA, how they contribute to the 
protective efficacy of the vaccine [274]. AVA is prepared from B. anthracis V770-NP1-R 
strain, with the antigenic component being adsorbed onto aluminium hydroxide gel and 
contains little EF and LF compared to AVP.  Both vaccines are protective as they 
generate IgG antibodies capable of toxin neutralisation whilst maintaining an intact host 
immune response capable of clearing the bacterium. Both have several limitations, 
including the duration of the primary schedule, annual boosters and reactogenicity and 
as a result they are generally only offered to personnel considered to be at high risk of 
B. anthracis exposure. The duration of vaccine immunity is unclear with circulating anti-
PA antibodies currently used as an indicator of protection [275] [276]. However PA-
specific IgG memory B cells may be important following re-exposure to B. anthracis 
following a decline in circulating antibodies [277] [278]. It is also likely that a CMI 
response is required to fully eradicate the infection and clear ungerminated spores, an 
immune characteristic vaccines formulated in alum are poor at inducing.  
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1.7 Current treatments 
Successful treatment of anthrax requires rapid diagnosis and administration of 
antimicrobial therapies, there is however limited experience in the identification and 
treatment of anthrax for the majority of clinicians. Treatment is intravenous in patients 
with a fulminant bacteraemia followed by oral antibiotics for 60 days. Currently two or 
more antimicrobial therapies are recommended with ciprofloxacin or doxycycline used 
for initial intravenous therapy. Intravenous ciprofloxacin, 400 mg every 12 hours or 
doxycycline, 100 mg every 12 hours are administered with oral antimicrobials provided 
when symptoms improve. Other potential therapies include rifampin, vancomycin, 
imipenem, chloramphenicol, penicillin and ampicillin, clindamycin and clarithromycin. 
Toxin-meditated morbidity is a major complication of systemic anthrax and 
corticosteroids have been suggested as adjunct therapy for the oedema, respiratory 
complications and meningitis associated with pulmonary anthrax [279]. For cutaneous 
anthrax, ciprofloxacin and doxycycline are also the preferred therapies. For both 
pulmonary and cutaneous anthrax, treatment regimens are recommended for 60 days 
to prevent reactivation of latent infection although it is likely that the bacterial spores 
will be cleared in a far shorter time frame. Antibiotic prophylaxis consists of 
ciprofloxacin 500 mg twice daily or doxycycline 100 mg twice daily taken orally for 60 
days. However, disease progression can be rapid, particularly following the inhalation of 
spores, with antibiotic therapy often insufficient to prevent fatalities, primarily due to 
systemic septicaemia and toxin production. Furthermore, despite prolonged 
antimicrobial therapy, some latent spores may persist to cause disease at a future time-
point [280]. Recently a monoclonal antibody therapy, raxibacumab, has been developed 
for the prophylactic and therapeutic treatment of inhalation anthrax. The monoclonal 
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antibody targets the PA component of anthrax toxins, blocking PA binding to its 
receptors [281].  
 
 Mouse models 1.7.1
Evaluation of anthrax vaccines and therapies relies on animal models [264] with the 
development and licensure of new products reliant on the FDA “Animal Rule”. 
Introduced in 2002 following the 2001 US Postal anthrax attack,  the Animal Rule 
enables appropriate studies in animals for certain diseases to provide substantial 
evidence towards licensure for new drugs and biological products for which adequate 
and well controlled clinical studies in humans cannot be ethically conducted and field 
efficacy studies are not feasible [282]. The testing of products for anthrax relies on the 
use of appropriate animal species and strains as many species are extremely susceptible 
to one or more anthrax virulence factor.  
 
Mice are highly susceptible to challenge with wild type (encapsulated, toxigenic) B. 
anthracis strains and to encapsulated non-toxigenic strains, succumbing at the same 
rate and LD50 as fully virulent strains [283]. Consequently, murine studies examining 
toxin responses for example vaccine studies, utilise toxigenic (pX01+) non-encapsulated 
(pX02-) strains, such as B. anthracis Sterne or STI [264] [284]. Additionally different 
inbred mouse strains show differences in susceptibility to B. anthracis infection, with 
immunocompetent mice resistant to infection with non-encapsulated toxigenic strains 
[285]. Consequently mice that are unable to control multiplication of the non-
encapsulated bacteria are used. To achieve this A/J or DBA/2 mice were used as they  
have a deficiency in the C5 component of the Complement cascade resulting in impaired 
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recruitment of neutrophils, monocytes and macrophages [286] with increased bacterial 
load and thus increased toxin production resulting in death due to toxaemia [287].  
 
 Biothreat 1.7.2
Biological weapons are unlike any other weapon as they can reproduce or persist in an 
environment, potentially making the contaminated area more dangerous over time or 
requiring decontamination. Furthermore if the organism is contagious humans can act 
as walking bombs, spreading disease [288].  Although B. anthracis is not transmissible 
from person-person or can cause global pandemics it is still regarded as one of the most 
likely candidates for a bioweapon due to its ease of dissemination, ability to survive in 
the environment, severe course of infection, aerosol infectivity and low infectious dose 
[288]. B. anthracis is classified by the Centers of Disease Control and Prevention (CDC) as 
a Category A bioterrorism agent, as in addition in the above characteristics it has the 
potential to: result in high mortality rates and have the potential for major public health 
impact; might cause public panic and social disruption; and require special action for 
public health preparedness [289]. 
 
The development of microorganisms as biological weapons accelerated in the US and 
the former USSR following the conclusion of the Second World War with the 
recommendation from a US committee for the development of an offensive and 
defensive biological programme in response to the Soviet threat [290]. Over the 
subsequent 20 years the US developed an arsenal of biological agents [288]. The 1972 
Biological Weapons Convention (BWC) aimed to remove the risk of biowarfare with 
signatories agreeing “not to develop, produce or stockpile, acquire or retain biological or 
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toxin agents in quantities that have no justification for prophylactic, protective or 
peaceful purposes” [291]. The weakness of the BWC was underlined in 1979 when an 
outbreak of anthrax occurred in Sverdlovsk, USSR. The outbreak originated from a 
military facility and resulted in the deaths of at least 66 civilians [288]. Post-mortem 
studies on the victims of the Sverdlovsk accident showed that the rapid death of the 
victims was correlated with both systemic bacterial infection and the effects of anthrax 
toxins on numerous cell types [292]. Only at the end of the Cold War was this 
acknowledged and the offensive Soviet programme revealed [288]. 
 
Intentional anthrax attacks, whilst rare, have the potential for major disruption and loss 
of life. An attempted attack in Tokyo during 1993 resulted in the release of B. anthracis 
spores from an eight-storey building. This was one of several failed attacks primarily due 
to the use of the attenuated Sterne strain [293]. The US postal anthrax attacks of 2001 
resulted in the deaths of five people, the infection of 17 other people and prophylactic 
antibiotics being administered to more than 30,000 people [294]. The attacks, whilst 
resulting in a relatively small number of fatalities, closed much of the Federal 
government in Washington DC, underlining the potential for disruption caused by 
bioweapon attacks. 
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1.8 Burkholderia pseudomallei 
Burkholderia pseudomallei, the etiological agent of melioidosis, is a Gram-negative, 
intracellular, asporogenic, motile bacillus, found widely throughout Southeast Asia and 
northern Australia together with other tropical and subtropical regions (Figure 1-5) . The 
Burkholderia genus consists of at least 43 species [295] [296] with the majority being 
non-pathogenic. However a few, including B. pseudomallei, B. mallei and B. cepacia 
cause severe life-threatening infections [297]. B. pseudomallei presents a global 
emerging disease problem [298] and is also regarded as a bioterrorism threat. 
 
The natural habitat of B. pseudomallei is still or stagnant water, rice paddies and moist 
tropical soil. A host is not required for environmental persistence [299] with B. 
pseudomallei being an opportunistic pathogen of both mammalian and non-mammalian 
hosts [300]. Melioidosis can manifest as an asymptomatic condition, a chronic disease 
frequently establishing latency within an intracellular niche, through to an acute disease 
with overwhelming septicaemia and a mortality rate as high as 50% in northeast 
Thailand [301]. B. pseudomallei infections are difficult to treat due to the absence of a 
licensed vaccine for prophylaxis, resistance of the bacteria to multiple antibiotics, ability 
to form biofilms and the establishment of a chronic, intracellular infection. 
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Figure 1-5: Melioidosis endemic regions.  
The map highlights the areas where melioidosis has been diagnosed or has been 
suspected. Red: definite cases where the organism has been isolated from soil or water 
with adequate identification by culture or B. pseudomallei-specific PCR, and evidence for 
melioidosis having been acquired in that country; Orange: probable cases but a failure 
to isolate B. pseudomallei from soil or water, and evidence for melioidosis having been 
acquired in that country; Yellow: possible cases where a member of the Burkholderia 
genus was isolated from soil or water that was considered to be B. pseudomallei, but 
the identification process was not sufficient to exclude other, non-pathogenic 
environmental Burkholderia spp. such as B. thailandensis, and no evidence for 
melioidosis having been acquired in that country [302]. 
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 Virulence factors 1.8.1
A critical component of B. pseudomallei pathogenesis is the ability to survive 
intracellularly both within phagocytic and non-phagocytic cells, allowing the bacterium 
to establish an infection whilst avoiding the host response  [303] [304]. The intracellular 
nature of B. pseudomallei helps explain some of the bacterium’s ability for latency, 
recrudescence and treatment difficulty [304]. B. pseudomallei has numerous virulence 
factors that enable it to enter, survive and exploit the intracellular niche. These include 
quorum sensing, capsular polysaccharide, type III secretion systems and 
lipopolysaccharide (LPS). These aid virulence by enabling cell adhesion, invasion, 
endosome escape, actin based motility, formation of multi-nucleated giant cells 
(MNGC), evasion of autophagy and interaction with host cell ubiquitination mechanisms 
[304].  
 
Quorum sensing is a cell density dependent communication system used by Gram-
negative bacteria utilising N-acyl-homoserine lactones (AHL) for the coordination of 
gene expression [305]. Quorum sensing relies on LuxI proteins for AHL biosynthesis with 
LuxR transcriptional regulators mediating gene expression. B. pseudomallei has three 
LuxI and five LuxR quorum sensing homologues [306]. Quorum sensing by B. 
pseudomallei is dependent on the BpeAB-OprB efflux pump [307], this and the AmrAB-
OprA and BpeEF-OprC efflux pumps help confer resistance to multiple antibiotics 
including aminoglycosides, macrolides, chloramphenicol and trimethoprim as well as 
enabling biofilm formation [308] [309]. Disruption of the genes responsible for quorum 
sensing in B. pseudomallei increases the LD50 and the time to death whilst decreasing 
organ bacterial colonisation [306]. 
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The B. pseudomallei extracellular capsule is a polysaccharide with the structure -3)-2-O-
acetyl-6-deoxy-β-D-manno-heptopyranose-(1- and is a major virulence factor [310]. 
Capsule expression is induced in the presence of serum and is required for virulence in 
animal models [311]. Capsule-deficient mutants undergo greater phagocytosis due to 
deposition of the Complement factor C3b on the cell surface [311]. Additional resistance 
to Complement is provided by bpaC, with bpaC mutants sensitive to both the classical 
and lectin pathways [312]. 
 
Type three secretion systems (T3SS) act as a molecular syringe, injecting pathogen 
effector proteins into the target cell cytosol, subverting host cell processes and aiding 
cell invasion [313] [314], although there is conflicting data surrounding the role of the 
importance of T3SS in cellular invasion [315]. The B. pseudomallei T3SS and Burkholderia 
secretion apparatus (bsa) share homology with other Gram-negative bacteria T3SS 
enabling escape from endocytic vacuoles, intercellular spread and pathogenesis [316] 
with mutations to the Bsa T3SS resulting in bacterial attenuation [298]. Following escape 
from endocytic vacuoles the T3SS enables bacterial propulsion through the cytoplasm by 
actin polymerization [317]. Cell to cell spread and the development of multinuclear giant 
cell (MNGC) is dependent on the B. pseudomallei Type six secretion system (T6SS) and 
aids the avoidance of host immune mechanisms [318].  
 
The LPS of B. pseudomallei is unable to trigger host immune responses such as nitric 
oxide synthase and TNF production when compared to other Gram-negative bacteria, 
for example E. coli [319]. As a consequence the TLR4 signalling pathway is not activated 
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and does not have a defensive role in experimental melioidosis [320]. B. pseudomallei 
infection is therefore able to supress macrophage effector mechanisms including the 
production IFNγ, key for production of nitric oxide (NO) an important antimicrobial 
molecule required for the clearance of many intracellular pathogens [304].   
 
Other virulence factors include Type 4 pili and the B. pseudomallei flagella. The ability of 
B. pseudomallei to adhere to and invade cells is directly correlated with virulence [321] 
with deletion of the pilus structural protein (PilA) resulting in reduced adherence in vitro 
and virulence in vivo [322]. Aflagellate mutants have been shown to exhibit reduced 
virulence in vivo with a decrease in bacterial colonisation of lung and spleen [323]. 
 
 Clinical disease 1.8.2
The majority of melioidosis cases are reported in Thailand and northern Australia where 
melioidosis is the third most frequent cause of death from infectious disease. The most 
frequent routes of infection are inoculation via skin cuts or abrasions, inhalation and 
ingestion. It is often difficult to identify a defined inoculating event as systemic 
dissemination with multi-organ involvement is a frequent outcome, and although 
pneumonic disease is  a common occurrence it is not an accurate indicator of inhalation 
of the bacterium [324] [325]. Inoculation via the skin presents the greatest number of 
cases although a higher number of pneumonic cases are observed during the rainy 
season with 75% of all cases presenting during this period, often with acute pneumonia 
and septicaemia  [326].  
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Clinical melioidosis has many manifestations that make it difficult to differentiate from 
other febrile tropical diseases [327]. The duration between initial exposure to B. 
pseudomallei and onset of clinical melioidosis is highly variable, with an average 
incubation period of 9 days before the onset of symptoms [324]. This incubation period 
is likely to be dependent on the inoculation dose [324] and latency can be extremely 
long, with a maximum reported duration of 62 years in a World War Two veteran[328].   
 
Clinical symptoms can be extremely variable but can include fever, headache, joint and 
muscle pain or ulceration associated with a septicaemic illness due to bacterial 
dissemination [325]. The lungs are the most commonly affected organ irrespective of 
route of infection, occurring in approximately 50% of all cases and indicate the highest 
mortality rates [324] [329] with untreated septicaemic cases having a mortality rate of 
up to 70% [330]. Additionally the liver and spleen are also commonly affected by 
multiple abscesses. Further clinical presentations include osteomyelitis, septic arthritis, 
superficial pustules, pyomyositis, neurological infections, genitourinary infections, 
prostatic abscesses and pericarditis [324] [331].  
 
Patients with acute melioidosis require intensive care treatment, many however 
contract the disease in regions where these resources are not available and this is 
reflected in the mortality rates of 50% for Thailand and 20% for Australia [332]. Acute 
septicaemic melioidosis elicits a strong proinflammatory cytokine response with high 
levels of IFNγ, IL-12, IL-15 and IL-18 present in infected patients compared to non-
septiceamic patients [333]. Additionally, fatal melioidosis is characterised by elevated 
levels of TNF, IL-6 and IL-10 [334] and the chemokines CXCL9 and CXCL10 [335]. It is 
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unclear as to whether these contribute to a poor outcome or are merely indicative of 
disease severity [336].  
 
Melioidosis often affects individuals with one or more pre-existing conditions associated 
with an altered immune system, particularly impairment of neutrophil function [332]. 
Conditions include diabetes mellitus (a risk factor in 37-60% of cases) chronic renal 
failure,  chronic liver disease, chronic lung disease, alcoholism, thalassemia and 
immunosuppressive therapies with one or more of these found in 60-90% of cases 
[326]. The majority of those exposed to B. pseudomallei do not develop active disease 
with approximately 80% of children in northeast Thailand having anti-B. pseudomallei 
antibodies by 4 years of age whereas only 0.0045 % of the population contracts disease 
annually [337]. 
 
Asymptomatic seropositive individuals have a stronger CMI response compared to those 
with a history of clinical melioidosis [338]. However, antibody titres for IgG, IgA and IgM 
are positively correlated with disease severity [332]. This suggests that an appropriate 
adaptive immune response may protect against disease and whilst CD4+ T cells are 
important for late host resistance in murine melioidosis [339] there is no negative 
association between HIV and human melioidosis, indicating a limited role for CD4+ T 
cells [332]. 
 
 Vaccination  1.8.3
Currently there is no licensed vaccine available to protect against melioidosis. There is 
thus a requirement for a vaccine capable of providing prophylactic protection for 
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susceptible populations living in melioidosis endemic areas and for visitors to those 
regions [297]. The development of a successful vaccine could have the additional benefit 
of inducing appropriate immune responses in individuals suffering from chronic 
melioidosis, aiding bacterial clearance alongside traditional antibiotic therapy. A 
successful vaccine would ideally provide sterilising immunity, by inducing antibody and 
CMI responses with a Th1 bias with associated IFNγ production important for survival 
[340]. However they could also be beneficial in delaying the onset of bacteraemia and 
septic shock or extending the window of opportunity for antibiotic therapy [297].  
 
To date B. pseudomallei vaccine development has explored strategies utilising live 
attenuated strains, killed whole cells, subunit vaccines, DNA vaccines and DC 
vaccination; each of these approaches are briefly described. Live attenuated vaccines 
(LAV) have a long history of successful use preventing diseases such as smallpox, polio 
and measles. LAV work by replicating within the host, stimulating a robust cellular and 
humoral memory immune response capable of protection before being cleared from the 
host. An additional benefit is that they often only require one immunising dose. This 
approach has been explored for the development of a B. pseudomallei vaccine with the 
use of defined B. pseudomallei mutants, however these have had limited success.  
 
A B. pseudomallei ilvI mutant and a purN- and purM- mutant which impacted upon  
synthesis of branched chain amino acids and purine biosynthesis respectively were both 
able to protect in an acute but not chronic disease model [341] [342] [343]. A B. 
pseudomallei bipD mutant with a dysfunctional TTSS provided partial protection [298] 
whilst an acapsular mutant failed to provide protection against challenge [341]. The 
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immune response to the acapsular mutant [341] was characterised with increased IFNγ 
production by CD4+ and CD8+ T cells in response to antigen recall. CD4+ T cell depletion 
resulted in decreased survival and mice succumbed to infection at the same rate as 
controls whilst CD8+ T cell depletion had no statistically significant impact on protection. 
This unusual response for an intracellular bacterium may be due to the immunising 
bacteria being attenuated and were thus less capable of invading host cells causing 
disease, reducing the host’s ability to generate a protective cytotoxic T cell response in 
this model [344]. As there was incomplete clearance the potential remains for the 
requirement for CD8+ T cells to clear B. pseudomallei [344]. More recently a strain of B. 
thailandensis, E555, with a capsule similar in structure to B. pseudomallei, was able to 
provide significant protection with no mice succumbing to disease but with incomplete 
clearance [345]. However safety concerns relating to LAV, particularly the potential for 
reversion to virulence and the fact they can cause disease in immunocompromised 
individuals, the major group associated with active melioidosis, means that a LAV for B. 
pseudomallei is an unlikely clinical option [346]. 
 
Killed whole cell (KWC) vaccines, such as the oral cholera vaccine and the previously- 
used Bordetella pertussis vaccine, have the advantage over LAV in that they are unable 
to replicate within the host and are thus much safer. KWC vaccines are able to induce 
strong antibody responses with good protective effects against extracellular bacteria but 
are poor inducers of cellular responses and are less effective against intracellular 
bacteria [347]. There have been mixed results for KWC vaccines used against B. 
pseudomallei with multiple low doses of a KWC vaccine being poorly immunogenic and 
unable to protect mice [348] whilst high doses have shown significant protection against 
73 
 
homologous and heterologous challenge [349]. KWC vaccines are limited by the 
requirement for multiple immunising doses together with the risk of reactogenicity and 
adverse effects. For example the KWC B. pertussis vaccine has been replaced with a 
much safer, if less immunogenic, acellular vaccine [346]. 
 
Subunit vaccines utilise discrete bacterial components with toxoid vaccines available for 
anthrax, tetanus and diphtheria and capsular polysaccharide vaccines for meningococcal 
and pneumococcal diseases [350]. The passive transfer of monoclonal antibodies against 
B. pseudomallei LPS or the capsular polysaccharide were protective against low (104 
CFU) but not higher (106 CFU) challenge doses [351]. The immunisation of mice with 
either of the antigens induced a high titre antibody response and both provided partial 
protection against i.p. but not aerosol challenge [352]. Using B. thailandensis LPS 
produced a similar result with limited protection and incomplete clearance [353]. More 
recently B. pseudomallei LPS conjugated to the Hc fragment of tetanus toxin has 
provided significant protection with reduced bacterial load, again without sterilising 
immunity [354].  
 
Defined bacterial antigens including the ABC transporters LolC, PotF and OppA [355]; 
the outer membrane proteins Omp3, Omp7 and Omp85 [356] [357] and components of 
the TTSS BipB, BipC and BipD [358] have been evaluated as potential vaccine candidates. 
Of these LolC, PotF, Omp3, Omp7 and Omp85 were found to provide protection against 
B. pseudomallei but with incomplete clearance  [355] [356] [357]. DNA vaccines have 
also been trialled with plasmid DNA encoding the flagellum protein fliC inducing a 
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humoral and cellular immune response with increased survival and decreased bacterial 
load [359]. 
 
DC vaccination has shown that DCs pulsed with heat-killed B. pseudomallei (i.d.) 
simultaneously administered with heat-killed B. pseudomallei in alum (i.m.) enhanced 
survival following lethal challenge, compared to mice receiving pulsed DCs or heat-killed 
B. pseudomallei in alum only. DC vaccination induced a substantial CMI response whilst 
heat-killed B. pseudomallei in alum induced a predominantly antibody response; the 
combined vaccination strategy produced both an antigen-specific CMI and antibody 
response associated with enhanced survival [86]. In a subsequent study, DCs pulsed with 
heat-killed B. pseudomallei and CpG were able to induce both a strong antigen-specific 
CMI and antibody response in vivo in the absence of a vaccination containing heat-killed 
B. pseudomallei formulated in alum. This approach protected 90% of mice against lethal 
challenge and demonstrated the potential benefit of appropriate adjuvant stimulation 
of DCs during ex vivo antigen pulsing [85].  
 
Taken together, whilst there are encouraging results in the ability of melioidosis 
vaccines to provide protection and reduce bacterial load, no vaccine to date has been 
able to provide complete clearance. For that reason, post-exposure therapies (including 
vaccines) are required to eliminate the bacterium from the host. To that end novel post-
exposure vaccines such as DC vaccination offer an alternative method to activate the 
immune system in an effort to eradicate the bacterium. 
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 Current treatments 1.8.4
Diagnosis of melioidosis relies on a limited number of methods with a positive culture 
being the gold standard, although a negative culture does not rule out melioidosis as 
patients may already be taking effective antimicrobials [360]. Serodiagnosis has no value 
in melioidosis endemic areas due to the background seropositivity of the healthy 
population but may be of some use for those with no previous history of visiting 
endemic areas [325]. 
 
B. pseudomallei is inherently resistant to numerous antibiotics including penicillin, first 
and second generation cephalosporins, macrolides, rifamycins, colistin and 
aminoglycosides [361] [326]. This is due to possession of efflux pumps that are capable 
of removing antibiotics from the cell together with the ability to form biofilms, reducing 
the surface area exposed and the permeability of the bacterial membrane to antibiotics. 
Resistance to antibiotics makes B. pseudomallei difficult to treat [362] and relapse 
frequently occurs when antibiotic treatment ends [363] as the bacterium can persist in 
the body to become reactivated later in life [364]. 
 
Successful treatment of melioidosis relies on rapid antimicrobial therapy as delayed or 
ineffective therapy is associated with a high mortality rate [365]. Initial therapy lasts for 
10-14 days, or until a clinical response is seen and can last for more than four weeks. 
Therapy consists of i.v. ceftazidime 50 mg/kg every 6-8 hours or carbapenem 25 mg/kg 
every 8 hours. Once a clinical improvement has been observed together with the 
absence of fever for 48 hours and a negative blood culture, treatment switches to oral 
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therapy consisting of co-trimoxazole alone (Australia) or in combination with 
doxycycline (Thailand) for 12-20 weeks guided by clinical response to therapy [325]. 
 
Antibiotic treatment is usually not fully effective with frequent relapses occurring 
despite the long treatment course. Recurrent melioidosis occurs in 5-25% of cases and is 
associated with a further mortality of 24% in Thailand [325]. This occurs when B. 
pseudomallei can be isolated from a patient who has completed a course of 
antimicrobial therapy with documented evidence of recovery or alternatively reinfected 
with a different strain [325]. Where recurrent melioidosis is due to the reactivation of a 
latent infection, this often occurs due to a decrease in the immunocompetence of an 
individual and can result in an acute, fatal infection [366]. 
 
 Mouse models 1.8.5
Three small animals of melioidosis have been predominantly used to identify virulence 
factors and evaluate treatments, including antibiotics and vaccines. The hamster and 
infant diabetic rat models are both highly susceptible to B. pseudomallei and are acute 
models with the majority of deaths occurring between 2 and 7 days [367]. Here I will 
concentrate on murine models as these are the most commonly used, best 
characterised and used exclusively in this study.  
 
The majority of studies have modelled acute disease within the first few weeks of 
infection and despite the long term latency and re-emergence of B. pseudomallei being 
a significant problem for clinical melioidosis, very few studies have modelled this in mice 
[368]. Despite their relative resistance to B. pseudomallei, chronic infections using 
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C57Bl6 mice are still lethal within a few months and the immune mechanisms of the 
later stages of chronic infection are unknown. Murine models for B. pseudomallei 
generally utilise susceptible BALB/c and resistant C57Bl/6 mice as acute and chronic 
models of disease respectively, with approximately a 100-200-fold difference in 
susceptibility [369].  Infection routes include aerosol, intranasal (i.n.) and intraperitoneal 
(i.p.) with B. pseudomallei more virulent when given as an aerosol or i.n. compared to 
i.p. due to pneumonic involvement [368]. The use of different infection routes makes 
direct comparison between experiments difficult.  
 
The 50% lethal dose (LD50) is about 100 times greater for C57Bl/6 mice compared to 
Balb/c mice when challenged i.n., with the development of bacteraemia in the lungs and 
spleen. Although the LD50 for Balb/c mice is dependent on the B. pseudomallei strain 
used, it is typically characterised by rapid death. However reducing the challenge dose 
can alter this model, for example low dose i.p. challenge of Balb/c mice (6 CFU) results in 
an undetectable bacterial persistence beyond 5 days suggesting that mice surviving 
challenge clear bacteria with a low likelihood of chronic persistence [370]. 
 
The resistance to B. pseudomallei by C57Bl/6 mice is due to both innate and adaptive 
immune responses. Peritoneal macrophages efficiently control the early stage of 
infection [369] whilst C57Bl/6 mice also produce serum (IgG) and mucosal (IgA) 
antibodies [371] and have a greater IgG2a response compared to Balb/c mice indicative 
of a Th1 bias [372]. Rapid IFNγ production is important for survival in all models with 
IFNγ-/- rapidly succumbing to disease [340] [373]. Depletion of IFNγ increases the 
susceptibility of mice to disease [340] whilst supplementation with IFNγ in Balb/c mice 
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increases survival [374]. Although Balb/c mice produce higher levels of TNF, IL-6 and IL-
1β this response is implicated in contributing to the acute nature of disease due to 
increased pathology [375]. Taken together this may indicate that a proinflammatory 
response in Balb/c mice does not contribute to mortality but a reduced IFNγ response 
may. Additionally, mirroring the clinical picture, depletion of neutrophils can result in an 
acute lethal infection with increased bacteraemia within the lungs and a reduction in 
innate cytokines including TNF, IFNγ and IL-6, suggesting an important role for 
neutrophils in early cytokine release [373].   
 
Mice are an excellent model for clinical melioidosis due to similarities in: susceptibility 
to infection via multiple routes; proinflammatory response to infection in both murine 
models and clinical cases; and involvement of similar target organs (lung, liver, spleen) 
[300]. However differences do exist in the pathogenesis of disease in different animal 
models and it may be necessary to use different animal models (species and strains) to 
model different aspects of clinical disease [368]. 
 
Non-human primate (NHP) models allow translation of small animal models to clinical 
melioidosis and fit under the FDA Animal Rule as an authentic model of human disease. 
Studies have included rhesus macaques [376], African green moneys [376], Hamadryas 
baboons [377] and marmosets [378]. NHP models have similar signs to the symptoms 
observed in clinical disease and may enable comparison between the two, enabling the 
transition of vaccines and therapeutics to a clinical setting. 
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 Biothreat 1.8.1
The threat of bioweapons has been outlined previously. B. pseudomallei has 
characteristics similar to B. anthracis due to its severe course of infection, aerosol 
infectivity, low infectious dose and antibiotic resistance. B. pseudomallei is classified by 
the Centers for Disease Control and Prevention (CDC) as a Category B bioterrorism 
agent, as in addition to the above characteristics it has the potential to be: moderately 
easy to disseminate; result in moderate morbidity rates and low mortality rates; and 
requires specific enhancements of CDC's diagnostic capacity and enhanced disease 
surveillance [289]. 
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1.9 Aims and objectives 
This thesis addresses the potential prophylactic and therapeutic role of DC vaccination 
and DC targeting in the disease contexts of anthrax and melioidosis respectively. Both 
etiological agents have the potential to cause latent or re-emerging disease due to 
persistent spores or bacteria respectively. Vaccines for these diseases would potentially 
benefit from an enhanced cellular immune response to aid protection and bacterial 
clearance. In summary this thesis examines the role of: 
 DC vaccination as a prophylactic approach to enhance CMI responses following 
the adoptive transfer of specifically primed DCs, in a murine model of B. 
anthracis. 
 DC maturation following pulsing with B. pseudomallei antigens and an evaluation 
of their immunogenicity in vivo. 
 DC vaccination as a post-exposure therapy to enhance B. pseudomallei specific 
CMI responses and to determine the impact on bacterial clearance and survival 
in a murine model of B. pseudomallei. 
 Targeting a B. pseudomallei antigen to DCs in situ as a post-exposure therapy to 
determine the impact on bacterial clearance and survival in a murine model of B. 
pseudomallei. 
 
 Hypothesis 1.9.1
Dendritic cells can beneficially modulate the immune system prior to, or in response to, 
pathogen challenge, using murine models. 
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Chapter 2: Materials and methods 
2.1 Mice 
Animal welfare was monitored by the Named Veterinary Surgeon and Named Animal 
Care and Welfare Officers.  All procedures were performed in accordance with the 
Animal (Scientific Procedures) Act 1986 and the revised legislation under EU Directive 
2010/63/EU by fully trained, competent and licensed members of staff. Procedures 
were performed under the authority of Project Licences PPL30/2488 or PPL30/3026.  
 
All efficacy studies were performed in a dedicated facility specifically designed for 
animal experiments using Containment Level 3 pathogens. Mice were held in rigid 
isolators with both in-flowing and out-flowing HEPA filtered air. Mice were monitored 
twice daily for the duration of the experiment with animals showing signs of severe 
illness culled at humane end-points. 
 
All experimental studies involving live bacteria or samples from mice infected with 
either B. anthracis or B. pseudomallei were conducted in a dedicated CL3 facility using 
Class III cabinets. 
 B. anthracis studies 2.1.1
Female 42-56 day old A/J mice were purchased from Charles River Laboratories and held 
in specific pathogen free facilities with free access to food and water. Mice were 
acclimatised for seven days prior to use. 
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 B. pseudomallei studies 2.1.2
Female 42-56 day old Balb/c mice were purchased from Charles River Laboratories or 
Harlan Laboratories and held in specific pathogen free facilities with free access to food 
and water. Mice were acclimatised for seven days prior to use. 
 
2.2 Bone marrow dendritic cell culture method 
Bone marrow dendritic cells (BMDCs) from both A/J and Balb/c mice were prepared 
using a method derived from previous reports [379] [380]. Briefly, bone marrow was 
flushed from the femur and tibia of mice and passed through a 40 μm cell sieve to 
create a single cell suspension. Bone marrow cells were washed in complete medium 
(RPMI-1640 (Gibco 21875-034) supplemented with 10% foetal calf serum (FCS) (Gibco 
10100-147), 1% penicillin-streptomycin-glutamine (Gibco 10378-016) and 50 μM 2-
mercaptoethanol (Gibco 31350-010) and red cells lysed using red cell lysis buffer (Sigma 
Aldrich R7757) before being washed again. Cells were seeded at 2.5 x 105 cells mL and 
cultured in a fully humidified atmosphere at 37 °C with 5% CO2; complete medium was 
supplemented with 20 ng/mL of GM-CSF (R&D Systems 415-ML-050). Medium was 
replaced at days 3 and 5 before loosely adherent cells were harvested at day 8. Cells 
were confirmed to be greater than 85% CD11c+ by flow cytometry for subsequent use in 
stimulation assays Figure 2-1. 
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Figure 2-1: Confirmation that cultured BMDCs were greater than 85% CD11c+  
BMDCs were cultured as described in Section 2.2 and subsequently  stained with anti-
CD11c Pacific Blue (Biolegend, clone N418). Expression of CD11c was measured using a 
FACS Canto II and analysed using FACS Diva (A). The percentage of CD11c+ BMDCs was 
determined via an appropriate isotype control.   
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2.3 Heat inactivation of B. anthracis and B. pseudomallei 
 B. anthracis heat inactivation 2.3.1
The strain of B. anthracis used for these studies, STI, is a pXO1+, pXO2- unencapsulated, 
toxigenic strain. B. anthracis was heat inactivated using a method previously reported 
[86]. Briefly, B. anthracis STI spores were harvested and washed three times by 
centrifugation before being resuspended in phosphate buffered saline (PBS). The spore 
suspension was inactivated by incubation in a water bath for 2 hours at 90 °C with 
occasional shaking. Inactivation was confirmed by inoculating 10 mL broths with heat-
killed suspension and incubating at 37 °C for one week. L-agar plates were subsequently 
inoculated with the entire broth and incubated for a further 7 days. An absence of 
growth indicated the spore suspension to be inactivated. 
 
 B. pseudomallei heat inactivation 2.3.2
B. pseudomallei K96243, a clinical isolate from a 34 year old female diabetic patient in 
Khon Kaen hospital Thailand [381] is now a widely-used laboratory strain. The heat-
inactivation of B. pseudomallei has been previously reported [86]. Briefly, viable B. 
pseudomallei K96243 were harvested and washed three times by centrifugation before 
being resuspended in PBS. The bacterial suspension was inactivated by incubation in a 
water bath for 4 hours at 80 °C with occasional shaking. Inactivation was confirmed by 
inoculating 10 mL broths with heat-killed suspension and incubating at 37 °C for one 
week. L-agar plates were subsequently inoculated with the entire broth and incubated 
for a further 7 days. An absence of growth indicated the bacterial suspension to be 
inactivated. 
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2.4 B. anthracis in vivo adoptive transfer studies 
 Immunogenicity Studies 2.4.1
The B. anthracis immunogenicity studies consisted of two phases. The first utilised DC 
vaccination alone with DCs stimulated with recombinant PA (rPA) (Pharmathene), heat-
killed B. anthracis, CpG ODN 1826 (Invivogen, tlrl-modn), alum (Brenntag Biosector), 
ISCOM (Abisco 20-0100-05) or AVP (PHE); as indicated in Table 1. 
 
 
Table 1: Immunisation groups for DC pulsing for B. anthracis immunogenicity studies 
Mice received 1 x 106/mL BMDCs that had been stimulated for 18 hours as indicated in 
the table below. Following stimulation cells were washed three times in PBS and 
adoptively transferred into naïve female Balb/c mice via the intra-dermal route. Mice 
were monitored for fourteen days at which point they were culled for immunological 
analysis. 
Naïve mice 
BMDCs stimulated with Unstimulated BMDCs 
BMDCs stimulated with rPA (10 μg/mL) 
BMDCs stimulated with rPA (10 μg/mL), heat-killed B. anthracis (104 CFU mL), CpG (6 
μg/mL) 
BMDCs stimulated with Heat-killed B. anthracis (104 CFU mL), CpG (6 μg/mL), alum 
(0.26% v/v) 
BMDCs stimulated with BMDCs stimulated with rPA (10 μg/mL), CpG (6 μg/mL), 
ISCOM 3 (μg/mL) 
BMDCs stimulated with rPA (10 μg/mL), alum (0.26% v/v), CpG (6 μg/mL), heat-killed 
B. anthracis (104 CFU mL) 
BMDCs stimulated with rPA (10 μg/mL), heat-killed B. anthracis (104 CFU mL) 
BMDCs stimulated with rPA (10 μg/mL), CpG (6 μg/mL) 
BMDCs stimulated with AVP (10 μg/mL) 
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The second phase included DCs stimulated together with some groups receiving an 
additional rPA and alum immunisation, indicated in Table 2. 
 
Table 2: DC vaccination in combination with rPA and alum vaccination 
Mice received 1 x 106/mL BMDCs that had been stimulated for 18 hours as indicated in 
the table below. Following stimulation cells were washed three times in PBS and 
adoptively transferred into naïve female Balb/c mice via the intra-dermal route. Two 
groups received rPA formulated in alum via the intramuscular route. Mice were 
monitored for seven or fourteen days at which point they were culled for analysis. 
Naïve mice 
Unstimulated BMDCs 
rPA (10 μg/mL) and alum (0.26% v/v) (i.m.) 
rPA (10 μg/mL) and alum (0.26% v/v) with dendritic cell vaccination (rPA (10 μg/mL), 
heat-killed B. anthracis and CpG (3 μg/mL)) 
 
 
 
For all studies BMDCs were stimulated, for 18 hours at 37°C. Cells were harvested, 
washed three times at 200 relative centrifugal force (rcf) to remove free antigen, 
enumerated and resuspended in PBS. Mice were immunised intradermally (i.d.) with 1 x 
106 cells resuspended in 100 μl PBS on Day 1. Alternatively, mice were immunised with 
rPA and alum and received 10 μg rPA formulated in 100 μl of 0.26% v/v alum (Brenntag 
Biosector), intramuscularly (i.m.), on Day 1.  Mice receiving both BMDCs and rPA and 
alum, received these formulations at the same time on Day 1. At days 7 and 14 post-
immunisation mice were culled with cardiac puncture and spleens taken for 
immunological analysis. 
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 B. anthracis efficacy study 2.4.2
Mice were immunised intradermally (i.d.) with 1 x 106 BMDCs stimulated as indicated in 
Table 2. Groups of ten mice were challenged by the intraperitoneal route (i.p.) fourteen 
days post-immunisation. B. anthracis STI spores were diluted from a pre-existing 
working stock to an estimated challenge dose of 1 x 103 CFU by serial dilution. Actual 
challenge dose was calculated by culturing the inoculum on nutrient agar plates for 48 
hours. Spleens were taken for bacteriology two days post-challenge and survival 
monitored for eight days.  
 
2.5 B. pseudomallei in vivo adoptive transfer studies 
 B. pseudomallei immunogenicity studies 2.5.1
DCs were stimulated for 18 hours at 37°C, as indicated in Table 3. Cells were 
subsequently harvested, washed three times at 200 rcf to remove free antigen, 
enumerated and resuspended in PBS. Mice were immunised i.d. with 1 x 106 BMDCs 
resuspended in 100 μl PBS on Day 1. At days 21 and 35 post-immunisation mice were 
culled with cardiac puncture and spleens taken for immunological analysis. LolC is a B. 
pseudomallei ATP-binding cassette (ABC) transporter, purchased from Lionex (GmBH). 
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Table 3: BMDCs were stimulated as indicated for B. pseudomallei immunogenicity 
studies 
Mice received 1 x 106/mL BMDCs that had been stimulated for 18 hours as indicated in 
the table below. Following stimulation cells were washed three times in PBS and 
adoptively transferred into naïve female Balb/c mice via the intra-dermal route. Mice 
were monitored for thirty-five days at which point they were culled for analysis. 
Naïve mice 
Unstimulated BMDCs 
BMDCs stimulated with CpG (6 μg/mL)  
BMDCs stimulated with Heat killed B. pseudomallei (104 CFU) 
BMDCs stimulated with Heat killed B. pseudomallei (104 CFU) and CpG (6 μg/mL) 
BMDCs stimulated with LolC (10 μg/mL) 
BMDCs stimulated with LolC (10 μg/mL) and CpG (6 μg/mL) 
 
 
 B. pseudomallei efficacy studies 2.5.2
Balb/c mice were challenged with B. pseudomallei K96243, at Dstl a working stock of 
known provenance has been prepared for use in efficacy studies from colonies isolated 
following passage in mice to ensure virulence (Dr Andrew Scott, personal 
communication). To prepare the challenge dose a 10 µL loop of the working stock was 
added to 100 mL of L-broth and incubated on an orbital shaker, 180 rpm at 37 °C for 18 
hours. The overnight culture was adjusted to an OD514 of 0.4 using a spectrophotometer, 
to give a known suspension of 4 x 108 B. pseudomallei K96243 CFU/mL. This was serially 
diluted in PBS to give 4 x 104 CFU/mL, with mice receiving 100 µL i.p. The actual 
challenge dose was calculated by culturing the inoculum on L-agar plates for 48 hours. 
Immediately following challenge mice received a BMDC vaccination. BMDCs were 
stimulated for 18 hours at 37°C as indicated in Table 4. 
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Table 4: BMDC stimulation groups for B. pseudomallei efficacy studies 
Mice were challenged with 3 x 104 CFU B. pseudomallei. Subsequently mice received 1 x 
106/mL BMDCs that had been stimulated for 18 hours as indicated in the table below. 
Following stimulation cells were washed three times in PBS and adoptively transferred 
into naïve female Balb/c mice via the intra-dermal route. Mice were monitored for 
thirty-five days at which point they were culled for analysis. 
Untreated 
Unstimulated BMDCs 
BMDCs stimulated with CpG (6 μg/mL)  
BMDCs stimulated with heat killed B. pseudomallei (104 CFU) 
BMDCs stimulated with heat killed B. pseudomallei (104 CFU) and CpG (6 μg/mL) 
 
 
Cells were subsequently harvested, washed three times at 200 rcf to remove free 
antigen, enumerated and resuspended in PBS to give 1 x 106 BMDCs/100 μL for each 
mouse. Mice were monitored for 35 days with survivors culled at this point with blood 
and organs taken to determine the antibody response, cytokine response and bacterial 
load. 
 
2.6 Targeting of DCs in situ 
The B. pseudomallei antigen LolC and Capsular Polysaccharide (CPS) were conjugated to 
an anti-DEC205 monoclonal antibody. The DEC205-LolC and DEC205-CPS conjugates 
were manufactured by BBI Detection using a previously published method [382]. A 
DEC205 hybridoma cell line was purchased from ATCC (ATCC HB-290) and the antibody 
produced by BBI detection. The CPS was a kind gift from Marc Bayliss (Dstl).  
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 Targeting DCs in situ: immunogenicity study 2.6.1
DEC-LolC immunogenicity studies followed the same model as DC vaccination with mice 
immunised i.m. as indicated in Table 5. At 21 and 35 days post immunisation mice 
underwent cardiac puncture and culled by cervical dislocation with spleens taken for 
immunological analysis. 
 
 
Table 5: Groups for Targeting LolC to DCs in situ 
Mice received LolC-DEC205 conjugate or controls with CpG as indicated in the table 
below via the intramuscular route. Mice were monitored for thirty-five days, at which 
point they were culled for immunological analysis. 
Naïve 
LolC-DEC205 (10 µg/mouse) & CpG (10 µg/mouse) 
LolC & DEC205 (10 µg/mouse) & CpG (10 µg/mouse) 
DEC205 (10 µg/mouse) & CpG (10 µg/mouse) 
 
 Targeting DCs in situ: efficacy study 2.6.2
Targeting efficacy studies followed the same model as the DC vaccination studies 
(section 2.5.2). Mice were challenged with B. pseudomallei K96243 at a target challenge 
dose of 4 x 103 CFU/mouse. Mice were subsequently immunised with the conjugate i.m. 
as per Table 6  and monitored for 35 days. Mice were culled with blood and organs 
taken to determine the antibody response, organ weights and bacterial load. 
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Table 6: Groups for Targeting LolC to DCs in situ 
Mice were challenged with 3 x 104 CFU B. pseudomallei. Subsequently mice received 
LolC-DEC205 conjugate or controls with CpG as indicated in the table below via the 
intramuscular route. Mice were monitored for thirty-five days, at which point they were 
culled for analysis. 
Naïve 
LolC-DEC205 (10 µg/mouse) & CpG (10 µg/mouse) 
LolC & DEC205 (10 µg/mouse) & CpG (10 µg/mouse) 
DEC205 (10 µg/mouse) & CpG (10 µg/mouse) 
 
2.7 Bacteriology 
Two days post-challenge (B. anthracis studies) or 35 days post challenge (B. 
pseudomallei studies) mice were culled for bacteriology. The lungs liver and spleen were 
macerated through a cell sieve into 3mL of sterile PBS. Single cell suspensions were 
serially diluted and 100 μL of each suspension added to either nutrient agar (B. 
anthracis) or L-agar (B. pseudomallei). Plates were incubated at 37 °C for 48 hours 
before colony forming units (CFU) were enumerated. 
 
2.8 Immunological techniques 
 Enzyme-Linked ImmunoSpot (ELISPOT)  2.8.1
The number of antigen specific IFNγ+ splenocytes from naïve and immunised mice was 
assessed using an IFNγ ELISPOT assay following the manufacturer’s instructions (Becton 
Dickinson 551083). Briefly, plates were coated with capture antibody diluted 1:200 in 
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sterile PBS, 100 µL of diluted antibody was added per well and incubated at 4 °C 
overnight. Subsequently plates were blocked by adding 200 µL of RPMI containing 10 % 
FCS and incubated at 37 °C for one hour. At 7 and 14 days (B. anthracis studies) or 21 
and 35 days (B. pseudomallei studies) post-immunisation mice were culled, spleens 
removed and macerated through a cell sieve. Cells were pelleted by centrifuging at 200 
rcf and red blood cells removed by resuspending the pellet in 2 mL of red cell lysis buffer 
for 2 minutes before being washed in PBS, counted using Trypan Blue exclusion (Sigma-
Aldrich, T8154) using an automated cell counter (Nexcelom Bioscience) and seeded at 2 
x 105 cells per well into 96-well ELISPOT plates.  
 
Cells were restimulated with 100 µL of rPA at 10 µg/mL (B. anthracis immunogenicity 
studies), heat-killed B. pseudomallei 1 x 104 CFU/mL or LolC at 10 µg/mL (B. 
pseudomallei immunogenicity studies) together with Con A (Sigma-Aldrich L7647), 2 
µg/mL, or left unstimulated (medium only), overnight in a humidified incubator at 37 °C, 
5% CO2.  
 
Assay development occurred as per the manufacturer’s instructions. Briefly, following 
overnight incubation plates were washed twice with 250 µL of distilled water with a two 
minute soak between each wash. Plates were then washed three times with 200 µL PBS 
containing 0.05% Tween-20 (Sigma Aldrich P-1379). The biotinylated detection antibody 
was diluted 1:250 in PBS containing 10% FCS and 100 µL added to each well with plates 
incubated for two hours at room temperature. The detection antibody solution was 
discarded and plates washed three times with PBS containing 0.05% Tween-20, soaking 
for 1-2 minutes between each wash. Streptavidin-alkaline phosphatase was diluted 
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1:100 in PBS plus 10% FCs and 100 µL added to each well with plates incubated for 1 
hour at room temperature. The enzyme conjugate solution was discarded and the plates 
washed four times with PBS containing 0.05% Tween-20 and then twice with sterile PBS. 
To develop the plates an AEC Chromogen kit (Becton Dickinson, 551951) was used with 
1 drop of chromogen solution added to 1 mL of buffer and 100 µL added per well. Plates 
were developed until clear spots were visible and stopped by washing under a cold 
water tap. Plates were dried in a 37 °C incubator overnight and counted using an 
automated AID ELISPOT reader. Results are presented as the difference in spot-forming 
cells (SFC) between unstimulated and re-stimulated splenocytes for a given condition, 
ΔSFC/mL splenocytes. 
 
 Enzyme-Linked Immunosorbent Assay (ELISA) 2.8.2
Anti-PA, anti-LolC, anti-CPS or anti-B. pseudomallei IgG antibody titres were determined 
as previously reported [86] [383]. Briefly, columns 1 and 2 of a 96-well microtitre plates 
were coated with 100 μL per well of 5 µg/mL anti-mouse IgG Fab (Sigma-Aldrich 
M4155), and with either 5 µg/mL rPA in PBS, or 106 heat-killed B. pseudomallei per well, 
columns 3-12, and incubated overnight at 4 °C. Plates were washed using PBS plus 
0.05% Tween-20 and blocked with PBS containing 1% weight/volume (w/v) skimmed 
milk powder and incubated for 2 hours at 37 °C. The IgG standard was prepared to give 
a top concentration of 200 ng/mL and double diluted to provide a standard curve to 
determine serum IgG concentration using the anti-mouse IgG Fab coated columns. 
Serum samples were tested in duplicate at a 1/20 dilution in PBS containing 1% w/v 
skimmed milk powder and incubated for 1 hour at 37 °C.  
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Binding of serum antibodies was detected using horse-radish peroxidise conjugated goat 
anti-mouse IgG (Serotec 103005), diluted 1 in 2000 in PBS with 100 µL added to each 
well and incubated for 1 hour at 37 °C. Plates were developed using the substrate 2,2-
Azinobis (3-ethylbenzthiazoline-sulfonic acid) (ABTS, Sigma-Aldrich A9942) diluted in 
citrate buffer plus 5 µL of 16% H2O2. Plates were read using a Multiskan plate reader 
(Thermo Scientific) at 405 nm. IgG titres were calculated by performing a third order 
polynomial equation of the standards and interpolating unknowns using GraphPad 
Prism. Results are presented as the mean of the two duplicate samples tested. 
 
 Flow cytometry  2.8.3
To assess the upregulation of MHC-II, CD80, CD86 and CD40, 1 x 106 BMDCs/mL were 
stimulated with rPA (10 µg/mL), heat-killed B. anthracis (1 x 106 CFU/mL), CpG (6 
µg/mL), heat killed B. pseudomallei (1 x 106 CFU/mL) or left unstimulated for 0, 2, 6, 18 
or 24 hours. Subsequently cells were harvested by centrifugation and stained using 
titrated CD11c-Pacific Blue (117322, clone N418), CD80-PE (104708, clone 16-10A1), 
CD86-APC (105012 clone GL-1), CD40-FITC (124608, clone 3/23), MHC-II-PerCPCy5.5 
(107626 clone M5/114.15.2), CCR7-PE (120106, clone 4B12) (all Insight Biotechnology) 
or CD205-APC (Ebiosciences, 17-2051-82, clone 205yekta), together with appropriate 
compensation and isotype matched controls. To stain the cells a master-mix of the 
above stains was prepared and added to the cells in a total volume of 50 µL. Cells were 
incubated at room temperature for 20 minutes before being washed in PBS plus 10% 
FCS and 0.05% sodium azide and fixed with 1% paraformaldehyde in PBS. Samples were 
stored at 4 °C in the refrigerator prior to acquisition on a FACS Canto II flow cytometer 
and data analysed using FlowJo v10.  
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 Mouse inflammation and Th1/2/17 cytometric bead array kits 2.8.4
Mouse Inflammation (552364) and Th1/2/17 (560485, both Becton Dickinson UK) 
Cytometric Bead Array (CBA) kits were used as per the manufactures instructions. 
Briefly, lyophilised standards were reconstituted in 2 mL of Assay Diluent and allowed to 
equilibrate for 15 minutes at room temperature. The standard was diluted in Assay 
diluent providing a 20-5000 pg/mL standard curve. Capture Beads were prepared by 
using 10 μL of Capture Beads per cytokine for each sample. The assay was performed 
using 96 well plates by adding 50 μL of Capture Beads to all appropriate wells. Standards 
and samples were added, 50 μL, to appropriate wells before the addition of 50 μL of the 
PE detection reagent to each well. Assay plates were incubated for 2 hours in the dark at 
room temperature. Samples were washed using Wash Buffer at 200 rcf for 5 minutes 
before being resuspended in 200 μL of Wash Buffer. Samples were analysed on a 
FacsCanto II flow cytometer. Cytokine concentrations were calculated by performing a 
third order polynomial equation of the standards and interpolating unknowns using 
GraphPad Prism.  
 
2.9 PCR arrays 
The alteration in expression of 84 genes involved in immune processes was assessed on 
stimulated DCs using the Qiagen Mouse Dendritic and Antigen Presenting Cell RT² 
Profiler PCR Array (Qiagen, PAMM-406Z). BMDCs were prepared as previously described 
(Section 2.2). BMDCs, 5 mL of 1 x 106, were either unstimulated or stimulated with heat-
killed B. pseudomallei (104 CFU/mL), CpG (6 µg/mL), heat-killed B. pseudomallei (104 
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CFU/mL) and CpG (6 µg/mL), LolC (10 µg/mL) or LolC (10 µg/mL)and CpG (6 µg/mL) for 
18 hours 
 
The genes assessed are focused on dendritic cell activation and maturation including 
cytokines, chemokines and their receptors together with other related cell surface 
receptors, signal transduction molecules and genes involved in antigen uptake, 
processing, and presentation with many of the genes showing significant alterations in 
expression during cell differentiation [384]. Table 7 shows the 96-well plate layout of the 
genes, the genes assessed were: 
 
Antigen Uptake: Cd44, Cdc42, Icam1, Icam2, Rac1, Tap2. 
Antigen Presentation: Cd1d1, Cd1d2, Cd209a, Cd28, Cd4, Cd40 (Tnfrsf5), Cd40lg 
(Tnfsf5), Cd74, Cd80, Cd86, Cd8a, Fcgrt, H2-Dma, Tapbp, Thbs1. 
Dendritic Cell Chemotaxis: Ccl19, Ccl5 (Rantes), Ccr1, Ccr2, Ccr5, Cxcr1 (Il8ra), Cxcr4.  
Dendritic Cell Differentiation: Cd40lg (Tnfsf5), Csf2 (GM-CSF), Lyn, Rag1, Relb, Tgfb1.  
Cytokines: Ccl11 (Eotaxin), Ccl12, Ccl17, Ccl19, Ccl2 (Mcp-1), Ccl3 (Mip-1a), Ccl20 (Mip-
3a), Ccl4, Ccl5 (Rantes), Ccl7 (Mcp-3), Ccl8 (Mcp-2), Csf2 (GM-CSF), Cxcl1, Cxcl10 (Inp10), 
Cxcl12 (Sdf1), Cxcl2, Flt3l, Ifng, Il10, Il12a, Il12b, Il16, Il2, Il6, Mif, Tgfb1, Tnf, Tnfsf11.  
Cytokine Receptors: Ccr1, Ccr2, Ccr3, Ccr5, Ccr9, Csf1r, Cxcr1 (Il8ra), Cxcr4, Erbb2, Flt3, 
Lyn.  
Other Cell Surface Receptors: Cd2, Cd33, Cd36, Cd40, Fcer1a, Fcer2a, Fcgr1, Lrp1, Tlr1, 
Tlr2, Tlr7, Tlr9. 
Signal Transduction: Cdkn1a (p21Cip1/Waf1), Cebpa, Clec4b2, Fas (Tnfrsf6), Irf7, Itgam, 
Itgb2, Nfkb1, Ptprc, Rela, Relb, Stat3. 
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Table 7: Plate layout for the Qiagen Mouse Dendritic and Antigen Presenting Cell RT² 
Profiler PCR Array 
Ccl1
1  
Ccl12 Ccl17 Ccl19 Ccl2 Ccl20 Ccl3 Ccl4 Ccl5 Ccl7 Ccl8 Ccr1 
Ccr2 Ccr3 Ccr5 Ccr9 Cd1d1 Cd1d2 Cd2 
Cd209
a 
Cd28 Cd33 Cd36 Cd4 
Cd40 
Cd40l
g 
Cd44 Cd74 Cd80 Cd86 Cd8a Cdc42 
Cdkn1
a 
Cebpa 
Clec4b
2 
Csf1r 
Csf2 Cxcl1 
Cxcl1
0 
Cxcl1
2 
Cxcl2 Cxcr1 
Cxcr
4 
Erbb2 Fas 
Fcer1
a 
Fcer2a Fcgr1 
Fcgrt Flt3 Flt3l 
H2-
DMa 
Icam1 Icam2  Ifng Il10  Il12a Il12b Il12b  Il2 
Il6  Irf7 Itgam Itgb2 Lrp1 Lyn Mif Nfkb1 Ptprc Rac1 Rag1 Rela 
Relb Stat3 Tap2 Tapbp Tgfb1 Thbs1  Tlr1 Tlr2 Tlr7 Tlr9 Tnf 
Tnfsf1
1 
Actb B2m Gapdh Gusb 
Hsp90ab
1 
MGD
C 
RTC RTC RTC PPC PPC PPC 
  
 
 RNA extraction 2.9.1
RNA was extracted from the stimulated DCs (section 2.9) using the Qiagen RNeasy mini 
kit (Qiagen, 74104) following the manufactures instructions for isolation of RNA from 
animal single cell suspensions. Briefly, the cells were pelleted by centrifugation (5 
minutes at 200 rcf), supernatant removed by aspiration and the cells disrupted by the 
resuspending in 600 μL of Buffer RLT, containing 10 μL β-mercaptoethanol per 1 mL of 
Buffer RLT. Cells were homogenised using QIAshredder spin column (Qiagen, 79656). 
The lysate was pipetted into the spin column and placed in a 2 mL collection tube, this 
was centrifuged for 2 min at 13,000 revolutions per minute (rpm). The lysate was 
transferred to a gDNA Eliminator spin column in a 2 mL collection tube, centrifuged for 
30 seconds 8000 x rpm and the flow-through retained. 600 μL of 70% ethanol was 
added to the flow-through and mixed by pipetting. The sample was transferred to an 
RNeasy spin column placed in a 2 mL collection tube and centrifuged for 15 seconds at 
8,000 rpm with the flow-through discarded. 700 μL Buffer RW1 was added to the 
RNeasy spin column and centrifuged for 15 seconds at 8,000 rpm with the flow through 
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discarded. 500 μL of Buffer RPE was added to the RNeasy spin column and centrifuged 
for 15 seconds at 8,000 rpm with the flow-through discarded. 500 μL of Buffer RPE was 
added to the RNeasy spin column and centrifuged for 2 minutes at 8,000 rpm, the flow-
through was discarded and the RNeasy spin column centrifuged at 13,000 rpm for 1 
minute to remove carryover of Buffer RPE. The RNeasy spin column was placed in a new 
1.5 mL collection tube to which 40 μL of RNase-free water was added directly to the spin 
column membrane. This was centrifuged for 1 min at 8,000 rpm to elute the RNA. This 
final step was repeated to ensure maximal recovery of RNA. 
 
2.9.1.1 NanoDrop ND1000 protocol 
The recovery of RNA was determined using a NanoDrop (Thermo Scientific). The upper 
and lower surfaces of the NanoDrop ND-1000 microspectrophotometer (LabTech 
International. UK) were cleaned using 2 μL of deionised water and machine initialised 
and blanked using 1 μL of deionised water. The concentration of RNA was measured by 
loading 1 μL of sample, results were expressed in ng/μL of RNA. The salt concentration 
260/230 nm ratio and protein contamination 260/280nm ratio had to be greater than 
1.8 and less than 2.2 respectively for the RNA to be considered acceptable for use. 
 
2.9.1.2 Agilent RNA 6000 nano assay protocol 
The quality of RNA was assessed using an Agilent RNA 6000 Nano chip (5067-1511). The 
supplied RNA ladder was denatured by incubating at 70 °C for 2 minutes, this was 
aliquoted into single use vials and stored at -80 °C. The RNA gel matrix was prepared by 
pipetting 550 μL into a spin filter and centrifuging at 1500 g for 10 minutes. This was 
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aliquoted into single use vials and stored at 4 °C. The Gel-Dye Mix was prepared by 
adding 1 μL of dye into a 65 μL aliquot of filtered gel and centrifuging at 13000 rpm for 
10 minutes. The Gel-Dye Mix was loaded onto a Nano RNA chip using the Agilent chip 
priming station. 9 μL of gel-dye mix was pipetted into the relevant well and the chip 
priming station closed. The plunger was inserted until held by the clip and released after 
30 seconds. The chip priming station was opened and 9 μL of gel- dye mix pipetted into 
the relevant wells. 5 μL of RNA marker was added to all sample and ladder wells and 1 
μL of sample or ladder added to each relevant well. The chip was vortexed for 1 min at 
2400 rpm and run on the Agilent 2100 Bioanalyzer (Agilent Technologies,UK). This 
required well defined 18s and 28s peaks with a low inter-peak region and minimal low 
molecular weight contamination with a RNA integrity number greater than 8.0 for the 
RNA to be considered a high enough quality to be used.  
 
 Conversion of RNA to cDNA 2.9.2
To convert RNA to cDNA for use in the RT² Profiler PCR Array the Qiagen RT2 First Strand 
Kit was used following the manufactures instructions. Briefly, the genomic DNA 
elimination mix for each RNA sample was prepared with 1 µg of sample RNA, 2 µL of 
Buffer GE and a variable amount of RNase-free water to give a total volume of 10 µL. 
This was incubated for 5 minutes at 42°C and then placed on ice for at least 1 min. The 
reverse-transcription mix consisted of: 4 µL of 5x Buffer BC3, 1 µl of Control P2, 2 µL of 
RE3 Reverse Transcriptase Mix and 3 µL of RNase-free water. The 10 µL of reverse-
transcription mix was added to each 10 µL genomic DNA elimination mix. This was 
incubated at 42°C for 15 minutes and then stopped by incubating at 95°C for 5 minutes.  
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91 µL of RNase-free water was added to the reaction and placed on ice for use in the RT² 
Profiler PCR Array.  
 
 RT² profiler PCR array protocol 2.9.3
The Mouse Dendritic and Antigen Presenting Cell RT² Profiler PCR Array was used 
according to the manufacturer’s instructions. Briefly, 102 µL of the cDNA synthesis 
reaction, 1350 µL RT2 SYBR Green Mastermix and 1248 µL of RNase-free water were 
mixed thoroughly. 25 µL or the mixture was added to each well of the RT2 Profiler PCR 
Array. The plate was sealed and centrifuged for 1 min at 1000 g. Array plates were run 
on an Applied Biosystems 7000 RT-PCR machine with an initial 10 minutes at 95°C 
followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Results were analysed 
using the manufacturers web based software available at 
www.SABiosciences.com/pcrarraydataanalysis.php and fold changes greater than 2 
reported.  
 
2.10 In vivo and ex vivo tracking of DCs  
 Labelling DCs with CellVue® Claret 2.10.1
DCs were labelled with CellVue® Claret (Sigma Aldrich, MIDCLARET-1KT) to enable 
visualisation of labelled fluorescent cells as part of in vivo and ex vivo experiments. 
CellVue® Claret is excited at 655 nm and emits at 675 nm with labelling occurring by 
partitioning of the lipophilic dye into cell membranes. In order to label DCs the 
manufactures instructions were followed. Briefly, 2 x 107 cells were washed in serum 
free medium at 300 rcf for 5 minutes. After centrifugation, supernatant was carefully 
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aspirated leaving no more than 25 μL of supernatant. 1 mL of Diluent C was added to 
the cell pellet and resuspended with gentle pipetting. Immediately prior to staining, the 
dye solution was prepared by the addition of 4 μL of CellVue® Claret ethanolic dye 
solution to 1 mL of Diluent C. This was mixed prior to addition of the cell suspension to 
the dye solution. The cell/dye suspension was incubated for 5 minutes with periodic 
mixing and staining stopped by the addition of an equal volume (2 mL) of FCS, this was 
incubated for 1 minute to allow binding of excess dye. Cells were centrifuge at 400 rcf 
for 10 minutes and the supernatant aspirated. Labelled cells were washed twice more 
using complete medium to remove unbound dye. Cells recovery, viability and 
fluorescence intensity was determined. 
 
 Immunisation of mice with fluorescent DCs 2.10.2
Mice were immunised with fluorescent DCs, 1 x 106 BMDCs in 100 µL PBS i.d. Mice were 
culled at 24 hour intervals and either imaged using an In Vivo Imaging System (Perkin 
Elmer) or dissected with inguinal and axillary lymph nodes removed as   
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Figure 2-2, for further analysis using an ImageStream X (Amnis). 
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Figure 2-2: The location of murine lymph nodes, spleen and thymus.  
The diagram shows the location of major secondary lymph nodes and was used to aid 
identification of murine lymph nodes, taken from Dunn 1954 [385].   
 
 
2.11 Statistical analysis 
Graphs and statistical analyses were undertaken using GraphPad Prism v6.02, with 
median values plotted on all graphs. All statistical analysis was performed following 
consultation with a biostatistician. Samples were analysed as indicated in figure legends 
using parametric or non-parametric tests where appropriate. Significant results are 
indicated on all figures (* p<0.05, ** p<0.01, ***p<0.001). 
 
Cytokine, antibody and bacteriological data were found to be exponential in nature and 
transformed to the logarithm of 10 in the first instance to better fit the requirements of 
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parametric analysis. Where data sets include several zero values 0.01 was added to all 
data points to prevent the zeros being lost. Transformation was not necessary for organ 
weight data that was all linear in nature. Suitability of the data for parametric analysis 
was assessed using a Brown-Forsythe test for unequal variance. Where significant 
differences in variance between groups were observed the data was found unsuitable 
for parametric analysis. It was therefore tested using the non-parametric Kruskal-
Wallace test with Dunn’s multiple comparisons post hoc test. 
 
Repeated in vivo studies were assessed by two-way ANOVA to establish the likelihood 
that the experiments differed with Tukey post-hoc test.  
 
Combined results for B. pseudomallei efficacy studies were subsequently analysed by 
means of a partial correlation [386] using IBM SPSS v21. To further visualise the 
experimental results, relatedness between the data was clustered on a dendrogram 
based on Pearson’s coefficients. Prior to construction of the Dendrogram data was 
standardised so that each of the variables was on a scale from -1 to +1. 
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Chapter 3: Prophylactic dendritic cell vaccination for Bacillus 
anthracis 
3.1 Introduction 
B. anthracis, the etiological agent of anthrax causes a rare but serious disease that has a 
number of infection routes, which determine key clinic-pathological features. 
Vaccination is an important strategy to protect at-risk individuals but current vaccines 
have several drawbacks. Licensed anthrax vaccines include AVP and AVA, together with 
next generation anthrax vaccines containing recombinant PA (rPA), require several 
priming doses followed by annual boosters. They protect against disease principally by 
inducing high titre anti-rPA IgG antibodies capable of neutralising anthrax toxins and 
inhibiting the early stages of infection [264] [276] [387]. However, the precise 
correlation between antibody titre and protection against infection has not been 
defined [388]. Despite the ability to induce a high titre antibody response, vaccines 
comprising  alum as an adjuvant are generally poor inducers of CMI responses and 
enhanced CMI responses may improve vaccine protective efficacy [389].   
 
Antibiotic therapy also has its limitations requiring prompt diagnosis for their successful 
use as advanced disease is characterised by both septicaemia, which antibiotics can 
reduce, but also toxaemia, upon which antibiotics have no effect and is a frequent cause 
of death. Additionally, antibiotic regimens require those suspected of exposure to B. 
anthracis to take prolonged antibiotic courses (60 days) with the risk of late-germinating 
spores following the completion of the course and poor compliance to the regimen. 
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Vaccination with antigens formulated in alum, include the current anthrax vaccines AVA 
and AVP. These are both excellent inducers of toxin-neutralising antibodies, an 
important protective mechanism against B. anthracis vaccines, preventing the 
establishment of a systemic infection [390]. Alum has been defined as any trivalent 
aluminium-containing salt, has a long history of safe clinical use and is capable of 
inducing an immune response characterised by high antibody titres [391] with a 
relatively weak cellular response. When protein antigens are delivered with alum they 
are delivered to DCs in a soluble form, promoting non-phagocytic antigen uptake [392].  
The antigen may enter cells by an endocytic pathway via interactions with lipids at the 
DC surface promoting processing and presentation of CD4-dependent antigens and thus 
an antibody based immune response [392]. Particulate antigens delivered without alum 
may be taken up by DCs via phagocytosis, this can trigger cross-presentation via transfer 
of antigens from the phagosome to the cytosol with processing and their display on 
MHC-I and activation of CD8+ T cells.  
 
Both AVA and AVP are poor inducers of cellular immune responses, which are important 
in clearing vegetative bacteria. In cases of suspected exposure, vaccines would also be 
offered in combination with prophylactic antibiotics to ensure bacterial clearance, 
together with the development of a natural immune response. Studies from natural 
infections in man have shown these T cell responses to be significantly longer in 
duration than those induced by vaccination [393].  
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The model used in this study employed the B. anthracis STI strain, a toxigenic, 
unencapsulated strain developed by the former USSR as a live attenuated vaccine for 
use in humans. Mice are highly susceptible to the B. anthracis capsule so a toxigenic 
model is used in vaccine studies as humans are less susceptible to the capsule with the 
majority of morbidity and mortality caused by anthrax toxins. The A/J mouse was used 
as it is deficient in the C5 component of the Complement system, C5 is cleaved by C5 
convertase to C5a and C5b. C5a is an anaphylotoxin, causing degranulation of mast cells 
and phagocytic cells, and also important for the chemotaxis of neutrophils, monocytes 
and macrophages to the site of inflammation; this deficiency enables rapid bacterial 
proliferation within the host and a concomitant build-up of anthrax toxins.  C5b is the 
first component of the Membrane Attack Complex, required for the destruction of 
target cells. These characteristics enabled a toxigenic model of anthrax to be used in a 
highly susceptible mouse model.  
 
The rPA and alum vaccine was used as it has a defined antigenic composition compared 
to AVA and AVP, which are prepared from live cultures of B. anthracis and contain other 
antigenic components. CpG oligonucleotides were used as they are potent activators of 
murine bone marrow dendritic cells [394] inducing a strong Th1 profile compared to 
other vaccine adjuvants [395], important for CMI responses and this activity  is 
maintained in the presence of Th2 promoting adjuvants, including alum [396].  
 
DC therapy has the potential to treat a variety of different diseases [40] with much 
research dedicated to the development of therapeutic DC vaccination for a variety of 
tumours; including the licensure of the first DC vaccine, Sipuleucel-T, for late stage 
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prostate cancer [77]. This vaccine demonstrated the development of CMI responses 
with a Th1 polarisation and antibody production, characteristics that are important for 
immunity to many pathogens. DC vaccination for infectious disease, using DCs pulsed ex 
vivo with pathogen-derived material and/or defined stimulatory antigens, with or 
without adjuvants, is able to direct the development of protective T cell responses in 
vivo. Pulsed DCs alone are able to induce specific Th1 immune responses via their ability 
to secrete IL-12 and act as natural adjuvants [84]. This effect can be enhanced when the 
ex vivo pulsing of DCs occurs in the presence of CpG, a potent inducer of Th1 responses 
[86]. The exploration of DC vaccination for bacterial pathogens has included Borrelia 
burgdorferi [88], Burkholderia pseudomallei [85], Mycobacterium tuberculosis [89], 
Coxiella burnetti [81], Chlamydia trachomatis [93] and Pseudomonas aeruginosa [96]. 
 
This chapter explores the synergistic effect of passively administering specifically-
activated DC at the same time as actively immunising mice with rPA and alum to 
determine whether this will accelerate and enhance the host’s ability to respond within 
14 days to a lethal anthrax challenge.  A key endpoint of this study, in addition to 
survival, has been a significantly enhanced ability of the host to clear bacteria from 
secondary lymphoid organs such as the spleen. 
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 Aims and objectives 3.1.1
 
To assess the ability of appropriately stimulated murine dendritic cells to enhance 
current B. anthracis vaccinations. 
 To determine if stimulated DCs are appropriately activated in vitro. 
 To determine if the adoptive transfer of stimulated DCs can induce a specific T cell 
response in vivo. 
 To determine if a co-vaccination strategy, consisting of the adoptive transfer of 
stimulated DCs together with a current anthrax vaccine, can enhance specific T cell 
responses in vivo.  
 To determine if the adoptive transfer of DCs can enhance the protective efficacy 
and enhance bacterial clearance provided by current anthrax vaccines. 
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3.2 Results 
 
 Activation of DCs 3.2.1
The gating strategy to identify BMDCs is shown in Figure 3-1. The activation of BMDCs, 
prior to their use for in vivo immunisation was investigated. BMDCs were stimulated ex 
vivo, with vaccine antigens (rPA or heat-killed B. anthracis STI spores) and adjuvant 
(CpG) or all three in combination and the upregulation of costimulatory markers 
assessed by flow cytometry. Pulsing of BMDC with rPA or heat-killed B. anthracis spores 
did not impact upon expression of CD40, CD80 CD86 or MHC-II, Figure 3-2, Figure 3-3. 
Pulsing BMDCs with CpG significantly upregulated expression of all the molecules 
studied (p<0.001), as did pulsing with rPA, heat-killed B. anthracis and CpG in 
combination. 
 
 Cellular immune response to DC vaccination 3.2.2
The cellular immune response to DC vaccination was characterised using an IFNγ 
ELISPOT to measure rPA-specific T cells. Whilst an increase in the number of IFNγ+ spot 
forming cells (SFC) was observed between sample day 7 (Figure 3-4A) and day 14 (Figure 
3-4B) for groups immunised with either unstimulated DCs or either of the DC vaccines, 
there was no significant difference in number of IFNγ+ SFC between splenocyte samples 
which were rPA stimulated ex vivo, or unstimulated, at either time-point. Figure 3-4 
highlights the response from the DC vaccine (BMDCs pulsed with rPA, heat-killed B. 
anthracis and CpG) that was taken forward into further studies including an efficacy 
study, whilst Figure 3-5 shows alternative regimens that were trialled but taken no 
further. 
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 Cellular immune response to DC vaccination in combination with active 3.2.3
immunisation 
Splenocytes from mice immunised with both DC vaccine (i.d.) and rPA and alum (i.m.) 
were re-stimulated ex vivo with rPA. There was a significant increase in IFNγ+ SFC from 
mice administered with rPA and alum compared to naïve mice at days fourteen (p<0.05, 
Figure 3-6B) but not seven days post vaccination (Figure 3-6A). Mice vaccinated with 
both rPA and alum and the DC vaccine had  a specific recall response to rPA seven days 
post vaccination compared to both naïve mice and mice receiving unstimulated DCs 
(p<0.05), Figure 3-6. There was no significant difference in SFC between the two 
immunised groups at either of the time points.  
 
 Antibody response to DC vaccination in combination with active 3.2.4
immunisation 
Analysis of sera taken from immunised mice showed an absence of rPA specific immune 
responses seven days post-vaccination (IgM or IgG) (data not shown). However, 
fourteen days post vaccination stimulated DCs were able to induce an anti-PA IgG 
response (Figure 3-7). Mice vaccinated with rPA in alum or rPA in alum and stimulated 
DCs, displayed significantly elevated anti-rPA IgG titres when compared with mice 
receiving stimulated DCs alone. In terms of antibody induction however, the 
combination of both immunisations had no additive effect.   
 
 Post-challenge bacteriology and survival 3.2.5
Mice were challenged with 3 x 104 CFU B. anthracis STI i.p. (approximately 10MLD) 14 
days post-immunisation. Two days post-challenge a cohort of mice from each treatment 
group was culled with spleens taken to ascertain bacterial loads. All mice receiving 
unstimulated DCs together with alum (no rPA) showed limited survival (Figure 3-8) with 
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all animals dead within 5 days and a bacterial load greater than all other groups (Figure 
3-9). Mice receiving the DC vaccine only had 60% survival but a significantly (p<0.01) 
reduced bacterial load compared with naïve mice, whilst mice immunised with rPA and 
alum only showed 80% survival with a significantly (p<0.05) reduced bacterial load 
compared with naive. However, mice vaccinated with both rPA and alum and DC vaccine 
had 100% survival and a highly significant reduction in bacterial load compared to naives 
(p<0.001) and to the rPA and alum vaccination (p<0.05). 
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Figure 3-1: Characterisation of BMDC expression of CD11c and MHC-II.  
BMDCs (2 x 106 cells/mL) were unstimulated (C) or stimulated for 18 hours with CpG 
ODN 1826 (6 µg/mL) (D). BMDCs were subsequently stained for the expression of CD11c 
and MHC-II and interrogated using a FACS Canto II flow cytometer. Events were gated 
based on their forward scatter/side scatter properties (A). Subsequently doublets were 
excluded via gating on forward scatter height/forward scatter area (B) and expression of 
CD11c and MHC-II assessed on unstimulated (C) and stimulated BMDCs (D). Data was 
analysed using FlowJo v10. 
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Figure 3-2: CpG is crucial for the 
upregulation of CD40, CD80, CD86 and 
MHC-II. 
BMDCs (1 x 106 cells mL) were 
stimulated for 18 hours with rPA (10 
µg/mL), B. anthracis STI (104 CFU/mL), 
CpG ODN 1826 (6 µg/mL) or all in 
combination. Events were gated based 
on their forward scatter/side scatter 
properties. Subsequently doublets were 
excluded via gating on forward scatter 
height/forward scatter area and CD11c+ 
cells assessed for expression of CD40, 
CD80, CD86 and MHC-II using a FACS 
Canto II flow cytometer. Data was 
analysed using FlowJo v10. The red line 
shows the unstimulated control whilst 
the blue line shows increased 
expression following stimulation. The 
data shown is representative of three 
independent experiments 
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Figure 3-3: CpG is required for the upregulation of MHC-II and co-stimulatory 
molecules.  
BMDCs (1 x 106 cells mL) were stimulated for 18 hours with rPA (10 µg/mL), B. anthracis 
STI (104 CFU/mL), CpG ODN 1826 (6 µg/mL) or all in combination. Events were gated 
based on their forward scatter/side scatter properties. Subsequently doublets were 
excluded via gating on forward scatter height/forward scatter area and CD11c+ cells 
assessed for expression of CD40, CD80, CD86 and MHC-II and interrogated using a FACS 
Canto II flow cytometer. Data was analysed using FlowJo v10. Costimulatory molecules 
on BMDCs were not upregulated following 18 hour stimulation with either rPA or heat-
killed B. anthracis. Expression of all molecules measured was increased when BMDCs 
were pulsed with CpG or CpG in combination with rPA and heat-killed B. anthracis. The 
data are from three combined independent experiments. Samples were analysed using 
a one-way-Anova with Dunnett’s multiple comparisons post-hoc test (* p<0.05, ** 
p<0.01, *** p<0.001). 
 
U
n
s
ti
m
u
la
te
d
rP
A
H
e
a
t-
k
il
le
d
 B
. 
a
n
th
ra
c
is
C
p
G
rP
A
, 
h
e
a
t-
k
il
le
d
 B
. 
a
n
th
ra
c
is
 &
 C
p
G
0
2 0
4 0
6 0
8 0
C D 4 0
%
 E
x
p
r
e
s
s
io
n
* * *
* * *
U
n
s
ti
m
u
la
te
d
rP
A
H
e
a
t-
k
il
le
d
 B
. 
a
n
th
ra
c
is
C
p
G
rP
A
, 
h
e
a
t-
k
il
le
d
 B
. 
a
n
th
ra
c
is
 &
 C
p
G
0
2 0
4 0
6 0
8 0
C D 8 0
%
 E
x
p
r
e
s
s
io
n
* * *
* * *
U
n
s
ti
m
u
la
te
d
rP
A
H
e
a
t-
k
il
le
d
 B
. 
a
n
th
ra
c
is
C
p
G
rP
A
, 
h
e
a
t-
k
il
le
d
 B
. 
a
n
th
ra
c
is
 &
 C
p
G
0
2 0
4 0
6 0
8 0
C D 8 6
%
 E
x
p
r
e
s
s
io
n
* * *
* * *
U
n
s
ti
m
u
la
te
d
rP
A
H
e
a
t-
k
il
le
d
 B
. 
a
n
th
ra
c
is
C
p
G
rP
A
, 
h
e
a
t-
k
il
le
d
 B
. 
a
n
th
ra
c
is
 &
 C
p
G
0
2 0
4 0
6 0
8 0
M H C -II
%
 E
x
p
r
e
s
s
io
n
* * *
* * *
116 
 
Figure 3-4: Induction of IFNγ ΔSFC measured by ELISPOT following DC vaccination, 
approaches taken forward into further studies. 
Mice received 1 x 106 BMDCs stimulated with rPA only (10 μg/mL) (DC vaccine rPA only) 
or with rPA (10 μg/mL), heat killed B. anthracis (104 CFU/mL) and CpG oligonucleotides 
(6 μg/mL) (DC vaccine) and administered i.d. to A/J mice (n=3). Spleens were taken at 7 
days (Panel A) or 14 days (Panel B) post- vaccination and restimulated ex vivo with rPA 
and ΔSFC enumerated. A Kruskal-Wallis test with Dunn’s multiple comparison post-hoc 
test was performed on the results, no significant differences were observed.  
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Figure 3-5: Induction of IFNγ ΔSFC measured by ELISPOT following DC vaccination, 
approaches not taken forward into further studies. 
Mice received 1 x 106 BMDCs stimulated as indicated on the x-axis and administered i.d. 
to A/J mice (n=3). Spleens were taken at 7 days (Panel A) and 14 days (Panel B) post- 
vaccination and restimulated ex vivo with rPA and ΔSFC enumerated. A Kruskal-Wallis 
test with Dunn’s multiple comparison post-hoc test was performed on the results, no 
significant differences were observed.  
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Figure 3-6: Induction of IFNγ ΔSFC measured by ELISPOT following administration of 
the DC vaccination and rPA and alum vaccination. 
Mice received 1 x 106 BMDCs stimulated with rPA (10 μg/mL), heat killed B. anthracis 
(104 CFU/mL) and CpG oligonucleotides (6 μg/mL), the DC vaccine. This was 
administered i.d. in combination with rPA in alum (10 μg mouse in 0.26% alum) given 
i.m to A/J mice (n=6). Spleens were taken seven (A) and fourteen (B) days post 
vaccination and restimulated with rPA with ΔSFC enumerated. A Kruskal-Wallis test with 
Dunn’s multiple comparison post-hoc test was performed on the results (* p<0.05, ** p< 
0.01, *** p<0.001). 
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Figure 3-7: Induction of a rPA specific IgG antibody response to vaccination 
Mice received 1 x 106 BMDCs stimulated with rPA (10 μg/mL), heat killed B. anthracis 
(104 CFU/mL) and CpG oligonucleotides (6 μg/mL), the DC vaccine. This was 
administered i.d. in combination with rPA in alum (10 μg mouse in 0.26% alum) given 
i.m to A/J mice (n=6). The IgG antibody response was enumerated 14 days post-
vaccination . Each point represents the mean of three replicates from six animals. A one-
way Anova with Tukey multiple comparison post-hoc test was performed on the results 
(* p<0.05, ** p< 0.01, *** p<0.001).  
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Figure 3-8: Post-challenge survival following vaccination with the DC vaccine, rPA and 
alum or both in combination. 
Mice received 1 x 106 BMDCs stimulated with rPA (10 μg/mL), heat killed B. anthracis 
(104 CFU/mL) and CpG oligonucleotides (6 μg/mL), the DC vaccine. This was 
administered i.d. in combination with rPA in alum (10 μg mouse in 0.26% alum) given 
i.m to A/J mice (n=5). Mice were challenged at 14 days post-immunisation with 3x104 
CFU B. anthracis STI (i.p.) and monitored for survival over the subsequent 8 days, at 
which point survivors were culled for further analysis.  
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Figure 3-9: Enumeration of viable B. anthracis in the spleens of cohorts of mice two 
days post challenge. 
Mice received 1 x 106 BMDCs stimulated with rPA (10 μg/mL), heat killed B. anthracis 
(104 CFU/mL) and CpG oligonucleotides (6 μg/mL), the DC vaccine. This was 
administered i.d. in combination with rPA in alum (10 μg mouse in 0.26% alum) given 
i.m to A/J mice (n=5). Mice were challenged at 14 days post-immunisation with 3x104 
CFU B. anthracis STI (i.p.) and monitored for two days.  At this point bacterial load within 
the spleen was enumerated with each point representing the mean of three replicates 
from five animals, four from the naïve group due to an early death. A Kruskal-Wallis test 
with Dunn’s multiple comparison post-hoc test was performed on the results (* p<0.05, 
** p< 0.01, *** p<0.001). 
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3.3 Discussion 
 
In this chapter I have taken a stepwise approach to vaccination, initially determining the 
immunological effect of DC vaccination on CMI responses, before the addition of a 
simultaneous rPA and alum vaccination to determine if DC vaccination can enhance 
existing vaccines, with the rationale that by enhancing CMI there could be a significant 
improvement in bacterial clearance post-exposure. 
 
Pathogens express a range of PAMPs, highly conserved microbial molecules critical to 
pathogen function and are recognised by germ-line encoded PRR’s including TLRs. 
Central to the process of developing an adaptive immune response is the uptake of 
antigen by DCs and their maturation due to PRR ligation. Maturation of DCs includes 
alterations to cellular morphology including the development of cellular extensions, 
increasing the surface area that can interact with T cells [397] and migration to 
secondary lymph organs. Additionally phenotypic changes include increased expression 
of MHC-II and costimulatory molecules at the cell surface, with the pattern of 
costimulatory molecules determining whether they have a tolerogenic or immunogenic 
affect upon naïve T cells. Currently it is unclear which PRRs B. anthracis vegetative bacilli 
ligate, with TLR2-/- and TLR4-/- mice being no more susceptible to aerosol infection than 
wild type mice [398]. However, MyD88-/- mice are susceptible to aerosol infection, 
indicating MyD88 signalling pathways, which is fundamental for signalling through 
multiple PRRs, to be important for host innate immune responses to B. anthracis [398].  
 
The cells cultured from bone marrow were assessed for their expression profile of 
CD11c and MHC-II and compared to a recent paper published by Helft et al [399]. These 
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cells were GM-CSF derived BMDCs and were shown to contain a heterogeneous mix of 
cells [399], they were all CD11c+ MHC-II+ so would be traditionally thought to be DCs. 
However, phenotypic and functional analysis split these cells into macrophages-like and 
DC-like populations [399]. The cells prepared for this thesis were broadly similar in their 
expression of CD11c and constitutive expression of MHC-II by unstimulated BMDCs with 
MHC-II upregulated following stimulation with CpG ODN.  
 
It is also important to note that there are significant differences in the culture methods 
used to prepare BMDCs in this thesis and by Helft et al [399]. Firstly there was a 
difference in the length of the culture period, seven days in this thesis compared to six 
by Helft et al; secondly there was a difference in replenishing the culture media in that 
cells prepared for this thesis were fed by replacing half the media at days three and five 
whilst Helft et al replaced half the media at day two and all the media at day three, 
thereby enriching for cells that were either adherent or loosely adherent; finally Helft et 
al together with a companion commentary [400] both note the importance of 
manufacturer and batch of media, foetal calf serum and GM-CSF in the preparation of 
BMDCs. For all reagents different manufacturers were used. All these variations could 
account for the differences in the dot plots observed. 
 
The in vitro maturation of DCs was dependent on the presence of CpG, with rPA and 
heat-killed B. anthracis spores having no impact upon the upregulation of MHC-II, CD80, 
CD86 and CD40.  A major function of immature DCs in peripheral tissues is the endocytic 
uptake of exogenous antigens derived from extracellular sources for processing within 
the cell and presentation on MHC-II to CD4+ T cells, important for initiating clonal 
expansion and an adaptive immune response. Previous reports have shown 
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upregulation of MHC-II on DCs in response to bacterial antigens to increase T cell activity 
[401]. However immature DCs do not efficiently produce MHC-II–peptide complexes and 
their expression at the cell surface is not stable due to ubiquitination of a single 
conserved lysine residue found in the cytoplasmic domain of the β-chain resulting in the 
breakdown of these complexes [402]. DC maturation signals, for example TLR ligation, 
ceases the ubiquitination process and MHC-II complexes accumulate at the cell surface 
for presentation of peptides to T cells [403] [404]. 
 
The costimulatory molecules CD80 and CD86 expressed on mature DCs bind to CD28 on 
T cells inducing  IL-2 secretion, crucial for the survival and proliferation of a primary T 
cell response [405]. CD86 is the main activation marker of murine BMDC and is strongly 
upregulated after maturation whilst CD80 expression is less pronounced [380]. 
Concomitantly T cells express CTLA-4 which has a higher affinity for CD80/CD86 than 
CD28, ligation of CTLA-4 down-regulates T cell responses serving as a regulator of T cell 
responses [406]. DCs and other APCs upregulate CD40 when activated. The CD40/CD40L 
interaction regulated cellular and humoral immunity, particularly T cell priming and 
differentiation [407]. 
 
Ligation of CD40 on DCs increases expression of costimulatory molecules, MHC-II 
expression and adhesion molecules together with increased production of IL-12 [408], 
[409]. However weak CD40/CD40L signalling induces IL-10 production associated with 
an anergic T cell response [410]. 
 
It is important to point out the differences in CD80, CD86, CD40 and MHC-II expression 
described in this thesis and the paper of this chapter published in PlosOne [411]. The 
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published paper demonstrated that rPA could upregulate all the molecules studied 
[411], however when rPA was reanalysed after publication it was found not to induce 
upregulation of any of these markers. For the published study a single aliquot of rPA was 
used to perform the stimulations, when it was reassessed a different aliquot of the same 
batch was used. Potentially, the aliquot used in the published study was contaminated, 
generating the ambiguous data. Multiple aliquots were trialled for the data presented in 
this thesis, providing confidence that this data is accurate.    
 
Specifically-stimulated DCs were administered i.d. to naïve mice with this approach 
failing to induce any detectable antigen-specific cellular immune response, as measured 
by IFNγ+ cells following ex vivo antigen restimulation, 14 days post vaccination. This 
should not be surprising as previous studies have shown a single DC vaccination to 
require 28 days[412] or multiple vaccinations over 28 [99] or 35 [86] days for an antigen-
specific IFNγ response. However, in other studies a single DC vaccination produced a 
detectable immune response after 14 days, but this was only partially protective against 
P. aeruginosa [96]. This provides evidence that a single DC vaccination is unlikely to be 
sufficient to provide rapid protective immunity against B. anthracis. 
 
To determine if the response could be enhanced, active immunisation with rPA and 
alum was combined with DC vaccination. Mice receiving this combined immunisation 
had significantly enhanced CMI responses at only 7 days, compared to those immunised 
with rPA and alum alone, demonstrating that DC vaccination both accelerated and 
enhanced the response to conventional active immunisation. T cell responses are 
important as they provide help to B cells to produce antibodies (CD4+ T cells), are 
capable of killing cells displaying epitopes perceived as dangerous on MHC-I (CD8+ T 
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cells), and produce cytokine and chemokines to recruit other leucocyte populations, 
including neutrophils and macrophages. As an inflammatory event resolves, regulatory T 
cells (Tregs) help dampen down the immune response together with the development of 
memory T cells that persist long after infection. 
 
An rPA-specific antibody response was absent seven days post-vaccination, this was to 
be expected due to the time required for antigen uptake by DCs and their migration to 
lymph nodes, the clonal expansion of helper T cells and antibody production by B cells. 
By fourteen days post-vaccination an rPA-specific antibody response had developed 
with significantly elevated antibody responses in both groups receiving rPA and alum 
compared to the group receiving the DC vaccine alone. As previously described anti-PA 
antibodies are crucial for preventing the establishment of a systemic infection and 
reducing the effects of the anthrax toxins [390]. 
 
The efficacy of the combined immunisation regimen was tested by challenging mice at 
day 14 post-immunisation with a lethal dose of B. anthracis. Whilst naïve mice rapidly 
succumbed to infection, 80% of those immunised with rPA and alum survived. The DC 
vaccine alone protected 60% of mice and this protection was attributed predominantly 
to the induction of a specific CMI response due to a decreased bacterial load compared 
to naïve mice, in the absence of a strong antibody response. The combined 
immunisation with rPA in alum and DC vaccine protected all the mice with a highly 
significant reduction in splenic bacteria compared to rPA and alum vaccinated mice.  
Mice receiving either the DC vaccine only or rPA in alum only had similar bacterial loads 
which were significantly reduced compared with naïve mice, but still elevated compared 
with the combined vaccine group.  
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This study provides proof-of-principle that a single immunisation with specifically 
activated DCs can augment the response to conventional active immunisation, with 
benefits in terms of accelerating time to immunity, specific CMI, survival and most 
significantly, clearance of B. anthracis in the murine model.  Whilst these are significant 
findings, the passive transfusion of pre-stimulated DCs is not a pragmatic approach to 
mass vaccination in people with DCs targeted with vaccine antigens in situ a more 
practical approach.  
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Chapter 4: In vitro stimulation of BMDCs with B. pseudomallei 
antigens and their migration in vivo  
4.1 Introduction 
Dendritic cells (DCs) have a wide distribution throughout the body and are particularly 
found at potential entry routes for pathogenic organisms including the lungs, 
gastrointestinal tract and skin. They have a major role in immune surveillance detecting 
dangerous antigens, either foreign or self and are the most potent APC [2]. DCs help to 
drive immune activation due to their ability to process and present antigens with high 
levels of costimulatory molecules and cytokine production, required for the 
differentiation, proliferation and polarisation of naïve T cells [66]. DCs commonly detect 
dangerous antigens in the periphery causing them to mature and migrate to secondary 
lymph organs where they activate naïve T cells.  
 
 Maturation and alteration of phenotype and function 4.1.1
Immature DCs have a phenotype and functionality whereby they take-up large 
quantities of antigen from the surrounding milieu without having the ability to stimulate 
T cells. To induce this ability DCs undergo a maturation process triggered by PRR, either 
membrane bound or cytosolic, ligation. PRRs include TLRs, C-type lectins (CTLs), NOD-
like receptors (NLRs) and RIG-1-like receptors (RLRs). Additional maturation signals 
include inflammatory cytokines including TNF, or cell signalling pathways such as CD40-
CD40L interactions [32].  
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CpG ODN’s have been previously introduced and throughout the studies reported here 
have been used as an adjuvant to help stimulate an immune response. Previously the B-
type CpG ODN 1826 has been shown to be crucial for prophylactic DC vaccination for B. 
pseudomallei with vaccination formulations lacking this of CpG resulting in decreased 
survival [85].  
 
 Migration of dendritic cells to lymph nodes 4.1.2
DCs migrate from the periphery to secondary lymph organs via lymphatic fluid. 
Lymphatic fluid is absorbed from interstitial fluid with a unidirectional flow from the 
periphery, passing through lymph nodes, en route to the thoracic duct where it re-
enters circulation [413]. Initial lymphatic vessels are blind ended, highly endocytic and 
permeable to proteins [414]. These collect into larger ducts where flow is regulated by 
smooth muscle cells and valves preventing cells or signalling molecules moving against 
the flow [413]. DCs reach lymph nodes via the afferent lymphatics where they enter the 
T cell zone and under appropriate conditions initiate an adaptive immune response. 
 
DCs continuously migrate from peripheral tissues to lymph nodes, under steady state 
conditions, however only a small proportion of DCs within a lymph node have migrated 
from peripheral tissues [415]. The majority of lymph node resident DCs are in an 
immature state [416] and are important for the deletion, anergy or regulation of auto-
reactive T cells [417]. Lymph node resident DCs are most prevalent in the marginal zone 
and red pulp and following maturation migrate to the T cell area [150]. Recently there 
has been a growing body of evidence to suggest that DCs that have migrated to lymph 
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nodes do not directly present antigen to T cells but instead deliver antigen to lymph 
node-resident DCs for the induction of adaptive immune responses [418-421].  
 
Chemokines are a small (~8-14kDa) structurally related group of molecules that regulate 
leukocyte trafficking via interactions with G-protein coupled receptors enabling 
directional migration of cells along a chemokine gradient [422]. Cell locomotion is crucial 
to the induction of innate and adaptive immune responses and pivotal to the 
recruitment of inflammatory cells to the site of inflammation [423]. Chemokines are 
rapidly produced in response to infection and are able to direct cellular migration and 
activation facilitating a key role of innate immunity [424]. Directed cell migration is a 
tightly regulated process which is critical for numerous biological functions including 
immune development and homeostasis, tissue development, wound healing and 
pathogen protection [422].  
 
Chemokines can be broadly divided into two major subfamilies, the CC chemokines and 
the CXC chemokines, further chemokine groups include the C and CX3C chemokines 
[425] [426]. The differentiation between the two subfamilies depends on the 
arrangement of the two N-terminal cysteine residues. CC chemokines are adjacent to 
each other whilst CXC chemokines have an amino acid residue between them [422]. 
Chemokine interactions with their receptors can be unique, for example CCL20-CCR6; 
others have multiple receptors with CCL5 binding to CCR1, CCR3 and CCR5; whilst other 
chemokine receptors have multiple ligands such as CCR2 binding to CCL2, CCL7, CCL8 
and CCL12 [427].  
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Immature DCs (iDCs) can migrate to inflamed tissues due to their expression of a variety 
of chemokine receptors that enable them to recognise and respond to inflammatory 
stimuli [428]. iDCs expression of chemokine receptors includes CCR1, CCR2, CCR5 and 
CCR6 [429] [430]. CCR1 enables iDC migration to the Peyer’s patches [431] and lung 
[432]; CCR2 to the lung  [433] and Langerhans cells to lymph nodes [434]; CCR5 pDCs in 
the blood to lymph nodes [435]; CCR6 enables iDCs to migrate to Peyer’s patches 
[436]and inflamed skin [437]. 
 
Maturation of DCs causes the downregulation of the majority of these receptors and the 
upregulation of CCR7 [438] and CXCR4 [439]. CCR7 enables migration along 
concentration gradients of CCL19 and CCL21 [440] which are highly expressed by lymph 
nodes whilst CXCR4 recognises CXCL12 also required for DC migration to lymph nodes. 
CCL19 is 10-100 fold more chemotactic than either CCL21 or CXCL12 in causing DC 
migration [441] however CXCR4 upregulation is required for the migration of cutaneous 
DCs to lymph nodes [439].  In order for CCR7+ DCs to respond to concentration gradients 
of CCL19 and CCL21 they are either required to express high levels of CCR7 or need to be 
sensitised by proinflammatory stimuli such as leukotrienes or prostaglandin E2 [442] 
[443].  Once DCs reach the T cell area of lymph nodes they are able to induce an 
adaptive immune response with the aim of eliminating the pathogenic organism and the 
establishment of immune memory. 
 
 In vivo imaging techniques 4.1.3
There are a variety of techniques that enable cell tracking in vivo. Cell tracking has been 
defined as the ability to follow specific cells in vivo, whether that be their localisation or 
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alternatively their fate, functionality or differentiation [444]. Techniques that can be 
used to track cells include single photo emission computed tomography (SPECT), 
positron emission tomography (PET), whole body scintigraphy, magnetic resonance 
imaging (MRI), fluorescence imaging (FLI) and bioluminescence imaging (BLI). All are 
powerful non-invasive tools that can be used for biomedical imaging or clinical diagnosis 
and therefore have an important role in the development of cellular therapies [445]. 
 
SPECT, PET, and whole body scintigraphy are all highly sensitive and quantifiable but 
require the use of radiolabels, exposing the subjects to radiation. As a consequence 
their dosage and use is limited and tightly regulated [444]. MRI labels cells with iron 
oxide nano or microparticles or alternatively with another metal such as gadolinium or 
manganese. MRI can be highly sensitive with single cell imaging possible but 
quantification is difficult although the development of 19F MRI may overcome this [446]. 
FLI and BLI are limited by the penetration of light into and out of tissues. They are widely 
used in preclinical studies but despite their ease of use there is limited potential for 
translation to clinical studies [444]. FLI requires a light source, fluorescence filters and a 
charge-coupled device (CCD) camera housed in a light tight chamber [447]. Fluorescence 
can be detected from expression of engineered proteins into cells [448], or by dyes used 
to label cells prior to adoptive transfer [449]. BLI is similar to FLI but requires the 
intracellular enzyme luciferase which catalyses its substrate luciferin to oxyluciferin with 
the release of a photon. This technique can only be used with transgenic viable cells but 
provides negligible background and good sensitivity [450]. 
 
Previously a variety of techniques to fluorescently label cells for in vivo tracking have 
been used. Cells have been directly labelled in situ rather than in vitro using the 
133 
 
fluorescent dye CFSE. This approach labelled all circulating leucocytes and following 
dissection of lymph nodes, using multicolour flow cytometry enable the migration of 
host DCs to lymph nodes to be monitored [451] but required mice to be culled for 
imaging to occur. Knock-in mice expressing the photoconvertable protein KikGR when 
exposed to violet light irreversibly converts KikGR fluorescence from green to red. After 
exposure of mice to skin injury and violet light, skin DCs could be tracked to lymph 
nodes [452]. Quantum Dots, semiconductor nanocrystals that exhibit very bright and 
photostable fluorescence have been used to both directly label BMDCs in vitro and also 
injected directly into mice with adjuvant where they enabled migration of skin DCs to 
lymph nodes to be followed [453]. 
 
All methods of tracking cells in vivo have their advantages and limitations. Dyes such as 
CellVue Claret, which label cells by partitioning into lipid regions of the cell membrane 
don’t alter cellular functions if used at the correct concentrations [454]. Additionally 
once intercalated into the lipid bilayer they are very stable due to strong hydrophobic 
interactions and have been used in numerous in vivo tracking studies[454] [455] [456]. 
The main limitation of such dyes is their partition into the lipid bilayer prevents their use 
in long-term in vivo studies, over weeks or months, as the dye intensity decreases with 
each round of cellular division [455]. However in the studies described below cells were 
only followed for 72 hours, negating this impact. 
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 Aims of this chapter 4.1.4
To assess the effect of stimulating BMDCs on their maturation and phenotype in vitro 
together with their ability to migrate to lymph nodes following adoptive transfer. To 
achieve this 
 The alteration in the expression over time of BMDC surface molecules that are 
important for the induction of an antigen specific T cell response will be assessed in 
vitro following stimulation with heat-killed B. pseudomallei and CpG . 
 Characterisation of the alteration in gene expression via RT-PCR array of BMDCs with 
heat-killed B. pseudomallei and CpG following in vitro stimulation. 
 To track adoptively transferred BMDCs in vivo, from injection site to lymph nodes. 
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4.2 Results 
 
 Activation of dendritic cells 4.2.1
To investigate the activation of DCs prior to their use for in vivo immunisations, DCs 
were stimulated ex vivo with heat-killed B. pseudomallei with and without CpG with the 
upregulation of costimulatory molecules assessed by flow cytometry at specific time 
points post-stimulation, Figure 4-1. Expression of CD40, CD80, CD86 and MHC-II was 
assessed two, six, eighteen and twenty-four hours post-stimulation. Two hours post-
stimulation none of the markers were significantly upregulated for any condition. By six 
hours groups stimulated with heat-killed B. pseudomallei and CpG, LolC and CpG or CpG 
alone had significantly upregulated CD40, CD80, CD86 and MHC-II, Table 8 shows p 
values for all conditions. At eighteen hours post-stimulation significant upregulation of 
CD40, CD80, CD86 and MHC-II was again observed for groups stimulated with heat-killed 
B. pseudomallei and CpG, LolC and CpG or CpG but also for heat-killed B. pseudomallei. 
Twenty-four hours post-stimulation upregulation of CD40, CD80 and CD86 persisted for 
groups stimulated with heat-killed B. pseudomallei and CpG, LolC and CpG or CpG and 
heat-killed B. pseudomallei. However there was no significant difference in MHC-II 
expression compared to the unstimulated control for any group.  
 
Following determination that 18 hours was the optimal stimulation time the 
upregulation of CCR7 and DEC205 was assessed following 18 hours of stimulation 
(Figure 4-2). Both were significantly upregulated (p <0.05) when BMDCs were stimulated 
by either heat-killed B. pseudomallei and CpG or CpG alone but not when stimulated by 
heat-killed B. pseudomallei alone.  
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 Assessment of gene upregulation by PCR array  4.2.2
The upregulation of genes important for DC antigen uptake, antigen presentation, 
dendritic cell chemotaxis, dendritic cell differentiation, cytokines, cytokine receptors 
and signal transduction was investigated. BMDCs were stimulated ex vivo for 18 hours 
with B. pseudomallei antigens and/or CpG as an adjuvant, mRNA was extracted, 
converted to cDNA and analysed using the Qiagen Mouse Dendritic and Antigen 
Presenting Cell RT² Profiler PCR Array. Following stimulation, gene expression levels for 
all groups were determined Figure 4-3, and compared to the unstimulated control group 
Figure 4-4, with genes that were upregulated or downregulated with at least a two-fold 
change shown in Table 9. This shows that a range of genes important for antigen 
presentation, chemotaxis, signal transduction together with the production of cytokines 
and chemokines were upregulated compared to the unstimulated control group. 
Amongst the genes upregulated were those for several chemokines: Ccl2, Ccl3, Ccl4, 
Ccl5, Ccl7, Ccl12, Cxcl1, Cxcl2 and Cxcl10; cytokines: Il10, Il12p35, Il12p40 and Il6; 
molecules important for antigen presentation: Cd40, Cd80, Cd86 and Thbs1; together 
with Fcgr1, Irf7 and Tlr1. The only gene to be down-regulated was Ccr2. Furthermore 
the bias of the genes towards a DC or macrophage phenotype is represented in Figure 4-
5. 
 
 Migration of dendritic cells to lymph nodes 4.2.3
In order to determine if stimulated, adoptively transferred BMDCs were migrating from 
injection site to lymph nodes BMDCs were fluorescently labelled prior to introduction to 
the host. This enabled the labelled BMDCs to be tracked in vivo using an In vivo Imaging 
System (IVIS). Immediately post injection (i.d.) BMDCs could be clearly viewed at the 
injection site, this fluorescence at the injection site persisted for the duration of the 
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study. By 48 hours post injection and persisting to 72 hours, a clear fluorescent area had 
emerged in the area of the axillary/brachial lymph nodes. To examine this more closely 
the skin overlying the lymph node was carefully removed revealing a clearly fluorescent 
lymph node underneath, Figure 4-6.  
 
Axillary, brachial, inguinal and popliteal lymph nodes from the 24, 48 and 72 hour time 
points were removed and macerated after imaging. Cells were stained with CD11c and 
the nuclear stain DAPI and interrogated using an ImageStream-X. Figure 4-7 shows the 
gating strategy and a data sample from this imaging flow cytometer. The percentage of 
nucleated, CellVue Claret+ and CD11c+ cells within the lymph node was determined, 
Figure 4-8. This shows the number of these triple positive cells to peak at 48 hours and 
then to slightly decrease by 72 hours. By 144 hours post-introduction of the stained cells 
levels of fluorescence within the lymph node had returned to baseline levels. 
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Figure 4-1: Upregulation of costimulatory molecules and MHC-II following stimulation 
of DCs. 
BMDCs (1 x 106/mL) were stimulated with: 106 CFU heat-killed B. pseudomallei, 6 µg/mL 
CpG,  106 CFU heat-killed B. pseudomallei and 6 µg/mL CpG, 10 µg/mL LolC or 10 µg/mL 
LolC and 6 µg/mL CpG and harvested at 2, 6, 18 or 24 hours. Events were gated based 
on their forward scatter/side scatter properties. Subsequently doublets were excluded 
via gating on forward scatter height/forward scatter area and CD11c+ cells assessed for 
expression of CD40, CD80, CD86 and MHC-II using a FACS Canto II flow cytometer. Data 
was analysed using FlowJo v10. The data shown is representative of three independent 
experiments. Samples were analysed using a two-way ANOVA and Dunnett’s multiple 
comparisons post hoc test. The star’s indicate where stimulation has significantly 
upregulated expression and for which groups, full details are provided in Table 8.   
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Table 8: Upregulation of activation markers following stimulation of DCs, p values for each condition.  
BMDCs (1 x 106/mL)  were stimulated with: 106 CFU heat-killed B. pseudomallei, 6 µg/mL CpG,  106 CFU heat-killed B. pseudomallei and 6 µg/mL CpG, 
10 µg/mL LolC or 10 µg/mL LolC and 6 µg/mL CpG and harvested at 2, 6, 18 or 24 hours. CD11c+ cells were assessed for their expression of CD40, 
CD80, CD86 and MHC-II using a FACS Canto II flow cytometer. The table below shows the p-values for each condition at each time point from Figure 
4-1. Samples were analysed using a two-way ANOVA and Dunnett’s multiple comparisons post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p 
< 0.0001. 
 
CD40 CD80 
 
2 hours 6 hours 18 hours 24 hours 2 hours 6 hours 18 hours 24 hours 
Unstimulated vs. Heat-killed B. pseudomallei  ns ns **** **** ns ns *** **** 
Unstimulated vs. CpG ns **** **** **** ns **** **** **** 
Unstimulated vs. Heat-killed B. pseudomallei & CpG ns **** **** **** ns **** **** **** 
Unstimulated vs. LolC ns ns ns ns ns ns ns ns 
Unstimulated vs. LolC & CpG ns *** **** **** ns **** **** **** 
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CD86 MHC-II 
 
2 hours 6 hours 18 hours 24 hours 2 hours 6 hours 18 hours 24 hours 
Unstimulated vs. Heat-killed B. pseudomallei  ns ns * ** ns ns *** ** 
Unstimulated vs. CpG ns ** **** ** ns **** *** ns 
Unstimulated vs. Heat-killed B. pseudomallei & CpG ns *** **** *** ns **** *** ns 
Unstimulated vs. LolC ns ns ns ns ns ns ns ns 
Unstimulated vs. LolC & CpG ns ** **** ** ns **** ** ns 
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Figure 4-2: Stimulation with CpG increases the expression of CCR7 and DEC205 by 
BMDCs  
BMDCs (1 x 106/mL) were stimulated for 18 hours with heat-killed B. pseudomallei (104 
CFU/mL), heat-killed B. pseudomallei (104 CFU/mL) and CpG (6 µg/mL) or CpG (6 µg/mL) 
alone. Events were gated based on their forward scatter/side scatter properties. 
Subsequently doublets were excluded via gating on forward scatter height/forward 
scatter area and CD11c+ cells  assessed for their expression of CCR7 or DEC205 using a 
FACS Canto II flow cytometer and data analysed using FlowJo v10. The data shown is 
representative of three independent experiments. Samples were analysed using a two-
way ANOVA and Dunnett’s multiple comparisons post hoc test, (* p < 0.05, ** p < 0.01, 
*** p < 0.001). 
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Figure 4-3: Heat map representing gene expression alteration for each stimulation 
condition.  
BMDCs (1 x 106/mL) were stimulated for 18 hours with heat-killed B. pseudomallei (104 
CFU/mL), heat-killed B. pseudomallei (104 CFU/mL) and CpG (6 µg/mL), CpG (6 µg/mL), 
LolC (10 µg/mL) or LolC (10 µg/mL) and CpG (6 µg/mL).  mRNA was extracted, quantified 
and converted to cDNA before gene upregulation assessed using the Qiagen Mouse 
Dendritic and Antigen Presenting Cell RT2 Profiler PCR Array. Green colouration depicts 
minimal gene expression whilst red colouration shows maximal gene expression. 
Experiments were performed in triplicate. 
  
Control Group: 
Unstimulated  
Group 1: Heat-killed B. 
pseudomallei 
Group 2: CpG  
Group 3: Heat-killed B. 
pseudomallei & CpG 
Group 4: LolC 
Group 5: LolC & CpG 
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Figure 4-4: Heat maps showing alteration in gene expression for each condition 
compared to unstimulated control. 
BMDCs (1 x 106/mL) were stimulated for 18 hours with heat-killed B. pseudomallei (104 
CFU/mL), heat-killed B. pseudomallei (104 CFU/mL) and CpG (6 µg/mL), CpG (6 µg/mL), 
LolC (10 µg/mL) or LolC (10 µg/mL) and CpG (6 µg/mL).  The heat maps show 
upregulation (red) or downregulation (green) of genes important for BMDC function. 
mRNA was extracted, quantified and converted to cDNA before gene alteration was 
assessed using the Qiagen Mouse Dendritic and Antigen Presenting Cell RT2 Profiler PCR 
Array, see Table 7 for gene layout. Experiments were performed in triplicate. 
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Table 9: Genes upregulated or downregulated following stimulation compared to unstimulated control 
The table shows all genes that were at least two-fold upregulated (red) or downregulated (green) compared to the unstimulated control in Figure 
4-4. Analysis was performed using SABiosciences RT2 Profiler PCR Array Data Analysis version 3.5. 
  
Heat-killed 
B. pseudomallei 
CpG Heat-killed 
B. pseudomallei & 
CpG 
LolC LolC & CpG 
Ccl12     4.05 
Ccl2  2.11 3.17  2.84 
Ccl3  2.14   2.03 
Ccl4  2.9   2.58 
Ccl5 2.74 10.06 10.53  33.62 
Ccl7  4.26 3.91  7.52 
Cd40  5.26 6.36  22.18 
Cd80  2.62 2.98  3.5 
Cd86  2.01 2.65  5.1 
Cxcl1  6.21 5.23  6.2 
Cxcl10  5.04 6.22  25.36 
Cxcl2  2.54 2.15  2.07 
Fcgr1  3.24 2.55  6.1 
Il10  3.71 5.31  13.78 
Il12a  2.54 2.00  2.05 
Il12b 6.53 35.85 66.56  414.34 
Il6  10.66 11.88  42.26 
Irf7 4.62 9.63 21.51  46.79 
Thbs1 23.85 24.43 20.82 22.43 11.46 
Tlr1  2.36 2.15  3.59 
Ccr2 -10.7  -5.4  -6.8 
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Dendritic cell populations Macrophage 
populations 
Dendritic cell populations Macrophage  
populations 
Heat map of genes expressed by DCs and macrophages 
that form the entire Qiagen Mouse Dendritic and Antigen 
Presenting Cell RT2 Profiler PCR Array.   
Heat map of genes expressed by DCs and macrophages 
that were upregulated as described in Table 9 when 
assessed using the Qiagen Mouse Dendritic and Antigen 
Presenting Cell RT2 Profiler PCR Array.   
A B 
Figure 4-5: Comparison of gene expression between DC and macrophages. 
The DC or macrophage bias of genes that form the Qiagen Mouse Dendritic and Antigen Presenting Cell RT2 Profiler PCR Array were determined using 
the www.immgen.org database. Genes from the entire assay (A) or those that were upregulated (B) were entered into the Immgen database and heat-
maps generated. These show low gene expression (blue) through to high gene expression (red) of a given gene for different DC and macrophage 
populations. 
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Figure 4-6: In vivo images of mice immunised with fluorescently labelled BMDCs 
BMDCs (1 x 106 cells/mL) were stimulated with heat-killed B. pseudomallei (104 CFU/mL) 
and CpG (6 µg/mL) for 18 hours, harvested and washed three times in PBS. Cells were 
labelled with CellVue Claret and mice received 1 x 106 cells i.d. in the scruff. Mice were 
imaged using an In Vivo Imaging System (IVIS) at 0, 48 and 72 hours post-injection.  
 
    0 hours             48 hours 
 
 
 
 
 
 
 
 
                  72 Hours               72 Hours, skin removed 
 
  
Injection site 
Lymph node 
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Figure 4-7: Identification of fluorescent cells within lymph nodes following adoptive 
transfer 
BMDCs (1 x 106 cells/mL) were stimulated with heat-killed B. pseudomallei (104 CFU/mL) 
and CpG (6 µg/mL) for 18 hours, harvested, washed three times in PBS and labelled with 
CellVue Claret. Mice received 1 x 106 labelled cells i.d. At 72 hours post-injection 
fluorescent lymph nodes were excised, macerated, stained for CD11c and analysed 
using an ImageStream X. The percentage of CD11c+ CellVue Claret+ cells was 
determined from cells that were in focus (a) single cells (b). The ImageStream X enables 
visualisation of stained cells to confirm localisation of fluorescent dyes (c). The staining 
for this experiment consists of CD11c (Yellow), DAPI (Blue) and CellVue Claret (Red).  
 
 
c) Visualisation of stained cells 
 
a) b) 
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Figure 4-8: Quantification of cell numbers within lymph nodes 
BMDCs (1 x 106 cells/mL) were stimulated with heat-killed B. pseudomallei (104 CFU/mL) 
and CpG (6 µg/mL) for 18 hours, harvested, washed three times in PBS and labelled with 
CellVue Claret. Mice received 1 x 106 labelled cells i.d. At 24, 48, 72 and 144 hours post 
injection lymph nodes were removed, macerated and stained for CD11c. The percentage 
of cells within the lymph nodes that were CD11c+ and CellVue Claret+ was assessed as 
the percentage of cells within the lymph node. 
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4.3 Discussion 
 
In this chapter I have examined the effect of stimulating DCs with heat-killed B. 
pseudomallei, CpG and the B. pseudomallei ABC transporter LolC. Initially the alteration 
in expression of MHC-II and the costimulatory molecules CD40, CD80 and CD86 was 
assessed over time. Subsequently the upregulation or downregulation of 84 DC genes 
important in immune responses was assessed before following the migration of 
stimulated DCs to lymph nodes in vivo.  
 
The maturation of dendritic cells in response to pathogens is a well-defined process and 
enables DCs to stimulate and coordinate an adaptive immune response. The process of 
DC maturation includes the upregulation of costimulatory molecules, cytokines, 
chemokines, chemokine receptors and adhesion molecules together with the 
downregulation of endocytic and phagocytic activity and alterations in cellular 
morphology [457] [458]. Several time course studies have demonstrated the process of 
DC maturation to be a highly complex and ordered transition [459] [460] [461]. 
 
Previously I have assessed the upregulation of CD80, CD86, CD40 and MHC-II on BMDCs 
in response to stimulation with heat-killed B. anthracis, rPA or CpG. As part of this 
chapter the changing expression of these costimulatory molecules over time was 
determined for a second pathogen, B. pseudomallei. The surface proteins were all 
rapidly upregulated (6 hours) when BMDCs were stimulated with CpG or with CpG in 
combination with either heat-killed B. pseudomallei or LolC. Stimulation with heat-killed 
B. pseudomallei also upregulated all the molecules assessed but a significant increase 
was not observed until 18 hours. Upregulation of the surface molecules peaked at 18 
150 
 
hours followed by a numerical decrease following 24 hours of stimulation. A similar 
pattern in the expression of the genes for CD86 and MHC-II following DC exposure to 
the contact allergen nickel sulphate has been previously described, although CD80 and 
CD40 were not assessed [460]. Microarray analysis of gene expression in vivo mediated 
by CpG ODNs has demonstrated a rapid upregulation in genes important for cell 
movement, immune response and cell signalling, followed by a steady decrease in their 
expression over three days [462]. A second peak in gene expression occurred five days 
after the administration of CPG ODNs. These genes were different from those earlier 
upregulated and were important for cell cycle together with DNA replication and repair 
[462]. This early peak and subsequent decline in gene activity may explain the decrease 
in costimulatory molecules observed, however long term in vitro experiments have been 
hampered by artefacts induced by cell culture altering gene expression [463]. 
 
CCR7 is upregulated upon DC maturation [438] enabling DC migration along 
concentration gradients of CCL19 and CCL21 to lymph nodes [440].  DEC205 is 
constitutively expressed at low levels on immature DCs with expression upregulated 
upon DC maturation [212]. Both CCR7 and DEC205 were upregulated following 
stimulation with CpG but this was antigen-independent as upregulation did not occur 
when BMDCs were stimulated with heat-killed B. pseudomallei alone. 
 
Once the optimal time duration to pulse BMDCs had been determined the alteration of 
gene expression was assessed using the Qiagen Mouse Dendritic and Antigen Presenting 
Cell RT2 Profiler PCR Array. This contains genes that are important for antigen uptake, 
antigen presentation, chemotaxis, cellular differentiation, cytokine production, signal 
transduction and other cell surface receptors. The importance of the genes upregulated 
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or downregulated by at least two-fold (Table 9) will be briefly discussed in the setting of 
infectious disease to highlight their importance upon host immunity. 
 
CCL2, CCL7 and CCL12 all bind to CCR2 which has an important role in the recruitment of 
monocytes, DCs and Tregs to sites of inflammation [464]. Murine infection with Listeria 
monocytogenes has shown both CCL2 and CCL7 are required for the recruitment of 
monocytes to the site of infection and that a lack of either chemokine results in 
impaired clearance of the bacterium and enhanced susceptibility to infection [427]. 
Furthermore CCR2 is important for DC recruitment in response to pulmonary infection, 
with CCR2-/- mice having equivalent circulating levels of CCL2 and CCL7 compared to 
CCR2+/+ mice but impaired DC recruitment with a Th2 bias compared to a Th1 bias in 
CCR2+/+ mice [433].  
 
Activated DCs and macrophages produce CCL3 and CCL4 early in their response [429]. 
These act as chemotactic factors for cells expressing CCR1, CCR2 CCR4 and CCR5 [465] 
[466]. This includes monocytes, macrophages, dendritic cells, activated Th1 and Th2 
cells, NK cells and eosinophils which accumulate at the site of inflammation [467]. CCL3 
enhances the differentiation of primed CD8+ T cells into effector cells and their release 
into circulation [468]. Mice deficient in CCL3 exhibit increased susceptibility to 
Aspergillus spp [469], Klebsiella pneumonia [470] and influenza virus [471] with a lack of 
leucocyte migration to sites of infection. This proinflammatory chemokine response is 
controlled by anti-inflammatory cytokines including IL-10, IL-13 and TGF-β preventing 
immunopathology and maintaining immune homeostasis. CCL3 and CCL4 are also 
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downregulated by IFNγ and NOS2, preventing further leukocyte infiltration into tissue 
and further host damage [472]. 
 
CCL5 is predominantly secreted by T cells, platelets, macrophages, endothelial and 
epithelial cells [473] recruiting Th1 cells, DCs, monocytes and NK cells to sites of 
inflammation [474]. CCL5 enhances antigen specific humoral and cellular responses via 
the activation of CD4+ Th cells which in turn enhance B cell responses [475]. CCL5-/- mice 
localise fewer APCs and chemokine receptor-positive T cells to sites of inflammation 
with impaired adaptive immune responses and poor pathogen control [476] [477]. 
 
CXCL1 and CXCL2 are important murine chemoattractants for neutrophils and are 
functional homologues to human IL-8 [478]. Both and are important for host defence 
against bacterial infections [479] including regulating host defence against bacterial 
pulmonary disease [480] and are essential for neutrophil recruitment to the lungs [481]. 
 
CXCL10, a member of the IFNγ inducible chemokine family (this also contains CXCL9 and 
CXCL10, which were not part of the gene panel assessed) favours a Th1 type response as 
their receptor (CXCR3) is expressed almost exclusively on activated Th1 cells [482]. 
CXCL10 is produced by DCs and various other activated immune cells following CpG 
stimulation and protective immunity induced by pulsed DCs stimulated with CpG-ODN 
has been demonstrated to be dependent on CXCL10 [483]. 
 
DCs and macrophages are major producers of IL-12, a heterodimer composed of IL-
12p35 and IL-12p40, which causes the differentiation of naïve CD4+ T cells into Th1 cells 
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[484] and also activates NK cells and CD8+ T cells [485]. IL-12 production by DCs requires 
several signals including PRR ligation, and the stimulation of CD40, CD80, CD86 and 
MHC-II by T cells [486].  IL-12 also stimulates the antimicrobial activity of macrophages 
[487] and thus bridges the early innate response with the Th1 adaptive response. IL-12 
is important for host defence against intracellular pathogens including: Burkholderia 
pseudomallei [85] Mycobacterium tuberculosis [488], Toxoplasma gondii [489], Listeria 
monocytogenes [490], Brucella spp [491], Leishmania spp [492], Francisella tularensis 
[493] and Helicobacter pylori [494].  
 
In addition to forming part of the IL-12 heterodimer, IL-12p40 also forms part of the IL-
23 heterodimer with the IL-23p19 subunit. IL-23 is important for the induction of Th17 
responses, required for the control of extracellular pathogens [495] with IL-12p40-/- 
mice having a severely impaired ability to produce IFNγ and IL-17 by CD4+ T cells [496]. 
 
IL-6 is a pleiotropic, proinflammatory cytokine secreted mainly by monocytes, 
macrophages and epithelial cells but also by endothelial cells, bone marrow cells, 
fibroblasts, neutrophils, mast cells, lymphocytes and mature DCs [497]. IL-6 regulates 
the physiological function of multiple immune and non-immune cell types and plays a 
critical role in the interphase between the immune, endocrine and neural systems [498]. 
The systemic role of IL-6 includes both an increase in body temperature [499] and the 
production of acute-phase proteins by hepatocytes [500]. IL-6 enhances the generation 
of CD8+ T cells and promotes Th2 differentiation via IL-4 production whilst inhibiting Th1 
and Treg differentiation, IL-6 also combines with TGF-β to promote Th17 differentiation 
[501] [502]. 
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IL-10 is an important anti-inflammatory cytokine that dampens down what would 
otherwise be overwhelming immune responses that would result in severe 
immunopathology. The majority of IL-10 is produced by monocytes, macrophages, DCs 
and lymphocytes [503]. It inhibits the production of pro-inflammatory cytokines and 
chemokines, reduces antigen presentation by downregulating MHC-II together with co-
stimulatory molecules [504] and suppresses pro-inflammatory cytokine production 
[505]. 
 
The FcγR1 receptor, the high affinity receptor for IgG, plays an important role in the 
activation and regulation of immune function. FcγR1 has a number of unique properties 
compared to other IgG Fc receptors: it is the only high affinity receptor for the Th1 
biased IgG2a isotype and is also the receptor for the T-independent IgG3, thus linking 
innate and adaptive immune systems [506]. FcγR1 is upregulated by IFNγ and is able to 
capture, internalise and deliver antigen into antigen presentation pathways [507]. FcγR1 
expression is generally restricted to cells involved in antigen processing and 
presentation [507]. 
 
Thrombospondin–1 (TSP-1) elicits potent anti-inflammatory properties in vivo and is 
produced by platelets, monocytes DCs and macrophages [508]. DCs produce TSP-1 at 
steady state and during activation with microbiological stimuli increasing TSP-1 
production. TSP-1 ligates CD47 and this ligation inhibits DC maturation, cytokine 
production and the ability to stimulate T cells [509] [510]. Thus TSP-1 acts as a negative 
regulator of DC function helping to resolve inflammation and maintain a steady state. 
High levels of TSP-1 are found in inflamed tissues with mice lacking TSP-1 having an 
advantage in surviving candidiasis and K. pneumonia as they more efficiently clear the 
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infection despite fewer infiltrating leukocytes [511] [512]. This is due to TSP-1 inhibiting 
the function of recruited leukocytes, increasing tissue pathology and host mortality 
[512]. However a careful balance is required as TSP-1-/- mice have persistent 
inflammation of multiple organs [513] [514]. 
 
Analysis of this data in the Immgen database has shown the panel as a whole to have a 
mixed pattern of gene expression split between DCs and macrophages. This is not 
surprising given the classification of DCs based on phenotypic and functional properties 
that are often shared with other cell types has led to difficulties in cell identification 
[515]. 
 
Given the panel is limited to 84 genes important for antigen presenting cells as a whole, 
the variation in gene expression between different DC and macrophage populations, the 
fact the Immgen analysis hasn’t been expanded to BMDCs or bone marrow 
macrophages and that DCs and macrophages share a common precursor cell and have 
overlapping functionality, it is difficult to draw too many conclusions given the limited 
data set. However some of the genes within the panel have a stronger macrophage bias 
compared to DCs, potentially indicating there to be some contaminating macrophages 
within the DCs population. 
 
A further observation from the upregulation of BMDC genes was the effect LolC and CpG 
had upon the upregulation of the genes for Ccl5, Cd40, Cxcl10, Il10 Il12b and Il6 
compared to stimulation with CpG alone. All of these genes were upregulated at least 
three times more for BMDCs stimulated with LolC and CpG compared to CpG alone. 
Why this would be is difficult to ascertain as the only difference between the culture 
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systems was the addition of LolC, which had no effect on the upregulation of these 
genes when used to stimulate BMDCs on its own. Without further work to investigate 
this, for example titrating LolC to determine how concentration affects the response, it 
is difficult to provide a reason for this variation. 
 
This work has shown that CpG ODN 1826 was essential for the rapid upregulation of 
MHC-II, CD40, CD80, CD86, CCR7 and DEC205, all important for the induction of an 
antigen specific immune response. The data demonstrated peak upregulation of MHC-II, 
CD40, CD80 and CD86 to occur after 18 hours of stimulation in vitro, providing a 
stimulation period to take forward into further in vitro and in vivo assays. Furthermore 
CpG ODN 1826 was able to upregulate a range of genes also important for the induction 
of adaptive immune responses. Amongst the genes upregulated were Cd40, Cd80 and 
Cd86 which also increased at the cell surface, providing confidence that the increase in 
mRNA observed would translate into protein expression. A two-fold up- or down-
regulation was observed for 21 of the 84 genes assessed. However gene expression was 
only assessed at a single time point and it may be that this time point was not 
appropriate to measure large alterations in some of the genes. Taken together, the data 
from these in vitro experiments have shown CpG to be essential for the maturation of 
BMDCs when using heat-killed B. pseudomallei, potentially due to virulence factors of B. 
pseudomallei making it a poor immunogen, which enables the long-term latency and re-
emergence of this pathogen. The data have provided evidence that stimulating cells 
with heat-killed B. pseudomallei and CpG is an appropriate strategy to generate mature 
DCs capable of inducing an antigen-specific immune response and was thus taken 
forward into in vivo experiments. 
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To determine if the pulsed BMDCs were capable of migrating to lymph nodes where 
they could induce an antigen specific immune response, in vivo migration studies 
following the adoptive transfer of pulsed BMDCs were performed. In the studies 
described I successfully used the fluorescent dye CellVue Claret to label pulsed BMDCs 
as it does not require live tissues for its fluorescent properties, unlike BLI, and following 
migration to lymph nodes cells can be subsequently interrogated using multicolour flow-
cytometry.  
 
In vivo imaging of the mice injected i.d. with labelled BMDCs revealed cells to have 
migrated to lymph nodes by 48 hours. However, removal of lymph nodes and their 
interrogation using an ImageStream-X revealed cells that had been introduced into the 
host to be detectable 24 hours post-injection. This discrepancy is likely due to a failure 
to detect sufficient fluorescence signal at 24 hours due to absorption by surrounding 
tissues. To partially ameliorate this, the near-infrared dye CellVue Claret (emission 
maximum 677 nm) was used in an attempt to minimise tissue absorbance of fluorescent 
signals compared to similar dyes that emit at a shorter wave-length, for example CFSE 
(emission maximum 517 nm). The longer the wave length of the light emitted the better 
the signal:noise ratio when imaging in vivo, due to absorption of shorter wave-lengths 
by host tissues. 
 
As expected, following adoptive transfer only 0.01-3% of DCs reach lymph nodes, 
depending on the number of cells initially introduced [516]. In this study 1 x 106 DCs 
were adoptively transferred per mouse, with a maximum of 0.17% of cells within lymph 
nodes being those that had been introduced. Despite the low number of cells reaching 
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lymph nodes this approach reproducibly induces robust immune responses for a variety 
of conditions demonstrating the potency of DCs at initiating adaptive immune responses 
[517].    
 
In this chapter I have shown that stimulation of cells with heat-killed B. pseudomallei 
alone takes significantly longer to induce maturation of BMDCs compared to co-culture 
with CpG. Additionally I have shown that the inclusion of CpG in the culture conditions 
to be critical for the upregulation of the majority of genes important for DC maturation 
and effector functions important to aid protection against multiple infectious diseases. 
The chapter concludes by showing that when BMDCs are pulsed with heat-killed B. 
pseudomallei and CpG these cells are capable of migrating to lymph nodes. The final 
results chapter will examine the immune response generated by these cells and the 
effect they have as a therapeutic DC vaccine for B. pseudomallei. 
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Chapter 5: Therapeutic DC vaccination for Burkholderia 
pseudomallei 
5.1 Introduction 
B. pseudomallei, the etiological agent of melioidosis can cause an acute or chronic 
disease. Current treatment for acute cases consists of i.v. antibiotics, typically for 14 
days followed by an oral course for 12-20 weeks. Despite the prolonged treatment 
relapse is a common occurrence with 5–25% of melioidosis patients suffering relapse 
often due to a decline in immunocompetence, with up to 75% of hospital readmission 
due to disease caused by the same strain as initial infection rather than a new infection. 
 
Currently there is no licensed vaccine for melioidosis and no vaccine in clinical trials. 
Approaches to developing a vaccine have included: live attenuated, inactivated bacteria, 
subunit and DC vaccines. The outcome of these studies has ranged from partial 
protection to no protection at all. These have contributed to demonstrate that both an 
antibody and cellular immune response are required for a protective effect with 
antibodies alone capable of providing protection against low but not higher challenge 
doses. 
 
The investigation of novel B. pseudomallei antigens identified LolC as a potential vaccine 
candidate. LolC is an ATP-binding cassette (ABC) transporter found within the cell 
membrane. ABC transporters bind ATP and are responsible for the generation of energy 
to transport molecules across the cell membrane and are important in bacterial survival, 
virulence and pathogenicity. It was therefore thought likely that some of the protein 
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would be exposed to the immune system during infection [355]. LolC-specific CMI and 
antibody based immune responses provide significant protection against challenge with 
B. pseudomallei  [355] [518]. Additionally LolC-specific CD4+ and CD8+ T cell responses 
have been demonstrated in patients who have recovered from melioidosis [519,520].  
 
DC vaccination has been approved as a cancer therapy with much interest in this area. It 
has also been used for vaccination strategies against various infectious diseases. 
Previously DC vaccination has been used as a prophylactic therapy inducing both a B. 
pseudomallei specific antibody and cellular immune response able to protect 90% of 
mice against lethal challenge [86] [85]. 
 
In this chapter I have taken the methodology successfully used previously in DC 
vaccination studies and used them as a therapeutic vaccination [85,86]. The aim of this 
novel DC vaccination strategy was to determine the effect of passively administering 
specifically-activated DC post challenge with B. pseudomallei in the Balb/c model. A key 
endpoint of this study, in addition to survival, was to determine whether this approach 
could significantly enhance the ability of the host to clear bacteria from secondary 
lymphoid organs such as the spleen, a challenge current therapies are not able to 
overcome. 
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 Aims and objectives 5.1.1
Using a murine model of B. pseudomallei infection this chapter aims to: 
 To determine if the adoptive transfer of B. pseudomallei stimulated DCs can 
induce a specific T cell response in vivo. 
 To determine if the post-infection adoptive transfer of B. pseudomallei 
stimulated DCs enhances survival and aids bacterial clearance. 
 To characterise the induction of specific T cell responses to LolC by the anti-
DEC205-LolC construct in vivo. 
 To determine if the anti-DEC205-LolC construct enhances survival and aids 
clearance of B. pseudomallei post-infection. 
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5.2 Results 
 Immune response to DC vaccination 5.2.1
To investigate the immune response generated by a DC vaccine, two independent 
immunogenicity studies, to confirm reproducibility, were conducted in uninfected 
animals. Mice were immunised with BMDCs pulsed for 18 hours with heat-killed B. 
pseudomallei with and without CpG ODN 1826, cohorts were taken 21 and 35 days post-
immunisation for analysis. 
 
5.2.1.1 Cellular response to DC vaccination 
The cellular immune response to DC vaccination was characterised using an IFNγ 
ELISPOT. Mice immunised with heat-killed B. pseudomallei pulsed DC with and without 
CpG, were culled 21 and 35 days post-immunisation and the ex vivo recall response of 
their splenocytes to B. pseudomallei determined in terms of IFNγ production per 1 x 106 
spot-forming cells, Figure 5-1. At days 21 and 35 post-immunisation there was a 
significant increase in the number of IFNγ+ SFC for the group receiving BMDCs pulsed 
with heat-killed B. pseudomallei compared to all other groups (p<0.001). The only 
exception to this, where the difference was more modest, was between the groups 
immunised with BMDCs stimulated with heat-killed B. pseudomallei and heat-killed B. 
pseudomallei and CpG (p<0.05), Figure 5-1. Additionally, at day 35 there was a 
significant increase in the number of IFNγ+ SFC for mice immunised with BMDCs pulsed 
with heat-killed B. pseudomallei and CpG compared to naïve mice (p<0.01).  
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5.2.1.2 Cytokine response to restimulation of splenocytes with heat-killed B. 
pseudomallei, post-DC vaccination 
Splenocytes isolated from immunised mice were restimulated with heat killed B. 
pseudomallei and the levels of secreted cytokines assessed at day 21 and 35 post-
immunisation, Figure 5-2. There was no significant recall response at day 21 (data are 
not shown). Mice that received BMDCs pulsed with heat-killed B. pseudomallei showed 
a significant recall response to heat-killed B. pseudomallei for IFNγ, IL6 and IL17A 
(p<0.001). Additionally there was a significant recall response for mice immunised with 
BMDCs pulsed with heat-killed B. pseudomallei and CpG for IFNγ (p<0.05), TNF (p<0.05), 
IL-6 (p<0.01) and IL-17A (p<0.001). For all groups there was no significant recall 
response for either IL-4 or IL-10. 
 
5.2.1.3 B. pseudomallei specific IgG response post-DC vaccination 
The IgG anti-B. pseudomallei antibody titre from immunised groups was assessed by 
ELISA. At 21 days post-immunisation mice that had received BMDCs pulsed with heat-
killed B. pseudomallei with or without CpG demonstrated a quantifiable antibody 
response however this was only significant in the absence of CpG (p<0.01), Figure 5-3. 
By day 35 the antibody titre had increased compared to day 21 for groups receiving 
BMDCs pulsed with heat-killed B. pseudomallei, with or without CpG and both groups 
showed a significant response compared to naïve mice or mice that received unpulsed 
BMDCs or BMDCs pulsed with CpG alone (p<0.05). 
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Figure 5-1: DC vaccination induces a B. pseudomallei specific IFNγ recall response to 
heat-killed B. pseudomallei. 
An antigen-specific recall response to B. pseudomallei was determined using an IFNγ 
ELISPOT. BMDCs were pulsed with heat-killed B. pseudomallei (104 CFU/mL) with or 
without CpG ODN 1826 (6 µg/mL) for 18 hours harvested and washed three times in 
PBS. Female Balb/c mice received 1 x 106 cells/mL i.d. with spleens taken 21 and 35 days 
post-immunisation (n=5). Splenocytes were restimulated ex vivo with 104 CFU/mL of 
heat-killed B. pseudomallei, ELISPOT was used to determine the number of antigen 
specific cells. The results show the mean of three technical replicates from two 
combined independent experiments which were determined statistically to be suitable 
for combination. A two-way ANOVA with Tukey’s multiple comparison post-hoc test was 
performed on the combined results (* p<0.05, ** p< 0.01, *** p<0.001).  
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Figure 5-2: DC vaccination induces a B. pseudomallei specific proinflammatory 
cytokine response 35 days post-vaccination  
An antigen-specific recall response was measured using a mouse Th1/2/17 cytometric 
bead array. BMDCs were pulsed with heat-killed B. pseudomallei (104 CFU/mL) with or 
without CpG ODN 1826 (6 µg/mL) for 18 hours harvested and washed three times in 
PBS. Female Balb/c mice received 1 x 106 cells/mL i.d. with spleens taken 21 and 35 days 
post-immunisation (n=5). Splenocytes were taken 21 and 35 days post-immunisation 
and were either unstimulated (closed bars) or restimulated ex vivo with heat-killed B. 
pseudomallei (104 CFU/mL) (open bars) for 18 hours.  The results are taken from two 
combined independent experiments which were determined statistically to be suitable 
for combination. A two-way ANOVA with Tukey’s multiple comparison post-hoc test was 
performed on the results (* p<0.05, ** p< 0.01, *** p<0.001). 
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Figure 5-3: DC vaccination induces a B. pseudomallei specific IgG antibody response 
The anti-B. pseudomallei IgG titre was measured 21 and 35 days post-immunisation. 
BMDCs were pulsed with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG 
ODN 1826 (6 µg/mL) for 18 hours harvested and washed three times in PBS. Female 
Balb/c mice received 1 x 106 cells/mL i.d. with spleens taken 21 and 35 days post-
immunisation (n=5). Mice were anaesthetised and blood taken by cardiac puncture 
before being culled by cervical dislocation. The results show the mean of two technical 
replicates. A Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test was 
performed on the results (* p<0.05, ** p< 0.01, *** p<0.001). 
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 Efficacy of the adoptive transfer of pulsed BMDCs against B. 5.2.2
pseudomallei 
To investigate the efficacy of DC immunisation as a therapeutic strategy for B. 
pseudomallei three independent efficacy studies were conducted. Mice were challenged 
with a target dose of 4.0 x 103 CFU B. pseudomallei K96243 i.p. and immediately 
received an i.d. DC immunisation (1 x 106 pulsed BMDCs). BMDCs were pulsed for 18 
hours with heat-killed B. pseudomallei with and without CpG ODN 1826. Mice were 
monitored for 35 days prior to determination of organ weights, bacterial burden and 
immunological analysis. 
 
5.2.2.1 First DC efficacy study: survival, organ weights, bacteriology and anti-B. 
pseudomallei titres  
Groups of 10 mice were challenged with 3 x 103 CFU B. pseudomallei K96243 i.p. and 
immediately received an i.d. DC immunisation (1 x 106 pulsed DCs). As before, 
immunisation groups were either untreated, unstimulated DCs or DCs stimulated with 
either: CpG, heat-killed B. pseudomallei or heat-killed-B. pseudomallei plus CpG. At 35 
days post-challenge survival was: 9/10 infected-untreated; 6/10 unstimulated DCs; 9/10 
DCs stimulated with CpG; 8/10 DCs stimulated with heat-killed B. pseudomallei; and 
8/10 DCs stimulated with heat-killed B. pseudomallei and CpG. There were no significant 
differences in survival between the groups, Figure 5-4. 
 
At day 35 survivors underwent cardiac puncture with anti-B. pseudomallei IgG 
antibodies determined (Figure 5-5A), spleen weights recorded (Figure 5-5B) and 
bacterial colonisation (Figure 5-5C) of each organ determined. There were no significant 
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differences between groups for anti-B. pseudomallei IgG titres in serum, organ weights 
or bacterial load. However all surviving mice that received BMDCs stimulated with heat-
killed B. pseudomallei and CpG had normal sized spleens with no abscess and an 
undetectable bacterial load.  
 
5.2.2.2 Second and third DC efficacy studies: survival, organ weights, bacteriology, 
antibody titres and splenic cytokines  
The second efficacy study contradicted the first study and therefore a third study was 
undertaken. The results from these were consistent with each other and where 
statistically appropriate have been combined, (see materials and methods for 
determination of how results were deemed appropriate for combination). 
 
5.2.2.2.1 Survival from the second DC efficacy study 
Mice were challenged with 1.5 x 103 CFU B. pseudomallei K96243 i.p and immediately 
received an i.d. DC immunisation (1 x 106 DCs). The immunisation groups were as 
outlined in section 5.2.2.1. At 35 days post-challenge survival was: 9/10 infected-
untreated; 7/10 unstimulated DCs; 8/10 DCs stimulated with CpG; 8/10 DCs stimulated 
with heat-killed B. pseudomallei; and 7/10 DCs stimulated with heat-killed B. 
pseudomallei and CpG (  
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Figure 5-6A). There were no significant differences in survival between the groups.  
 
5.2.2.2.2 Survival from the third DC efficacy study  
Mice were challenged with 1.5 x 103 CFU B. pseudomallei K96243 i.p. and immediately 
received an i.d. DC immunisation (1 x 106 DCs). The immunisation groups were as 
outlined in section 5.2.2.1. At 35 days post-challenge survival was: 11/20 infected-
untreated; 9/20 unstimulated DCs; 12/20 DCs stimulated with CpG; 14/20 DCs 
stimulated with heat-killed B. pseudomallei; and 15/20 DCs stimulated with heat-killed 
B. pseudomallei and CpG (Figure 5-6B). There were no significant differences in survival 
between the groups.  
 
5.2.2.2.3 Organ weights: lungs, liver and spleen  
At day 35 surviving mice were culled and the weights for the lungs, liver and spleen, 
lungs and liver weights recorded (Figure 5-7). There was a significant increase in the 
weight of the spleens from mice receiving DCs pulsed with heat-killed B. pseudomallei 
and CpG compared to infected-untreated mice (p<0.05). There were no other significant 
differences in organ weights.  
 
5.2.2.2.4 Bacterial load: lungs liver and spleen 
At day 35, surviving mice were culled and the bacterial load of the lungs, liver and 
spleen determined. A significant increase was observed in the bacterial load of the 
spleens from mice receiving DCs pulsed with heat-killed B. pseudomallei and CpG 
(p<0.001) or unpulsed DCs (p<0.01) compared to infected-untreated mice, Figure 5-8. 
There were no other significant differences for bacterial load for the spleen or the liver.  
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The bacterial load from the lungs was significantly different between the two studies 
and had to be analysed independently. There were no significant differences in bacterial 
load within the lungs for the second efficacy study. The third efficacy study exhibited a 
significant increase in the bacterial load of the lungs from mice receiving DCs pulsed 
with heat-killed B. pseudomallei (p<0.05) or unpulsed DCs (p<0.01) compared to 
infected-untreated mice. There were no other significant differences for bacterial load 
within the lungs.  
 
The bacteriology data from the lungs was deemed not to be suitable for combination as 
there were significant differences between the same groups for the two studies. The 
second efficacy study showed DC vaccination to increase bacterial load for groups that 
received either unpulsed BMDCs or BMDCs pulsed with heat-killed B. pseudomallei 
although the other two groups had an increased bacterial load that was not significantly 
different compared to the infected untreated group. The bacteriology for the lungs from 
the third study was bimodal, with some mice having quite a large bacterial load whilst 
other mice within the same group had no detectable bacteriology. This pattern was 
repeated in all groups. 
 
5.2.2.2.5 Anti-B. pseudomallei IgG titre 
The anti-B. pseudomallei titre was measured 35 days post-challenge. There were no 
significant differences in antibody titres between any of the groups with all mice 
displaying a similar IgG response to infection irrespective of treatment, Figure 5-9, 
indicating all mice had been exposed to B. pseudomallei.   
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5.2.2.2.6 Cytokines from splenic supernates 
Cytokines in splenic supernates were assessed using a Th1/2/17 CBA kit. There were 
significant differences between the results of the second and third efficacy studies and 
have therefore been treated as independent studies.  
 
The second efficacy study showed a significant increase in IL-6 for mice that received 
DCs pulsed with heat-killed B. pseudomallei compared to infected-untreated mice 
(p<0.05). There was also a significant increase in IFNγ for mice that received DCs pulsed 
with heat-killed B. pseudomallei with or without CpG compared to infected-untreated 
mice (p<0.05). Finally there was a significant increase in TNF for mice that received DCs 
pulsed with heat-killed B. pseudomallei and CpG compared to infected-untreated mice 
(p<0.05), Figure 5-10. There was a detectable IL-2 response but no significant 
differences between the groups. For the other cytokines that form part of the panel (IL-
4, IL-10 and IL-17A) production was below the limit of detection of the assay, data not 
shown.   
 
For the third efficacy study there were no significant differences between the groups, 
with limited cytokine production for all groups, Figure 5-11. For the other cytokines that 
form part of the panel (IL-4, IL-10 and IL-17A) production was below the limit of 
detection of the assay data not shown.   
 
5.2.2.2.7 Partial correlation and dendrogram 
All experimental parameters measured for the second and third efficacy studies were 
combined and analysed using a partial correlation, Table 10. The relatedness was 
visualised using a dendrogram, Figure 5-12. This showed the cytokines IL-6, IFNγ and 
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TNF to correlate strongly with each other. Liver CFU, spleen weight, spleen CFU, lung 
CFU and liver weight also grouped together. Lung weight, IL-2 and anti-B. pseudomallei 
IgG were poorly correlated to any of the other parameters. 
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Figure 5-4: DC vaccination does not increase survival following challenge with B. 
pseudomallei K96243. 
Groups of 10 female Balb/c mice were challenged with 3 x 103 CFU of B. pseudomallei 
K96243 i.p. Immediately post-challenge mice were vaccinated with 1 x 106 BMDCs i.d. 
stimulated with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG ODN 
1826 (6 µg/mL) for 18 hours or were infected but untreated. Survival was monitored for 
35 days post-challenge. There were no significant differences in survival between the 
groups. 
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Figure 5-5: DC vaccination does not enhance circulating B. pseudomallei specific IgG 
antibodies or alter splenic weight or bacterial counts 35 days post-challenge. 
Groups of 10 female Balb/c mice were challenged with 3 x 103 CFU of B. pseudomallei 
K96243 i.p. Immediately post-challenge mice were vaccinated with 1 x 106 BMDCs i.d. 
stimulated with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG ODN 
1826 (6 µg/mL) for 18 hours or were infected but untreated. Surviving mice underwent 
cardiac puncture 35 days post-challenge with blood taken for B. pseudomallei specific 
IgG antibodies (A). Subsequently their spleens were weighed (B) prior to maceration for 
bacterial counts (C). A Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test 
was performed on the results (* p<0.05, ** p< 0.01, *** p<0.001). 
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Figure 5-6: Therapeutic DC vaccination does not increase survival following challenge 
with B. pseudomallei K96243. 
Groups of 10 female Balb/c mice were challenged with 1.5 x 103 CFU (A) or 20 female 
Balb/c mice with 2.5 x 103 CFU (B) of B. pseudomallei K96243 i.p. Immediately post-
challenge mice were vaccinated with 1 x 106 BMDCs i.d. stimulated with heat-killed B. 
pseudomallei (104 CFU/mL) with or without CpG ODN 1826 (6 µg/mL) for 18 hours or 
were infected but untreated. Survival was monitored for 35 days post-challenge. There 
were no significant differences in survival between the groups. 
 
Adoptive Transfer Efficacy Study 2 
 
Adoptive Transfer Efficacy Study 3 
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Figure 5-7: Therapeutic DC vaccination increases splenic weight 35 days post-
challenge. 
Groups of 10 female Balb/c mice were challenged with 1.5 x 103 CFU (study 2) or 20 
female Balb/c mice with 2.5 x 103 CFU (study 3) of B. pseudomallei K96243 i.p. 
Immediately post-challenge mice were vaccinated with 1 x 106 BMDCs i.d. stimulated 
with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG ODN 1826 (6 µg/mL) 
for 18 hours or were infected but untreated. Survivors were culled 35 days post-
challenge with lungs, livers and spleens weighed prior to maceration for bacterial 
counts. The results are taken from two combined independent experiments which were 
statistically determined to be suitable for combination. A two-way ANOVA with Tukey’s 
multiple comparison post-hoc test was performed on the results (* p<0.05, ** p< 0.01, 
*** p<0.001). 
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Figure 5-8: Therapeutic DC vaccination increases viable B. pseudomallei colonies in the 
spleen and lungs. 
Groups of 10 female Balb/c mice were challenged with 1.5 x 103 CFU (study 2) or 20 
female Balb/c mice with 2.5 x 103 CFU (study 3) of B. pseudomallei K96243 i.p. 
Immediately post-challenge mice were vaccinated with 1 x 106 BMDCs i.d. stimulated 
with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG ODN 1826 (6 µg/mL) 
for 18 hours or were infected but untreated. Survivors were culled 35 days post-
challenge with lungs, liver and spleens macerated through a cell sieve, serially diluted 
and plated on L-agar to determine viable bacterial counts. The spleen and liver results 
were statistically determined to be suitable for combination and analysed using a two-
way ANOVA with Tukey’s multiple comparison post-hoc test (* p<0.05, ** p< 0.01, *** 
p<0.001). Results from the lungs were not suitable for combination and were analysed 
with a Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test (* p<0.05, ** 
p< 0.01, *** p<0.001). 
 
  
In
fe
c
te
d
 -
 u
n
tr
e
a
te
d
U
n
p
u
ls
e
d
 B
M
D
C
P
u
ls
e
d
 B
M
D
C
s
: 
C
p
G
 o
n
ly
P
u
ls
e
d
 B
M
D
C
s
: 
H
e
a
t  
k
il
le
d
 B
. 
p
s
e
u
d
o
m
a
lle
i
P
u
ls
e
d
 B
M
D
C
s
: 
H
e
a
t  
k
il
le
d
 B
. 
p
s
e
u
d
o
m
a
lle
i 
&
 C
p
G
1 0 0
1 0 2
1 0 3
1 0 4
1 0 5
1 0 6
1 0 7
1 0 8
1 0 9
1 0 1 0
1 0 1 1
S p le e n
B
. 
p
s
e
u
d
o
m
a
ll
e
i
C
F
U
/m
L
 s
p
le
e
n
A d o p tiv e  tra n s fe r  e ff ic a c y  s tu d y  2
A d o p tiv e  tra n s fe r  e ff ic a c y  s tu d y  3
L O D
* *
* * *
In
fe
c
te
d
 -
 u
n
tr
e
a
te
d
U
n
p
u
ls
e
d
 B
M
D
C
P
u
ls
e
d
 B
M
D
C
s
: 
C
p
G
 o
n
ly
P
u
ls
e
d
 B
M
D
C
s
: 
H
e
a
t  
k
il
le
d
 B
. 
p
s
e
u
d
o
m
a
lle
i
P
u
ls
e
d
 B
M
D
C
s
: 
H
e
a
t  
k
il
le
d
 B
. 
p
s
e
u
d
o
m
a
lle
i 
&
 C
p
G
1 0 0
1 0 2
1 0 3
1 0 4
1 0 5
1 0 6
1 0 7
L iv e r
B
. 
p
s
e
u
d
o
m
a
ll
e
i
C
F
U
/m
L
 L
iv
e
r
A d o p tiv e  tra n s fe r  e ff ic a c y  s tu d y  2
A d o p tiv e  tra n s fe r  e ff ic a c y  s tu d y  3
L O D
In
fe
c
te
d
 -
 u
n
tr
e
a
te
d
U
n
p
u
ls
e
d
 B
M
D
C
P
u
ls
e
d
 B
M
D
C
s
: 
C
p
G
 o
n
ly
P
u
ls
e
d
 B
M
D
C
s
: 
H
e
a
t  
k
il
le
d
 B
. 
p
s
e
u
d
o
m
a
lle
i
P
u
ls
e
d
 B
M
D
C
s
: 
H
e
a
t  
k
il
le
d
 B
. 
p
s
e
u
d
o
m
a
lle
i 
&
 C
p
G
1 0 0
1 0 2
1 0 3
1 0 4
1 0 5
1 0 6
1 0 7
1 0 8
L u n g s : a d o p t iv e  tr a n s fe r  e f f ic a c y  s tu d y  2
B
. 
p
s
e
u
d
o
m
a
ll
e
i
C
F
U
/m
L
 L
u
n
g
s
L O D
In
fe
c
te
d
 -
 u
n
tr
e
a
te
d
U
n
p
u
ls
e
d
 B
M
D
C
P
u
ls
e
d
 B
M
D
C
s
: 
C
p
G
 o
n
ly
P
u
ls
e
d
 B
M
D
C
s
: 
H
e
a
t  
k
il
le
d
 B
. 
p
s
e
u
d
o
m
a
lle
i
P
u
ls
e
d
 B
M
D
C
s
: 
H
e
a
t  
k
il
le
d
 B
. 
p
s
e
u
d
o
m
a
lle
i 
&
 C
p
G
1 0 0
1 0 2
1 0 3
1 0 4
1 0 5
1 0 6
L u n g s : a d o p t iv e  tr a n s fe r  e f f ic a c y  s tu d y  3
B
. 
p
s
e
u
d
o
m
a
ll
e
i
C
F
U
/m
L
 L
u
n
g
s
* *
*
L O D
178 
 
Figure 5-9: Therapeutic DC vaccination does not boost circulating antibody. 
Groups of 10 female Balb/c mice were challenged with 1.5 x 103 CFU (study 2) or 20 
female Balb/c mice with 2.5 x 103 CFU (study 3) of B. pseudomallei K96243 i.p. 
Immediately post-challenge mice were vaccinated with 1 x 106 BMDCs i.d. stimulated 
with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG ODN 1826 (6 µg/mL) 
for 18 hours or were infected but untreated. Survivors were culled 35 days post-
challenge with blood taken by cardiac puncture and assessed for B. pseudomallei 
specific IgG antibodies. The results are taken from two combined independent 
experiments which were statistically determined to be suitable for combination. A two-
way ANOVA with Tukey’s multiple comparison post-hoc test was performed on the 
results (* p<0.05, ** p< 0.01, *** p<0.001). 
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Figure 5-10: Post-challenge cytokines in splenic supernates from the second 
therapeutic DC vaccination study for B. pseudomallei. 
Groups of 10 female Balb/c mice were challenged with 1.5 x 103 CFU B. pseudomallei 
K96243 i.p. Immediately post-challenge mice were vaccinated with 1 x 106 BMDCs i.d. 
stimulated with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG ODN 
1826 (6 µg/mL) for 18 hours or were infected but untreated. Survivors were culled 35 
days post-challenge with spleens macerated using a cell sieve and 500 µL of the 
supernate taken for cytokine analysis. Results were statistically determined not to be 
suitable for combination and were analysed with a Kruskal-Wallis test with Dunn’s 
multiple comparison post-hoc test (* p<0.05, ** p< 0.01, *** p<0.001). 
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Figure 5-11: Post-challenge cytokines in splenic supernates from the third therapeutic 
DC vaccination study for B. pseudomallei. 
Groups of 10 female Balb/c mice were challenged with 2.5 x 103 CFU B. pseudomallei 
K96243 i.p. Immediately post-challenge mice were vaccinated with 1 x 106 BMDCs i.d. 
stimulated with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG ODN 
1826 (6 µg/mL) for 18 hours or were infected but untreated. Survivors were culled 35 
days post-challenge with spleens macerated using a cell sieve and 500 µL of the 
supernate taken for cytokine analysis. Results were statistically determined not to be 
suitable for combination and were analysed with a Kruskal-Wallis test with Dunn’s 
multiple comparison post-hoc test (* p<0.05, ** p< 0.01, *** p<0.001). 
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Figure 5-12: Dendrogram showing linkages between the different parameters 
measured for the second and third B. pseudomallei DC immunisation efficacy studies. 
Groups of 10 female Balb/c mice were challenged with 1.5 x 103 CFU (study 2) or 20 
female Balb/c mice with 2.5 x 103 CFU (study 3) of B. pseudomallei K96243 i.p. 
Immediately post-challenge mice were vaccinated with 1 x 106 BMDCs i.d. stimulated 
with heat-killed B. pseudomallei (104 CFU/mL) with or without CpG ODN 1826 (6 µg/mL) 
for 18 hours or were infected but untreated. Survivors were culled 35 days post-
challenge with organ weight and bacterial load, circulating antibody and cytokine titres 
measured. The dendrogram clusters data based on their relatedness following analysis 
with Pearson’s correlation coefficients. 
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Table 10: Partial correlation values for the results of the second and third efficacy studies.  
Data has been combined and analysed using a partial correlation with IBM SPSS v21 to indicate where interactions between different experiment 
parameters exists. Significant correlation (p<0.05) between parameters are shown in bold.  
  Spleen 
CFU 
Lungs 
CFU 
Liver 
CFU 
Spleen 
Weight 
Lungs 
Weight 
Liver 
Weight 
anti-B. 
pseudomallei 
IgG IL-2 IL-6 IFNγ TNF 
Spleen CFU Correlation 
1 0.314 0.5 0.544 0.104 0.224 0.063 -0.005 0.206 0.201 
0.064 
Significance 
(2-tailed) . 0.005 0 0 0.366 0.049 0.587 0.965 0.07 0.078 
0.579 
Lungs CFU Correlation 
0.314 1 0.578 0.34 0.178 0.341 0.12 0.386 0.105 0.11 
0.321 
Significance 
(2-tailed) 0.005 . 0 0.002 0.119 0.002 0.295 0 0.358 0.339 
0.004 
Liver CFU Correlation 
0.5 0.578 1 0.632 0.141 0.343 0.03 0.238 0.055 0.179 
0.245 
Significance 
(2-tailed) 0 0 . 0 0.219 0.002 0.795 0.036 0.635 0.116 
0.03 
Spleen 
Weight 
Correlation 
0.544 0.34 0.632 1 0.105 0.455 -0.006 0.168 0.215 0.316 
0.301 
Significance 
(2-tailed) 0 0.002 0 . 0.358 0 0.956 0.141 0.059 0.005 
0.007 
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Spleen 
CFU 
Lungs 
CFU 
Liver 
CFU 
Spleen 
Weight 
Lungs 
Weight 
Liver 
Weight 
anti-B. 
pseudomallei 
IgG IL-2 IL-6 IFNγ TNF 
Lungs Weight Correlation 
0.104 0.178 0.141 0.105 1 0.277 -0.119 0.161 -0.058 -0.037 
-0.046 
Significance 
(2-tailed) 0.366 0.119 0.219 0.358 . 0.014 0.301 0.158 0.615 0.747 
0.691 
Liver Weight Correlation 
0.224 0.341 0.343 0.455 0.277 1 0.087 0.337 0.151 0.163 
0.236 
Significance 
(2-tailed) 0.049 0.002 0.002 0 0.014 . 0.447 0.003 0.187 0.155 
0.038 
anti-B. 
pseudomallei 
IgG 
Correlation 
0.063 0.12 0.03 -0.006 -0.119 0.087 1 0.021 -0.067 -0.033 
0.01 
Significance 
(2-tailed) 0.587 0.295 0.795 0.956 0.301 0.447 . 0.858 0.559 0.771 
0.932 
IL-2 Correlation 
-0.005 0.386 0.238 0.168 0.161 0.337 0.021 1 0.093 0.062 
0.308 
Significance 
(2-tailed) 0.965 0 0.036 0.141 0.158 0.003 0.858 . 0.419 0.59 
0.006 
IL-6 Correlation 
0.206 0.105 0.055 0.215 -0.058 0.151 -0.067 0.093 1 0.873 
0.791 
Significance 
(2-tailed) 0.07 0.358 0.635 0.059 0.615 0.187 0.559 0.419 . 0 
0 
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Spleen 
CFU 
Lungs 
CFU 
Liver 
CFU 
Spleen 
Weight 
Lungs 
Weight 
Liver 
Weight 
anti-B. 
pseudomallei 
IgG IL-2 IL-6 IFNγ TNF 
IFNγ Correlation 
0.201 0.11 0.179 0.316 -0.037 0.163 -0.033 0.062 0.873 1 
0.816 
Significance 
(2-tailed) 0.078 0.339 0.116 0.005 0.747 0.155 0.771 0.59 0 . 
0 
TNF Correlation 
0.064 0.321 0.245 0.301 -0.046 0.236 0.01 0.308 0.791 0.816 
1 
Significance 
(2-tailed) 0.579 0.004 0.03 0.007 0.691 0.038 0.932 0.006 0 0 
. 
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 Targeting of LolC to the DEC205 receptor of DCs in situ 5.2.3
Following the use of pulsed BMDCs as a therapeutic vaccine for B. pseudomallei the use 
of LolC, a B. pseudomallei ABC transporter, conjugated to a monoclonal antibody 
specific for the endocytic receptor DEC205 was also investigated as a therapeutic 
vaccine.  
 
5.2.3.1 Immune response to targeting LolC to DEC205 
To investigate the immune response generated by targeting LolC to DEC205 an 
immunogenicity study was conducted. Mice were immunised with LolC conjugated to 
DEC205 (LolC-DEC205), unconjugated LolC and DEC205 (LolC & DEC205) or DEC205, all 
in combination with CpG ODN 1826, cohorts were taken 21 and 35 days post-
immunisation for analysis. 
 
5.2.3.1.1 IFNγ spot-forming cells measured by ELISPOT 
The cellular immune response to targeting LolC to DEC205 was characterised using an 
IFNγ ELISPOT. Immunised mice were culled 21 and 35 days post-immunisation and the 
ex vivo recall response of their splenocytes to LolC determined in terms of IFNγ 
production per 106 spot-forming cells, Figure 5-13. At both time points there were no 
significant differences in the number of IFNγ+ SFC between the groups. 
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5.2.3.1.2 Antibody response post-DC vaccination 
The IgG anti-LolC antibody titre from immunised groups were assessed by ELISA. At 21 
days post-immunisation there was no detectable anti-LolC IgG response (data not 
shown). By day 35 an antibody response had developed in the group that received 
unconjugated LolC with DEC205 (p<0.01), but not in the group receiving conjugated 
LolC-DEC205 or any other group, Figure 5-14. 
 
5.2.3.2 Efficacy of targeting LolC to DEC205 
To investigate the efficacy of targeting LolC to DEC205 as a therapeutic strategy for B. 
pseudomallei an efficacy study was conducted. Groups of 10 mice were challenged with 
a target dose of 4.0 x 103 CFU B. pseudomallei K96243 i.p., subsequently determined to 
be  2.2 x 103 CFU, and immediately received LolC conjugated to DEC205 together with 
CpG ODN 1826, i.m. Mice were monitored for 35 days prior to determination of organ 
weight, bacterial burden and immunological analysis. 
 
5.2.3.2.1 Survival  
At 35 days post-challenge survival was: 7/10 infected-untreated; 8/10 LolC-DEC205 
conjugate with CpG; 8/10 LolC and DEC205 unconjugated with CpG; 8/10 DEC205 and 
CpG (Figure 5-15). There were no significant differences in survival between the groups.  
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5.2.3.2.2 Organ weights and bacterial load 
At day 35 survivors were culled, lungs, liver and spleen weights recorded (Figure 5-16) 
and bacterial colonisation of each organ determined, Figure 5-17. There were no 
significant differences between the groups. 
 
5.2.3.2.3 Anti-B. pseudomallei and anti LolC IgG titres 
The anti-B. pseudomallei and anti-LolC IgG titre was measured 35 days post-challenge. 
There were no significant differences in anti-B. pseudomallei IgG antibody titre between 
any of the groups with all mice displaying a similar IgG response to infection irrespective 
of treatment Figure 5-18.  There was a significant increase in anti-LolC IgG antibodies in 
the group receiving unconjugated LolC and DEC205 compared to the group receiving 
them conjugated (p<0.001) and the infected-untreated or DEC205 alone groups (p<0.01)  
 
5.2.3.2.4 Cytokines from splenic supernates 
Cytokines in splenic supernates were assessed using a Th1/2/17 CBA kit. There were no 
significant differences between the groups, Figure 5-19.  
 
5.2.3.2.5 Partial correlation and dendrogram 
All experimental parameters measured for the second and third efficacy studies were 
combined and analysed using a partial correlation, Table 11. The relatedness was 
visualised using a dendrogram, Figure 5-20. This showed the cytokines IL-6, IFNγ and 
TNF and spleen weight to correlate strongly with each other.  Spleen CFU, liver CFU and 
188 
 
liver weight also group together. Lung CFU, lung weight, IL-2, anti-LolC IgG and anti-B. 
pseudomallei IgG were poorly correlated to any of the other parameters. 
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Figure 5-13: Immunisation with LolC conjugated to an anti-DEC205 monoclonal 
antibody failed to induce an IFNγ recall response.  
An antigen-specific recall response to B. pseudomallei was determined using an IFNγ 
ELISPOT. Groups of five female Balb/c mice received LolC conjugated to an anti-DEC205 
monoclonal antibody (LolC-DEC205, 10 µg/mouse), unconjugated LolC and anti-DEC205 
(LolC & DEC205, 10 µg/mouse) or anti-DEC205 alone (10 µg/mouse), all in combination 
with CpG ODN 1826 (10 µg/mouse) delivered i.m. Splenocytes were isolated 21 or 35 
days post-immunisation and restimulated ex vivo with 10 µg/mL of LolC with ELISPOT 
used to measure the number of IFNγ+ SFC. The results show the mean of three technical 
replicates. A Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test was 
performed on the results (* p<0.05, **p<0.01, ***p<0.001).  
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Figure 5-14: Immunisation with LolC conjugated to an anti-DEC205 monoclonal 
antibody failed to induce an anti-LolC IgG response.  
Groups of five female Balb/c mice received LolC conjugated to an anti-DEC205 
monoclonal antibody (LolC-DEC205, 10 µg/mouse), unconjugated LolC and anti-DEC205 
(LolC & DEC205, 10 µg/mouse) or anti-DEC205 alone (10 µg/mouse), all in combination 
with CpG ODN 1826 (10 µg/mouse) delivered i.m. Blood was taken 35 days post-
immunisation and assessed for anti-LolC antibodies by ELISA. A LolC specific antibody 
response was only detected in groups where LolC had been mixed with anti-DEC205 and 
CpG, not when conjugated. The results show the mean of three technical replicated. A 
Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test was performed on the 
results (* p<0.05, **p<0.01, ***p<0.001).  
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Figure 5-15: Targeting LolC to DEC205 does not increase survival following challenge 
with B. pseudomallei K96243. 
Groups of 10 female Balb/c were challenged with 2.2 x 103 CFU of B. pseudomallei 
K96243. Immediately post-challenge mice were immunised with LolC conjugated to an 
anti-DEC205 monoclonal antibody (LolC-DEC205, 10 µg/mouse), unconjugated LolC and 
anti-DEC205 (LolC & DEC205, 10 µg/mouse) or anti-DEC205 alone (10 µg/mouse), all in 
combination with CpG ODN 1826 (10 µg/mouse) delivered i.m. Survival was monitored 
for 35 days post-challenge. There were no significant differences in survival between the 
groups. 
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Figure 5-16: Targeting LolC to DEC205 does not impact on organ weight following 
challenge with B. pseudomallei K96243. 
Groups of 10 female Balb/c were challenged with 2.2 x 103 CFU of B. pseudomallei 
K96243. Immediately post-challenge mice were immunised with LolC conjugated to an 
anti-DEC205 monoclonal antibody (LolC-DEC205, 10 µg/mouse), unconjugated LolC and 
anti-DEC205 (LolC & DEC205, 10 µg/mouse) or anti-DEC205 alone (10 µg/mouse), all in 
combination with CpG ODN 1826 (10 µg/mouse) delivered i.m. Lungs, livers and spleens 
were taken at day 35 and weighed prior to maceration for bacterial counts. A one-way 
Anova with Kruskal-Wallis post-hoc test was performed on the results (* p<0.05, ** p< 
0.01, *** p<0.001). 
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Figure 5-17: Targeting LolC to DEC205 does not impact on bacterial load within the 
lungs, liver or spleen following challenge with B. pseudomallei K96243. 
Groups of 10 female Balb/c were challenged with 2.2 x 103 CFU of B. pseudomallei 
K96243. Immediately post-challenge mice were immunised with LolC conjugated to an 
anti-DEC205 monoclonal antibody (LolC-DEC205, 10 µg/mouse), unconjugated LolC and 
anti-DEC205 (LolC & DEC205, 10 µg/mouse) or anti-DEC205 alone (10 µg/mouse), all in 
combination with CpG ODN 1826 (10 µg/mouse) delivered i.m. Viable B. pseudomallei 
colonies from the lungs liver and spleen were determined 35 days post challenge. A one-
way Anova with Kruskal-Wallis post-hoc test was performed on the results (* p<0.05, ** 
p< 0.01, *** p<0.001). 
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Figure 5-18: Immunisation with LolC conjugated to an anti-DEC205 monoclonal 
antibody failed to increase B. pseudomallei specific IgG antibodies or induce an anti-
LolC IgG response following challenge with B. pseudomallei K96243. 
Groups of 10 female Balb/c were challenged with 2.2 x 103 CFU of B. pseudomallei 
K96243. Immediately post-challenge mice were immunised with LolC conjugated to an 
anti-DEC205 monoclonal antibody (LolC-DEC205, 10 µg/mouse), unconjugated LolC and 
anti-DEC205 (LolC & DEC205, 10 µg/mouse) or anti-DEC205 alone (10 µg/mouse), all in 
combination with CpG ODN 1826 (10 µg/mouse) delivered i.m. Blood was taken 35 days 
post-challenge and assessed for anti-B. pseudomallei and anti-LolC antibodies. A one-
way Anova with Kruskal-Wallis post-hoc test was performed on the results (* p<0.05, ** 
p< 0.01, *** p<0.001). 
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Figure 5-19: Targeting LolC to DEC205 does not impact on cytokines in splenic 
supernates following challenge with B. pseudomallei K96243.  
Groups of 10 female Balb/c were challenged with 2.2 x 103 CFU of B. pseudomallei 
K96243. Immediately post-challenge mice were immunised with LolC conjugated to an 
anti-DEC205 monoclonal antibody (LolC-DEC205, 10 µg/mouse), unconjugated LolC and 
anti-DEC205 (LolC & DEC205, 10 µg/mouse) or anti-DEC205 alone (10 µg/mouse), all in 
combination with CpG ODN 1826 (10 µg/mouse) delivered i.m. Spleens were macerated 
and 500 µL of the supernate taken for cytokine analysis via CBA. Results were analysed 
with a Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test (* p<0.05, ** 
p< 0.01, *** p<0.001). 
 
  
In
fe
c
te
d
 -
 U
n
tr
e
a
te
d
L
o
lC
-D
E
C
2
0
5
 &
 C
p
G
L
o
lC
 &
 D
E
C
2
0
5
 &
 C
p
G
D
E
C
2
0
5
 &
 C
p
G
0
2
4
6
8
1 0
IL -2
p
g
/m
l
In
fe
c
te
d
 -
 U
n
tr
e
a
te
d
L
o
lC
-D
E
C
2
0
5
 &
 C
p
G
L
o
lC
 &
 D
E
C
2
0
5
 &
 C
p
G
D
E
C
2
0
5
 &
 C
p
G
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
IL -6
p
g
/m
l
In
fe
c
te
d
 -
 U
n
tr
e
a
te
d
L
o
lC
-D
E
C
2
0
5
 &
 C
p
G
L
o
lC
 &
 D
E
C
2
0
5
 &
 C
p
G
D
E
C
2
0
5
 &
 C
p
G
0
2 0 0
4 0 0
6 0 0
8 0 0
IF N 
p
g
/m
l
In
fe
c
te
d
 -
 U
n
tr
e
a
te
d
L
o
lC
-D
E
C
2
0
5
 &
 C
p
G
L
o
lC
 &
 D
E
C
2
0
5
 &
 C
p
G
D
E
C
2
0
5
 &
 C
p
G
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
T N F
p
g
/m
l
196 
 
Figure 5-20: Dendrogram showing linkages between the different parameters 
measured for the B. pseudomallei DC efficacy study targeting DEC205 to LolC on DCs. 
Groups of 10 female Balb/c were challenged with 2.2 x 103 CFU of B. pseudomallei 
K96243. Immediately post-challenge mice were immunised with LolC conjugated to an 
anti-DEC205 monoclonal antibody (LolC-DEC205, 10 µg/mouse), unconjugated LolC and 
anti-DEC205 (LolC & DEC205, 10 µg/mouse) or anti-DEC205 alone (10 µg/mouse), all in 
combination with CpG ODN 1826 (10 µg/mouse) delivered i.m. Survivors were culled 35 
days post-challenge with organ weight and bacterial load, circulating antibody and 
cytokine titres measured. The dendrogram clusters the data based on their relatedness 
following analysis with Pearson’s correlation coefficients.  
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Table 11: Partial correlation values for the results of the efficacy study targeting LolC to DEC205.  
Data has been combined and analysed using a partial correlation with IBM SPSS v21 to indicate where interactions between different experiment 
parameters exists. Significant correlation (p<0.05) between parameters are shown in bold.  
    
Spleen 
CFU 
Lungs 
CFU 
Liver 
CFU 
Spleen 
Weight 
Lungs 
Weight 
Liver 
Weight 
anti-B. 
pseudomallei 
IgG 
anti-
LolC  
IgG IL-2 IL-6 IFNγ TNF 
Spleen CFU Correlation 1 0.003 0.056 0.262 -0.103 0.102 -0.056 -0.126 -0.242 0.43 0.345 0.311 
Significance 
(2-tailed) . 0.983 0.701 0.069 0.482 0.487 0.702 0.388 0.094 0.002 0.015 0.03 
Lungs CFU Correlation 0.003 1 0.074 0.227 -0.037 0.146 0.149 0.304 -0.139 0.139 0.322 0.226 
Significance 
(2-tailed) 0.983 . 0.612 0.117 0.802 0.318 0.307 0.034 0.342 0.34 0.024 0.118 
Liver CFU Correlation 0.056 0.074 1 0.121 0.006 0.338 -0.129 -0.141 0.14 0.071 0.182 0.205 
Significance 
(2-tailed) 0.701 0.612 . 0.407 0.966 0.018 0.377 0.333 0.337 0.629 0.21 0.157 
Spleen 
Weight 
Correlation 0.262 0.227 0.121 1 -0.011 0.212 -0.009 -0.12 -0.186 0.492 0.753 0.907 
Significance 
(2-tailed) 0.069 0.117 0.407 . 0.94 0.144 0.953 0.411 0.202 0 0 0 
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Spleen 
CFU 
Lungs 
CFU 
Liver 
CFU 
Spleen 
Weight 
Lungs 
Weight 
Liver 
Weight 
anti-B. 
pseudomallei 
IgG 
anti-
LolC  
IgG IL-2 IL-6 IFNγ TNF 
Lungs 
Weight 
Correlation -0.103 -0.037 0.006 -0.011 1 0.21 -0.214 -0.175 0.372 -0.064 -0.075 0.027 
Significance 
(2-tailed) 0.482 0.802 0.966 0.94 . 0.147 0.14 0.23 0.009 0.662 0.609 0.854 
Liver Weight Correlation 0.102 0.146 0.338 0.212 0.21 1 0.117 0.043 0.078 0.241 0.285 0.272 
Significance 
(2-tailed) 0.487 0.318 0.018 0.144 0.147 . 0.425 0.767 0.593 0.095 0.047 0.059 
anti-B. 
pseudomallei 
IgG 
Correlation -0.056 0.149 -0.129 -0.009 -0.214 0.117 1 -0.068 -0.304 0.216 0.104 -0.036 
Significance 
(2-tailed) 0.702 0.307 0.377 0.953 0.14 0.425 . 0.644 0.034 0.136 0.478 0.807 
anti-LolC  IgG Correlation -0.126 0.304 -0.141 -0.12 -0.175 0.043 -0.068 1 0.322 -0.232 -0.153 -0.15 
Significance 
(2-tailed) 0.388 0.034 0.333 0.411 0.23 0.767 0.644 . 0.024 0.109 0.295 0.302 
IL-2 Correlation -0.242 -0.139 0.14 -0.186 0.372 0.078 -0.304 0.322 1 -0.146 -0.185 -0.131 
Significance 
(2-tailed) 0.094 0.342 0.337 0.202 0.009 0.593 0.034 0.024 . 0.315 0.203 0.368 
IL-6 Correlation 0.43 0.139 0.071 0.492 -0.064 0.241 0.216 -0.232 -0.146 1 0.758 0.65 
Significance 
(2-tailed) 0.002 0.34 0.629 0 0.662 0.095 0.136 0.109 0.315 . 0 0 
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Spleen 
CFU 
Lungs 
CFU 
Liver 
CFU 
Spleen 
Weight 
Lungs 
Weight 
Liver 
Weight 
anti-B. 
pseudomallei 
IgG 
anti-
LolC  
IgG IL-2 IL-6 IFNγ TNF 
IFNγ Correlation 0.345 0.322 0.182 0.753 -0.075 0.285 0.104 -0.153 -0.185 0.758 1 0.889 
Significance 
(2-tailed) 0.015 0.024 0.21 0 0.609 0.047 0.478 0.295 0.203 0 . 0 
TNF Correlation 0.311 0.226 0.205 0.907 0.027 0.272 -0.036 -0.15 -0.131 0.65 0.889 1 
Significance 
(2-tailed) 0.03 0.118 0.157 0 0.854 0.059 0.807 0.302 0.368 0 0 . 
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5.3 Discussion 
In this chapter, two therapeutic strategies for B. pseudomallei have been explored. 
Firstly, the protective effect of adoptively transferred DCs stimulated with heat-killed B. 
pseudomallei together with CpG ODN 1826 was explored. Subsequently the protective 
B. pseudomallei LolC was targeted to DCs in situ using an anti-DEC205 monoclonal 
antibody. Both exploited a Balb/c mouse model of B. pseudomallei infection.  
 
Previously, a DC vaccine for B. pseudomallei administered prophylactically, provided 
significant protection in a Balb/c model characterised by an enhanced CMI response and 
decreased bacterial load compared to a KWC vaccine [86] [85]. The DC vaccine 
described in this chapter was delivered as a post-exposure treatment, immediately 
following challenge with a dose previously demonstrated to allow survival of naïve 
Balb/c to 35 days post-challenge (personal communication from Dr. Andrew Scott, Dstl).  
 
It is important to note that the heat inactivation methodology used in this study, 4 hours 
at 80 °C, differs to that of Healy and Elvin in their papers, 3 hours at 70 °C [86] [85]. All 
these studies were performed at Dstl Porton Down and the change in methodology 
reflects an improvement to the Safety Risk Assessment. Additionally the culture method 
for BMDCs varied slightly from Healy and Elvin in that the studies presented in this 
thesis didn’t include TNF in the BMDC culture. Previously the addition of TNF to BMDC 
cultures has upregulated CD40, CD80 and CD86 together with the downregulation of 
phagocytosis with BMDCs exhibiting a phenotype indicative of having undergone 
maturation [521]. This mature phenotype would prevent DCs from taking up exogenous 
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antigens and inducing a T cell response. For that reason TNF was removed from the 
culture conditions.  
 
Prior to exploring the potential of DCs pulsed with heat-killed B. pseudomallei and CpG 
as a therapeutic strategy for B. pseudomallei the immune response to this strategy was 
investigated. CpG was shown to be important for the maturation of BMDCs as part of in 
vitro assays. However, following adoptive transfer BMDCs pulsed with heat-killed B. 
pseudomallei with or without CpG ODN were able to induce an antigen-specific immune 
response as demonstrated by both IFNγ ELISPOT and secretion of IFNγ, TNF, IL-6 and IL-
17 following restimulation, together with a B. pseudomallei specific IgG response. DCs 
have been shown to act as natural adjuvants when pulsed with antigen with the absence 
of further stimulation, secreting IL-12 and inducing an adaptive immune response [84] 
potentially why a significant adaptive immune response was observed in the absence of 
CpG stimulation.   
 
The data complements previous work which showed BMDCs pulsed with heat-killed B. 
pseudomallei to induce a specific immune response [85] [86]. The additional 
measurement of several cytokines important in the polarisation of an immune response 
included a significant recall response of the proinflammatory cytokines IFNγ, TNF, IL-6 
and IL-17A. There was no significant recall response for either IL-4 or IL-10, indicating a 
strong Th1/Th17 bias to the immune profile generated following immunisation with 
BMDCs pulsed with heat-killed B. pseudomallei, with or without CpG. However, it is 
important to note that the IFNγ recall response from the group that received BMDCs 
stimulated with B. pseudomallei alone was greater than that for the group that received 
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BMDCs stimulated with B. pseudomallei and CpG. Potentially this is because of the 
previously described differences in culture conditions resulting in differences between 
the two studies. 
  
DCs present antigens on MHC-II and MHC-I molecules to CD4+ and CD8+ T cells 
respectively, initiating an adaptive immune response. CD4+ T cells have several functions 
that aid protection against pathogens. These include: recruitment of lymphoid cells to 
secondary lymph organs where CD4+ T cells promote the engagement of CD8+ T cells 
with DCs [44]; recruitment of innate and antigen specific cells to infected tissues [45]; 
help the expansion and function of other effector cells; direct effector functions via 
cytokine production of cell mediated cytotoxicity; maintain CD8+ T cell functionality 
during chronic infections [46]; aid development of CD8+ T cell memory; provide help to B 
cells for development of antibody production and differentiation of plasma cells [48]. All 
these functions are important for protection against pathogens with the function of 
CD8+ T cells particularly important for protection against intracellular pathogens, such as 
B. pseudomallei. 
 
The cytokines produced following restimulation included IFNγ. Naïve CD4+ T cells 
differentiate into Th1 cells in the presence of IFNγ or IL-12 and secrete large quantities 
of IFNγ. This helps recruit and activate macrophages to sites of infection where they 
phagocytose infected cells, important for the control of intracellular pathogens [49]. 
They are also required for the activation and maintenance of CD8+ T cells and the 
induction of IgG class switching. IFNγ is required for the control of intracellular 
infections and has been shown to be generated by antigen-pulsed BMDCs, enhancing 
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both immune responses and protective efficacy for a range of pathogens [92] [94] [98] 
[104] [108] [82]. IFNγ is crucial for resistance to B. pseudomallei infection in both mouse 
models [340] [373] and clinical disease [374] with IFNγ-/- mice rapidly succumbing to 
disease and IFNγ supplementation boosting survival [340]. 
 
Also observed following restimulation was IL-17, the hallmark cytokine of Th17 cells. 
Th17 cells require IL-6 and TGF-β for their development, their activation results in the 
production of IL-17, which is chemotactic for neutrophils, an important defence 
mechanism against B. pseudomallei infection [373] [522]. Th17 cells play an important 
role in protection against intracellular infections [49] [53] and in addition to neutrophils 
are able to recruit monocytes and Th1 cells to sights of infection. A reduced IL-17 
response has been suggested as indicative of an increased risk of disease susceptibility, 
particularly in diabetic patients [523].  
 
Three efficacy studies were undertaken to assess the potential of antigen-pulsed BMDCs 
as a therapeutic intervention for B. pseudomallei. In all studies there were no 
differences in survival between any of the groups. The results from the first efficacy 
study, although not statistically significant, were viewed as a positive outcome with 
normal spleen weights, no abscesses or enlargement and no detectable bacterial load 
for mice immunised with BMDCs pulsed with heat-killed B. pseudomallei and CpG. The 
second and third efficacy studies employing this approach contradicted these initial 
findings and showed therapeutic DC vaccination for B. pseudomallei to have a negative 
impact upon spleen weight, bacterial load and cytokine levels. Why this variation 
between studies occurred is unclear, however a recent publication by Helft et al [399] 
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has demonstrated the culture of BMDCs in GM-CSF to yield a heterogeneous population 
of cells, including populations with DC and macrophage functionality that are both 
CD11c+ and MHC-II+, a phenotype that would traditionally have classified a bone-
marrow derived cell as a DC [399]. There is therefore the potential that the percentage 
of DCs varied between the studies providing the variation in results. 
 
The differences in BMDC culture conditions compared to previously published results 
[86] [85] meant there was a need to confirm these BMDCs to be protective against B. 
pseudomallei when administered prophylactically and this should have occurred before 
advancing to therapeutic studies. 
  
It is unclear why therapeutic DC vaccination increased bacterial load, particularly as at 
the time of commencing these studies DCs were thought to be effective at killing B. 
pseudomallei albeit using in vitro methods [524] [525]. However, Williams et al have 
recently shown that BMDCs infected with B. pseudomallei in vitro and subsequently 
administered to C57BL/6 mice caused systemic dissemination of B. pseudomallei [526]. 
Furthermore, a comparative study assessing the use of heat-killed or paraformaldehyde-
killed B. pseudomallei as prophylactic vaccines revealed paraformaldehyde-killed B. 
pseudomallei to provide significant protection against lethal challenge compared to 
naïve mice or mice vaccinated with heat-killed B. pseudomallei [527]. Potentially 
paraformaldehyde-killed B. pseudomallei may contain protective antigens that the heat-
killing process has damaged  [527]. For the studies described in this thesis the use of 
paraformaldehyde fixed B. pseudomallei was considered as an alternative to heat-killing. 
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However, from the outset the aim was to use the prophylactic method previously 
developed [85] [86] as a therapeutic vaccine to enable direct comparison. 
 
An additional hypothesis for the observed increase in bacterial load following 
immunisation with BMDC pulsed with heat-killed B. pseudomallei is that the pulsed 
BMDCs are causing migration of host leucocytes due to the release of proinflammatory 
cytokines and chemokines. As described in the previous chapter, pulsing with B. 
pseudomallei and CpG upregulated the mRNA of a range of proinflammatory cytokines 
and chemokines including Il-6, Il-12p40, Il-12p70, Ccl2, Ccl3, Ccl4, Ccl5, Ccl7, Ccl12, 
Cxcl1, Cxcl2 and Cxcl10. Their chemotactic nature for a variety of leucocytes has been 
previously discussed but there is the potential that their release by stimulated 
adoptively transferred BMDCs may enhance the recruitment of phagocytic cells such as 
DCs, macrophages, monocytes and neutrophils, aiding the systemic spread of B. 
pseudomallei. Interestingly, increased organ weight and bacterial load was repeatedly 
observed for mice receiving heat-killed B. pseudomallei and CpG but not mice 
administered with either heat-killed B. pseudomallei alone or CpG alone indicating the 
combination of the two is synergistic in increasing this deleterious effect.    
 
Whilst a mixture of LolC, anti-DEC205 and CpG ODN induced a LolC specific immune 
response, the failure of targeting LolC to DEC205 to either induce an antigen-specific 
immune response or reduce bacterial burden was surprising. Targeting antigens to 
DEC205 has been shown to induce antigen-specific immune response in multiple studies 
[155] [163] [164] [165] [166] [170] [528]. It is known that LolC is capable of inducing a 
protective, antigen-specific immune response [355] so the lack of an immune response 
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is likely to be due to a failure of the conjugation process rather than the antigen per se. 
The conjugate was prepared using a previously published methodology [155], 
potentially this process could have degraded the antigen, preventing the generation of a 
specific immune response. The generation of a LolC-DEC205 genetic construct for 
expression in a mammalian cell line was explored. However this approach is often 
thwarted by the fact that many antigens, when fused to the C terminus of the 
monoclonal antibody H chain, are not efficiently secreted by mammalian cells [529]. In 
preliminary studies this was found to be the case, hence why the conjugate approach 
was taken. 
 
Previously Judy et al [530] have shown the prophylactic treatment of mice with CpG 
ODN, 48 hours prior to infection with B. pseudomallei, to recruit phagocytic cells to the 
site of infection, providing a moderate and sustained production of cytokines and 
chemokines including IL-6, IL-12p40, IL-12p70, IFNγ, TNF, CCL2, CCL3, CCL4, CCL5 and 
CXCL1, all observed in the current study, with enhanced survival. However the 
therapeutic use of CpG resulted in a greater release of these cytokines and chemokines 
associated with increased immunopathology and reduced survival [530]. These data 
imply that an uncontrolled release of cytokines and chemokines is an indicator of poor 
disease control and this has been reported in clinical cases of melioidosis [333-335].   
 
As previously discussed two mouse models are predominantly employed in B. 
pseudomallei research, the resistant C57BL/6 and susceptible Balb/c models [369]. 
Broadly speaking the LD50 is 100-fold greater for C57BL/6 mice compare to Balb/c mice 
for a given challenge route (personal communication from Dr. Andrew Scott, Dstl). In 
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the current studies the Balb/c model was utilised as although this is traditionally 
thought of as an acute model, mice are capable of surviving for prolonged periods 
following low challenge doses (<4 x 103 CFU, unpublished data) [370] developing a 
chronic infection whilst maintaining a detectable bacterial load. C57Bl/6 mice at the 
same challenge dose would have an undetectable bacterial load 35 days post-challenge. 
Increasing the challenge dose would potentially ameliorate this but to date the majority 
of research into melioidosis has been conducted using the Balb/c model. However there 
is a growing consensus that C57Bl/6 mice may provide a more realistic model of clinical 
disease when there are no other underlying medical complications [531]. Additionally, 
due to the large variation in detectable bacterial load observed, from below the lower 
limit of detection (< 10 CFU/mL) to 2.07 x 1010, in hindsight a higher challenge dose with 
a shorter study duration may have led to a more consistent bacterial load within the 
groups. This may have enabled a greater possibility of reproducible results for the same 
treatment between independent studies. 
 
Previous therapeutic strategies for infectious diseases have had mixed results with 
antigen-pulsed DCs rarely being used. DCs pulsed with Mycoplasma pulmonis antigens 
induced a specific T cell response but this response enhanced disease associated lung 
pathology [532]. Therapeutic strategies for HIV aim to enhance antiviral CD4+ and CD8+ T 
cell responses. Clinical trials involving DC therapy have been found to be safe and well 
tolerated but viral control has been hard to accomplish [533]. Recently a clinical trial  
that involved pulsing DCs with heat-inactivated HIV decreased viral load by greater than 
one log with enhanced HIV-specific T cell responses [534]. 
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Other therapeutic vaccines involving more conventional vaccine strategies have failed to 
reduce Mycobacterium tuberculosis bacterial burden or affect primary lesions within the 
lungs [535]. However the combination of therapeutic vaccines with antibiotics has been 
shown to be more efficacious. Mice infected with M. tuberculosis that received 
therapeutic vaccination in combination with oral antibiotics demonstrated an enhanced 
antigen specific T cell response, decrease bacterial burden and associated lung 
pathology together with a reduction in the duration required for antibiotic therapy 
[535]. Similarly the combination of post-challenge vaccination with antibiotics enhanced 
survival and reduced bacterial burden in a mouse model of Francisella tularensis. [536].  
 
The absence of a licensed vaccine for melioidosis, or one undergoing clinical trials, 
together with high disease mortality when untreated and treatment that often fails to 
eradicate the bacterium necessitates the development of successful therapies, possibly 
in combination with one another. Therefore, the use of antibiotics in therapeutic models 
of B. pseudomallei infection should be considered, particularly given the data observed 
in the studies described in this chapter. 
 
This approach is the first of its kind to attempt a B. pseudomallei antigen-specific 
therapeutic immunotherapy. Previously non-specific therapies for B. pseudomallei have 
included the use of CpG ODNs [537] [530] and the inhibition of the cyclooxygenase-2 
(COX-2) enzyme [538]. Therapeutic treatment with CpG ODNs 1 hour post-infection 
resulted in 100 % survival when given i.n. or 90 % when given i.p compared to 40% 
survival for untreated mice. However this study employed an aerosolised challenge of B. 
pseudomallei 1026b (a clinical isolate from a 29 year old diabetic female [539]), 
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compared to an i.p. challenge with B. pseudomallei K96243 in the current studies [537]. 
When CpG ODN was administered i.n. 24 hours post-challenge there were no 
differences compared to untreated controls following i.n. infection with B. pseudomallei 
K96243 [530]. COX-2 is important in the production of prostaglandin E2 (PGE2) which 
promotes B. pseudomallei survival within macrophages and enhances bacterial virulence 
[538]. Therapeutic inhibition of COX-2 resulted in supressed B. pseudomallei growth 
within macrophages and provided protection against pneumonic disease [538].  
 
These previous approaches to therapeutic treatment of B. pseudomallei together with 
the data presented here suggests that therapeutic immunisation is a risky strategy but 
with potentially high rewards. Despite the encouraging immunogenicity data for DC 
vaccination, the efficacy data was contradictory but suggested that therapeutic DC 
vaccination enhanced B. pseudomallei infection. Furthermore, targeting LolC to DEC205 
failed to have a positive impact upon survival or bacterial burden within multiple organs. 
A more clinically appropriate strategy of combining DC vaccination with antibiotics may 
have provided an opportunity for an adaptive immune response to initiate prior to the 
development of a large bacterial burden.  
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Chapter 6: General Discussion 
This thesis addresses the potential prophylactic and therapeutic role of DC vaccination 
in the disease contexts of anthrax and melioidosis. Additionally the therapeutic potential 
of targeting a protective B. pseudomallei antigen to DCs was evaluated. Both B. 
anthracis and B. pseudomallei have the potential to cause latent or re-emerging 
infections due to the persistence within the host of spores or bacteria respectively. 
Whilst there is a licensed vaccine for B. anthracis it has several limitations which restrict 
its use, whereas there is no licensed vaccine for B. pseudomallei or one in clinical 
development.  
 
As reviewed in Chapter 1, DC vaccines have been developed as a strategy for a variety of 
pathogens where conventional vaccines (e.g. antigen formulated in alum) have failed to 
induce a protective immune response. This is often the case when pathogens are either 
intracellular [90] [132] or have complex interactions within the host [104]. Vaccines for 
these pathogens, in addition to the strong antibody response generated by conventional 
vaccines, often require the development of CMI responses with a Th1 bias, a failure of 
some conventional formulations. DC vaccination has reproducibly induced CMI 
responses with a Th1 bias and for this reason has been examined in the above disease 
contexts. In summary this thesis has examined the role of: 
 DC vaccination as a prophylactic approach to enhance CMI responses following 
the adoptive transfer of specifically primed DCs, in a murine model of B. 
anthracis. 
 DC maturation following pulsing with B. pseudomallei antigens and an evaluation 
of their immunogenicity in vivo. 
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 DC vaccination as a post-exposure therapy to enhance B. pseudomallei specific 
CMI responses and to determine the impact on bacterial clearance and survival 
in a murine model of B. pseudomallei. 
 Targeting a B. pseudomallei antigen to DCs in situ as a post-exposure therapy to 
determine the impact on bacterial clearance and survival in a murine model of B. 
pseudomallei. 
The overarching hypothesis for this thesis was that DCs can beneficially modulate the 
immune system prior to, or in response to, pathogen challenge.  
 
6.1 Setting the results in context 
The development of vaccines with the ability to induce robust T cell immunity, capable 
of controlling and eradicating infectious disease within the host is a significant 
challenge. Following infection, B. anthracis spores are taken up by phagocytic cells, 
including DCs, which migrate to secondary lymph organs, inducing an adaptive immune 
response. Spore phagocytosis triggers germination, and the trafficking of DCs to 
secondary lymph organs serves to disseminate bacteria within the host [540]. The 
symptoms and lethality of B. anthracis are due to systemic septicaemia and toxin 
production and although antibiotic treatment can clear bacteria, toxaemia can still be 
fatal [250]. 
 
Whilst the currently licensed anthrax vaccines (AVP and AVA) are both excellent 
inducers of toxin neutralising antibodies and help prevent the establishment of a 
systemic infection [390], both are poor inducers of CMI responses. Natural infections 
generate greater T cell responses in comparison [393]. Additionally, current vaccines are 
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limited by a long primary schedule, required to generate an immune response 
considered protective and have the requirement for annual boosters. Next generation 
anthrax vaccines have a defined antigenic composition (rPA in alum) although it is not 
clear if they are able to induce a greater CMI response.  
 
In this thesis the ability of DCs to induce a CMI response has been explored using murine 
models. Maturation of BMDCs was dependent on CpG being present in the culture, 
characterised by the upregulation of CD40, CD80, CD86 and MHC-II. In the B. anthracis 
model used, DC immunisation did not induce an antigen-specific immune response 
within 14 days, in all likelihood this was too early to detect a CMI response. Previous 
reports have shown DC vaccination to require 28 or 35 days to develop an antigen-
specific immune response [99] [86]. The combinatorial approach of DC vaccination 
together with administration of the rPA in alum vaccine, boosted the CMI response 
observed for rPA in alum alone. This combinatorial approach protected all mice in a 
lethal challenge model, with a significantly lower bacterial load compared to mice 
immunised with rPA in alum alone, or pulsed DCs alone. 
 
The results have demonstrated that prophylactic DC vaccination strategies for B. 
anthracis could indeed have a positive effect on survival and bacterial load, and 
demonstrates that the development of anthrax vaccines with enhanced CMI responses 
have the potential to improve on those already licensed. These conclusions align with 
other reports examining the potential of DC vaccination as a strategy for bacterial 
pathogens and the mechanisms elucidated that help mediate protection. DC vaccination 
has enhanced protection for B. burgdorferi [88], M. tuberculosis [92], C. burnetii [81], 
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Chlamydia spp. [94] [95] and P. aeruginosa  [96], all characterised by a Th1 bias and 
enhanced CMI responses. 
 
There is currently no licensed vaccine for melioidosis, nor one in clinical development. 
The strategy employed in this thesis aimed to determine if therapeutic vaccination could 
enhance survival and reduce bacterial load in a murine model. Complementing the B. 
anthracis studies, maturation of DCs in vitro was dependent on the presence of CpG and 
was antigen-independent. Maturation was characterised by the upregulation of CD40, 
CD80, CD86, MHC-II, CCR7 and DEC205. Additionally, stimulated cells were assessed for 
changes in the expression of 84 genes important in the development of an adaptive 
immune response. This showed the stimulation regimen to rapidly alter the expression 
of 21 of these genes by greater than two-fold, compared to the unstimulated control. A 
large proportion of the genes upregulated were for chemokines, important in the 
migration of leucocytes in response to infection and inflammation.  
 
In vivo imaging studies demonstrated that in vitro stimulated BMDCs were able to 
migrate to lymph nodes within 48 hours following adoptive transfer. Separate in vivo 
immunogenicity studies demonstrated DCs cultured under identical conditions to induce 
a CMI response with a mixed Th1/Th17 profile, characterised by an antigen recall 
response to IFNγ and IL-17. Both cytokines are important for effector functions against 
intracellular pathogens and have been shown to be important for resistance in models 
of M. tuberculosis [541].  
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Following these encouraging results, mice were immunised with stimulated DCs in a 
therapeutic model of melioidosis. Unfortunately this approach was unsuccessful; DC 
vaccination did not affect survival in three independent experiments and had a 
deleterious effect on splenic bacterial load in two of the three studies. Compared to the 
previously successful use of DCs as a  prophylactic vaccine for B. pseudomallei [86] [85] 
this was disappointing but not wholly unexpected.  
 
B. pseudomallei has multiple virulence factors aiding immune evasion including: quorum 
sensing, capsular polysaccharide, T3SS, T6SS, LPS, flagella and efflux pumps capable of 
removing multiple antibiotics from the bacterium. Following infection, B. pseudomallei 
rapidly enters host cells both passively, via phagocytosis with escape of primary 
endosomes into the cytoplasm, mediated by T3SS and actively via cellular invasion. 
Although the T3SS has been implicated in cellular invasion [314], more recent data 
contradicts this and a clear virulence determinant has yet to be described [315]. The B. 
pseudomallei T6SS functions downstream of the T3SS and mediates intracellular spread 
and MNGC formation [318] which occurs within 12 hours of infection [315]. In the 
current studies, the absence of either antibiotics or a B. pseudomallei-specific adaptive 
immune response at the time of infection enabled bacteria to replicate to a level which 
the mice were unable to control.  
 
Two possible explanations for the increase in spleen size and bacterial load have been 
previously discussed: 1) that the adoptively transferred DCs act as a vector, directly 
disseminating B. pseudomallei systemically; 2) that chemokines released by, and in 
response to, the adoptive transfer of stimulated DCs caused host leucocytes to become 
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infected by B. pseudomallei and disseminate bacteria in this way. Of these I feel the 
latter to be the more likely given the small number of cells introduced (1x106) compared 
to the number of phagocytic cells within a mouse, together with the ability of B. 
pseudomallei to actively invade host cells.  
 
To investigate a more clinically appropriate alternative, the protective B. pseudomallei 
antigen, LolC was conjugated to a monoclonal antibody specific for the DC endocytic 
receptor, DEC205. This approach failed to induce either an immune response in vivo or 
impact upon survival or bacterial load in an efficacy study. Although a previously 
published method was used the most likely explanation for this is that the conjugation 
process damaged LolC, preventing an immune response to it being generated. This is all 
the more likely given that a LolC-specific antibody response was measured when it was 
administered mixed with anti-DEC205 and CpG ODN. However, whilst LolC induces a 
potent antibody response in vivo, providing some protection in murine models, to date 
CMI responses to LolC have been poor (unpublished data, personal communication from 
Dr. Andrew Scott, Dstl). 
 
Taken together, these data and the previously published literature show B. pseudomallei 
to have numerous mechanisms to infect, avoid host immunity and resist antibiotic 
therapy making developing vaccines and therapeutic strategies for this bacterium 
challenging. 
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6.2 Limitation of the current work and future research strategies 
BMDCs have been widely used to aid understanding of the immune bias required to 
develop protective vaccines against infectious disease. A major limitation of the use of 
DCs derived from bone marrow cultured ex vivo is that they do not account for different 
migratory events that occur between different DC subsets in vivo [416]. The 
development of DC subset cell lines may aid in ascertaining their differential roles in 
disease, helping to assess the impact that different DC subsets have on the polarisation 
of the immune response [542]. 
 
The use of prophylactic DC vaccination for anthrax was successful and given the 
limitations of existing anthrax vaccines, the development of a vaccine that can provide 
enhanced CMI responses in addition to maintaining antibody responses should be 
evaluated to assess the potential benefits of this approach. Targeting of rPA to 
endocytic receptors on DCs, such as DEC205 or Clec9A would provide an evaluation of 
this strategy. This approach has been successfully pursued using an LcrV-DEC205 
vaccine, targeting DEC205 on DCs. This has demonstrated a greater CMI response 
compared to the antigen formulated in alum, with comparable antibody responses and 
protective efficacy  against Y. pestis [177] [179]. The development of a vaccine 
containing rPA targeting DCs in situ should be a strategy explored to determine if the 
enhanced CMI responses observed when mice were co-vaccinated with specifically-
pulsed DCs and the rPA and alum could be replicated with a more clinically appropriate 
approach.  
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The failure of pulsed DCs to either enhance survival or reduce bacterial load in a 
therapeutic model of B. pseudomallei infection was a disappointment. Conditioning the 
injection site has been shown to enhance migration of DCs to lymph nodes, but this has 
primarily been following the adoptive transfer of small numbers of DCs (1 x 104 BMDCs) 
and not to enhance migration at higher numbers (1 x 106 BMDCs) [516]. As mice each 
received 1 x 106 BMDCs, conditioning the injection site was considered but thought 
unlikely to be beneficial, based on cell numbers, but could be worth revisiting in future 
studies. 
 
The use of DCs on their own as a therapeutic immunotherapy for B. pseudomallei may 
have been inadequate as a method to impact survival or bacterial clearance for this 
persistent intracellular bacterium. The immune responses generated as part of the 
immunogenicity studies indicate that these are appropriate to provide protection in a 
prophylactic model, as has been previously reported [86] [85]. As a consequence, any 
future therapeutic studies should also involve the administration of antibiotics, as would 
occur clinically, to determine if DC vaccination can indeed clear the infection under 
these conditions. However, even when administered six hours post-infection, antibiotics 
fail to clear the bacterium in all mice [543,544] but would extend the therapeutic 
window for DC vaccination to enhance the CMI response. A delay in antibiotic 
administration allows infection to establish and is associated with increased mortality 
[544] which is why the approach using DCs to enhance CMI responses was initiated. 
 
As previously discussed, there are growing doubts as to whether the Balb/c mouse is an 
appropriate model for melioidosis due to its innate susceptibility to the pathogen. There 
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is a growing consensus that despite the majority of work having been conducted using 
Balb/c mice, the C57Bl/6 mouse may provide a more robust model of clinical disease, 
particularly when looking at chronic infection models. Clinical disease is often chronic in 
nature with a failure to clear the bacterium and associated relapses are a common 
feature. The use of a more resistant mouse strain may therefore provide a more realistic 
model for the clinical picture and should be considered in future therapeutic treatment 
models 
 
The development of a genetic construct of the protective B. pseudomallei antigen, LolC 
and an anti-DEC205 monoclonal antibody to target to DCs in situ was limited by the 
failure for this to express appropriately in mammalian cell lines, a frequent problem 
when developing antigen-antibody complexes for targeting to DCs in situ [529]. 
Previously chemical conjugation of antigens to antibodies to enable DC targeting has 
proved effective at inducing a mixed CMI and antibody response with a Th1 bias [155]. 
Following this previously published methodology, a conjugate was prepared but when 
trialled in animal models it proved to be ineffective at either inducing a LolC-specific 
immune response, increasing survival or decreasing bacterial load as part of efficacy 
studies. Given that targeting DCs in situ has become an established method for 
generating CMI responses with a Th1 bias in murine models and more recently in clinical 
trials, this approach should be further explored. The non-covalent assembly of antigens 
and antibodies that are independently expressed but able to bind via linker molecules of 
cohesin and dockerin respectively, enables the repertoire of antigens suitable for 
targeting studies to be greatly increased. This is a potential solution to the inefficiencies 
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observed when trying to express the anti-DEC205-LolC construct as a whole molecule 
and should be explored in future studies. 
 
6.3 Concluding remarks 
There remain multiple challenges in the development of vaccines for many infectious 
diseases, particularly the identification and characterisation of protective antigens 
together with the determination of correlates of protection. Many diseases are 
controlled by host adaptive immune responses, although chronic infections can 
establish in the absence of sterilising immunity. Thus new prophylactic vaccines need to 
be able to stimulate appropriate immune responses capable of maximising pathogen 
clearance. As demonstrated in the anthrax model, the ability to enhance specific 
immune responses via pulsing DCs ex vivo with antigen prior to their adoptive transfer, 
shows the benefit of enhanced CMI responses in clearing microbial infections. An 
alternative to this, targeting vaccine antigens to DCs directly may provide a more 
clinically relevant strategy. However, the use of therapeutic DC vaccination as a method 
to elucidate host responses may be too complex, given the ongoing host response to 
infection. Thus the use of DC vaccination as a tool to aid development of new and 
improved vaccines for melioidosis should be restricted to prophylactic approaches in the 
absence of additional immunotherapeutics in post-exposure models. 
 
Although DC vaccination was able to induce or enhance an antigen-specific immune 
response in both disease contexts, and also provided enhanced clearance of B. 
anthracis, it failed to have a positive impact on either survival or bacterial clearance in a 
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therapeutic murine model of melioidosis. The original hypothesis that “DCs can 
beneficially modulate the immune system in response to pathogen challenge” has been 
shown to be partially correct. When used as a prophylactic strategy, immunisation with 
DCs did indeed have a positive effect on survival and bacterial clearance; however their 
therapeutic use for melioidosis failed to do so. Nevertheless, the manipulation of DCs 
will remain important for the identification of immune pathways important for 
pathogen protection and also for the identification of correlates of protection as part of 
vaccine development.   
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